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Abstract 
Streptococcus pneumoniae causes life-threatening invasive diseases in children and 
older adults. Although effective at reducing the incidence of disease, the two currently 
available vaccines against S. pneumoniae have significant limitations that a vaccine 
based on protein antigens may overcome. For this thesis I have investigated the role of 
S. pneumoniae ABC transporters during infection, and have assessed as potential 
vaccine candidates the lipoprotein components of two ABC transporters. 
Eleven ABC transporters were chosen for investigation of their role during 
infection, and disruption mutant strains were successfully constructed for 9 of these. 
Two mutant strains disrupting the Sp0148-52 and Sp0749-53 ABC transporters, which 
BLAST searches suggest have methionine and branched chain amino acids (BCAAs) as 
substrates respectively, were markedly attenuated in systemic and pulmonary mice 
models of virulence. Western blotting and PCR confirmed that the lipoprotein 
components of these ABC transporters, Sp0149 and Sp0749, are present in all the S. 
pneumoniae strains investigated and are membrane-localised. Radioactive and 
fluorescence ligand binding experiments showed the Sp0749 lipoprotein specifically 
bound to BCAAs, confirming Sp0749-53 encodes a BCAA ABC transporter.  
Vaccination of mice with His6-Sp0149 and His6-Sp0749 induced specific IgG 
which was able to increase complement activity against and phagocytosis of S. 
pneumoniae. Intranasal immunisation of mice with His6-Sp0749 and His6-PiaA, 
affected the immune response to subsequent intranasal challenge with S. pneumoniae 
and increased lung inflammation upon subsequent S. pneumoniae intranasal challenge. 
However, both intraperitoneal and intranasal immunisation of mice with His6-Sp0149 
and His6-Sp0749 resulted in only minor degrees of protection against S. pneumoniae 
septicaemia and pneumonia respectively. These results demonstrate that the S. 
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pneumoniae BCAA ABC transporter is required for the full virulence, and its 
lipoprotein component can elicit immune responses against invasive S. pneumoniae that 
although weakly protective could contribute towards a multivalent vaccine. 
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TCSTS  Two-component signal transduction system 
TCS   Two-component system 
THY   Todd-Hewit yeast extract 
TBS-T   Tris buffered saline-tween 
Tris-HCL  Tris-hydrochloric acid 
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TSA   Tris sodium chloride azide 
TA   Thymine Adenine 
Th1, 2 response T-helper 1, 2 response 
USA   United States of America 
UK   United Kingdom 
UCL   University College London 
WHO   World Health Organisatin 
W1, 2   Washes 1, 2 
XbaI   Restriction enzyme 
YidC   E. coli secretory protein  
Ybt    Yersinobactin 
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    Chapter 1 
 Introduction to Streptococcus pneumoniae 
 
1. 1 GENERAL 
Streptococcus pneumoniae are Gram-positive, encapsulated cocci, facultative 
anaerobic and α-haemolytic bacteria usually arranged in short chains. S. pneumoniae 
is a human pathogen which inhabits the upper respiratory tract of healthy individuals 
and commonly causes diseases such as pneumonia, septicaemia, acute otitis media 
and meningitis. It can rarely cause other infections such as sinusitis, arthritis, 
pericarditis and peritonitis. Infants, elderly people and patients with predisposing 
medical conditions such as chronic lung disease, alcohol abuse, malignant disease, 
immunosuppressive therapy, diabetes, splenectomy and renal dialysis are particularly 
susceptible to S. pneumoniae infections (McKenzie et al., 2000). Based on the 
polysaccharide capsule, more than 90 serotypes of S. pneumoniae have been 
identified. 
S. pneumoniae belongs to the Streptococcus mitis-Streptococcus oralis group 
(Smit group) of viridans group streptococci, also known as the oral streptococcal 
group which includes S. mitis, S. oralis, S. cristatus, S. infantis, S. peroris. To 
differentiate S. pneumoniae from other viridans group streptococci, four phenotype 
tests are routinely performed, which are colony morphology, optochin sensitivity and 
bile solubility tests and agglutination with antipolysaccharide capsular antibodies. 
However, some S. pneumoniae strains resistant to optochin and bile insoluble (bile 
insoluble-atypical pneumococci) have been reported (Whatmore et al., 2000), and 
concerns have also been raised on the sensitivity and specificity of the commercially 
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available agglutination test kits containing capsular antibodies to known S. 
pneumoniae serotypes as S. pneumoniae cells lacking capsule (atypical pneumococci) 
may not react and cross-reaction has been observed with other S. mitis group bacteria 
(Arbique et al., 2004). The availability of complete genome sequence of the capsular 
serotype 4 strain (TIGR4) of S. pneumoniae and virulence studies performed in 
animal models has allowed conserved virulence genes to be used as an alternative 
way to identify S. pneumoniae. Amplification of virulence genes of S. pneumoniae 
such as autolysin gene (lytA), pneumolysin gene (ply), pencillin binding protein genes 
and specific regions of 16s rRNA gene have all been used to identify S. pneumoniae 
from other viridans group streptococci (Arbique et al., 2004), although contradictory 
results suggest that the lytA, and ply genes can be occasionally present in both S. mitis 
and S. oralis (Kawamura et al., 1999; Muller-Graf et al., 1999; Whatmore et al., 
2000). Despite the inaccuracies of each of the above techniques, optochin sensitivity 
test and bile solubility tests remain the routine methods for identification of S. 
pneumoniae.  
 
1.2 CLINICAL CONSIDERATIONS 
1.2.1 Nasopharyngeal carriage 
 
S. pneumoniae is a commensal residing in the upper respiratory tract of healthy 
children and adults. Transmission of the bacteria between people is through airborne 
droplets of respiratory secretions (Obaro and Adegbola, 2002). The first step in the 
nasopharyngeal colonisation of S. pneumoniae is adherence of the bacteria on to the 
epithelial surface with the help of various surface proteins (McCullers and Tuomanen, 
2001). Transition from asymptomatic nasopharyngeal carriage to invasive disease is 
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thought to depend on the balance between the host’s defence mechanisms and the 
ability of the bacteria to cause the disease. 
The normal flora of the nasopharynx includes various haemolytic streptococci, 
S. pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Staphylococcus 
aureus and Moraxella cattarrhalis (Bogaert et al., 2004). Despite the genetic 
dissimilarities between S. pneumoniae, H. influenzae and N. meningitidis, they share 
some common features in their mode of pathogenesis, such as asymptomatic 
nasopharyngeal carriage with the capability of invading the lungs, blood stream, ear, 
brain and a tendency to target the elderly and the very young (McCullers and 
Tuomanen, 2001). Competition between the pathogenic bacteria during the 
colonisation in the respiratory tract has also been reported, where hydrogen peroxide 
produced by S. pneumoniae is bactericidal to other bacteria residing in the respiratory 
tract. Phosphorylcholine, a cell wall component produced by S. pneumoniae and H. 
influenzae mediates the adherence to the receptor of platelet activating factor leading 
to competition between the two bacteria. Since phosphorylcholine is antigenic, 
antibodies raised against one species of bacteria can cross-react and aid in the 
clearance of various bacterial species also expressing phosphorylcholine (Pericone et 
al., 2000). Bogaert et al and Regev-Yochay et al have shown an age effect on the 
dominant pathogen colonising the nasopharynx. S. aureus colonizes the nasopharynx 
of 50% of children by the age of 10 years compared to 10% in their early years, whilst 
S. pneumoniae colonisaton was highest in infants (43%). Bogaert et al performed a 
cohort study on age-dependent carriage in children and adults aged 1-19 years and 
found that the peak of S. pneumoniae colonisation was 55% at the age of 3 years, 
declining to 8% after the age of 10 years. Other factors of relevance in S. pneumoniae 
colonisaton include socioeconomic background and environmental factors such as the 
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number of siblings, larger family size, income, smoking, children attending day care 
centre and previous respiratory viral infections (Vives et al., 1997) (Bogaert et al., 
2004). The incidence of nasopharyngeal carriage in children in developing countries 
such as Gambia (Lloyd-Evans et al., 1996), Pakistan (Mastro et al., 1993), Papua 
New Guinea (Gratten et al., 1989), Zambia (Frederiksen and Henrichsen, 1988), 
Australian aborinal infants (Watson et al., 2006) and the Philippines (Lankinen et al., 
1994) is higher than in developed countries. 
 
1.2.2 Diseases caused by S. pneumoniae 
S. pneumoniae causes less severe mucosal infections such as sinusitis and acute otitis 
media and also causes more severe diseases such as pneumonia, septicaemia, 
meningitis. Transition from an asymptomatic carrier state to disease causing state 
occurs when the bacteria are aspirated from the nasopharynx into the lungs causing 
pneumonia or when the bacteria penetrate the nasopharyngeal mucosa and invade the 
blood stream to cause septicaemia and invasion across the blood-brain barrier leading 
to meningitis (Figure 1.1). S. pneumoniae also invades the blood from the lungs as a 
consequence of pneumonia. Risk of invasive disease after pneumococcal colonisation 
is higher in certain ethnic groups such as African American, Native American and 
Alaskan native population.  
 
(a) Acute otitis media 
Acute otitis media (AOM) is a common infection of the middle ear and is associated 
with the upper respiratory tract infections in up to 90% children. Nasopharyngeal 
carriage is the main risk factor for bacterial AOM. S. pneumoniae serotypes isolated 
from the nasopharynx and the middle ear during AOM are usually the same (Syrjanen 
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et al., 2005), and the rate of nasopharyngeal carriage is higher in children with 
respiratory infections and AOM (Syrjanen et al., 2001). A Finnish cohort study 
performed in children found S. pneumoniae in 26% of patients with AOM, with most 
of the other cases due to M. cattarrhalis (23%) and H. influenzae (23%) (Kilpi et al., 
2001). Synergy between S. pneumoniae and the influenza viruses has been reported 
(Syrjanen et al., 2005) (McCullers, 2006) in which a previous viral infection of the 
respiratory tract helps the establishment of bacterial superinfection. Influenza virus 
induces epithelial damage, and impairs the ability of respiratory epithelium to clear 
pathogens. Furthermore, the neuraminidase activity of the virus cleaves the terminal 
sialic acid from the cell surface aiding S. pneumoniae adherence (McCullers, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Diseases caused by S. pneumoniae 
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(b) Septicaemia 
Septicaemia is a systemic infection during which the bacteria invade in to the blood 
and multiply, and may seed other sites to cause focal disease. Septicaemia caused by 
S. pneumoniae usually occurs secondary to pneumonia, but S. pneumoniae is also 
capable of establishing bacteremia in the absence of evidence of infection, 
presumably due to direct invasion from the nasophayrnx, a phenomena observed in 
15% of cases of bacteremia in children (Gillespie and Balakrishnan, 2000). The 
incidence of bacteremia caused by S. pneumoniae is higher than bacteremia caused by 
other bacterial pathogens such as H. influenzae, N. meningitidis and S. aureus in 
children ≤ 1 year, the incidence decreasing with age (Schutzman et al., 1991; Eskola 
et al., 1992; Brent et al., 2006). The incidence of bacteremia is also high in people 
over 65 years of age, and in adults with predisposing medical conditions (Breiman et 
al., 1990). Other factors contributing to the high incidence of bacteremia are ethnicity, 
living conditions such as crowding, socioeconomic conditions such as family size, 
active / passive smoking and recent antibiotic use and age. The incidence of invasive 
S. pneumoniae infection in certain ethnic groups such as Alaskan natives were 4 times 
higher than non-natives and are associated with lack of breast feeding, attendance of 
day care centre and smoking tobacco (Gessner et al., 1995; Davidson et al., 1994). 
 
(c) Pneumonia 
S. pneumoniae is the commonest cause of community acquired pneumonia (CAP) 
(Lim, 2004). Translocation of the pneumococci from the nasopharynx into lower 
respiratory tract (lungs) is thought to occur through microaspiration (Obaro and 
Adegbola, 2002). S. pneumoniae is particularly likely to be established in the lungs in 
conditions where the host’s structural barriers are altered such as damage to epithelial 
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lining and ciliary function following respiratory viral infection and smoking. The 
incidence of pneumonia is increased in metabolic and nutritional abnormalities such 
as diabetes mellitus and vitamin A deficiency (Obaro and Adegbola, 2002) and in 
patients with impaired immunity such as HIV infection, patients on 
immunosuppressive therapy and congenital immunoglobulin and complement 
deficiences (Bogaert et al., 2004). Respiratory tract infections with influenza virus 
and / or S. pneumoniae are a serious worldwide health problem and together are the 
6th leading cause of death worldwide (McCullers and Tuomanen, 2001). 
 
(d) Meningitis 
Meningitis is usually caused by nasopharyngeal colonisation with S. pneumoniae 
followed by asymptomatic bacteraemia and invasion of the central nervous system 
(CNS). S. pneumoniae meningitis has a 20% mortality and is particularly associated 
with moderate to severe neurological damage which is observed in 50% of the 
survivors (Arditi et al., 1998) (Muhe and Klugman, 1999). Invasion of the CNS 
occurs by crossing the blood-brain barrier but the mechanism used by S. pneumoniae 
to cause meningitis is not properly understood. In the CSF, S. pneumoniae can 
multiply and reach cell densities of 109 cfu ml-1, which induces a strong inflammatory 
reaction in response to cell wall components after autolysis of the bacteria. 
Proinflammatory cytokines (TNF-α, IL-1 and IL-6) and chemokines [IL-8, 
macrophage inflammatory protein (MIP-1 and MIP-2)] are known to be raised, which 
leads to the recruitment of macrophages and granulocytes for the clearance of 
bacteria. The neurological damage partially results as a consequence of the severity of 
the inflammatory reaction to S. pneumoniae (Meli et al., 2002). 
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1.3 VACCINES AGAINST S. PNEUMONIAE 
After S. pneumoniae was isolated and cultured by Sternberg and Pasteur 
simultaneously in 1881, pursuit for an effective vaccine against S. pneumoniae 
infections has continued until today. Although a whole-cell pneumococcal vaccine 
clinical trial performed in 1911 was unsuccessful, groundwork for the role of 
antibodies against S. pneumoniae capsular polysaccharide was laid which initiated the 
development of the polyvalent pneumococcal capsular polysaccharide vaccine 
(Reinert, 2004). At present, the pneumococcal capsular polysaccharide vaccines 
(PPV) and pneumococcal conjugate vaccine (PCV) have their own advantages and 
disadvantages. Protein based vaccines may offer some advantages over the PPV and 
are also currently under investigation.  
 
(a) S. pneumoniae serotype distribution 
As the existing vaccines protect against specific S. pneumoniae serotypes, the 
distribution of disease causing serotypes will dictate the potential efficacy of the 
vaccine at reducing S. pneumoniae disease. There are more than 90 serotypes of S. 
pneumoniae and the serotype distribution varies with geographic area and age group. 
In the USA, serotypes 4, 6, 9, 14, 18, 19, 23 causes 80-90% of invasive diseases, and 
in Europe the same serotypes cause 61-81% invasive diseases in children. In India, 
serotypes 14, 8, 19F, 7 and 11 are known to cause systemic and ophthalmic infections 
(Kar et al., 2006) and serotypes 1, 6, 19, 5, 23 and 7 are prevalent in south India, with 
serotype 1 being the main cause of meningitis and pneumonia (Kanungo and 
Rajalakshmi, 2001). In Taiwan, serotypes 14, 23F, 6B, 19F, and 3 were found to be 
prevalent in 1999-2004. The reasons for the variation in serotype prevalence with 
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geographic location are unclear, but could include socio-economic status and 
differences in the age distribution in the study population (Hausdorff, 2002). 
 
Table 1.1 S. pneumoniae serotype distribution causing invasive pneumococcal diseases 
(IPD) in various parts of the world (Hausdorff, 2002, Sleeman et al, 2001) 
 
 
 
(b) S. pneumoniae capsular polysaccharide vaccines 
The pneumococcal capsular polysaccharide vaccine is a polyvalent vaccine based on 
the formulation of various capsular polysaccharide antigens. In 1977, a 14-valent 
capsular PPV was licensed first and was followed by a 23-valent vaccine in 1983 
which is still in current use (French, 2003). The capsular polysaccharide antigens 
included are from 23 serotypes of S. pneumoniae that commonly cause invasive 
disease and provides a broad spectrum of protection (up to 90% of invasive strains) 
even though the epidemiology of the distribution of serotypes differs according to the 
geographical area (Jefferson and Demicheli, 2002). In the U.S.A, PPV are 
recommended for elderly people aged 65 and over, and in children above 2 years or 
adults with the predispositions to S. pneumoniae infections. Although the PPV is 
effective in healthy adults, it is not recommended to children under the age of 2 years 
as it only induces a T-cell independent immune response (TI) which is ineffective in 
S.  pneumoniae ST causing IPD Geographical distribution of IPD  ST
s 
Developing countries 1, 5, 7, 14, 19, 23 
Latin America, W. Europe 1, 3, 4, 6, 7, 9, 14, 15, 18, 19, 23   
United Kingdom. 1, 3, 4, 6, 7, 8, 14, 18, 19    
Australia, Canada, U.S.A. 4, 6, 9, 12, 14, 18, 19, 23  
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infants. The antibody concentration and protection induced by PPV wanes with time 
and this vaccine does not effectively induce protection in the elderly (French, 2003). 
Furthermore PPV induces protection mainly against septicaemia and meningitis and 
its efficacy at preventing S. pneumoniae pneumonia is poor (Huss et al., 2009; 
Moberley et al., 2008). 
 
(c) S. pneumoniae conjugate vaccines 
To improve the efficacy of PPV, epidemiologically important serotypes of S. 
pnemoniae are covalently coupled to protein carriers such as diphtheria toxoid (PncD 
conjugate vaccine), tetanus toxoid (PncT), and meningococcal outer membrane 
complex (OMPC). Covalent coupling of the polysaccharide antigens with the carrier 
proteins converts the immune response to T-cell dependent and increases the 
immunogenicity. 
The first PCV licensed in the U.S in 2000 was 7-valent vaccine conjugated to 
non-toxic mutant diphtheria toxoid (CRM197), commercially known as Prevenar® 
(Wyeth-Ayerst laboratories, Philadelphia, USA) and later introduced in Europe in 
2001. The serotypes present in the 7-valent PCV are 4, 6B, 9V, 14, 18C, 19F and 23F 
which cause 51-82% of invasive infections in children and 58% of those causing 
AOM. Two more PCVs, a 9-valent PCV including the additional serotypes 1 and 5 
and an 11-valent vaccine including the additional serotypes 3 and 7V are in clinical 
trials. Although the addition of 4 more serotypes covers 73-92% of invasive 
infections, increasing the vaccine valency within the limits of the quantity of protein 
carrier and also maintaining the immunogenicity is technically difficult. 
High antibody responses are observed in children to conjugate vaccines 
compared to no response to the unconjugated polysaccharide antigens (Feikin et al., 
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2004). In addition to children, other risk group such as elderly and 
immunocompromised patients (bone marrow transplant patients, HIV-infected 
people) who have shown suboptimal immunogenicity to polysaccharide vaccines have 
exhibited good antibody response to the conjugate vaccine (Reinert, 2004). Clinical 
trials have shown that conjugated vaccines are very effective at preventing invasive 
infections due to S. pneumoniae, and unlike the unconjugated vaccine also prevent 
pneumonia and otitis media in children (WHO report, 2007, 2008). In addition, the 
incidence of S. pneumoniae infections caused by vaccine serotypes in adults is 
reduced presumably due to herd immunity effects (WHO report, 2008). 
The main disadvantages with conjugate vaccines are the limitation of the 
number of capsular serotypes that could be used in vaccine formulation and high costs 
of its production. As more than 90 capsular serotypes are present and only a limited 
number of capsular serotypes are used in the conjugate vaccine, serotype replacement 
may occur, where the ‘vaccine serotype’ may be replaced by the ‘non-vaccine 
serotype’ (Singleton et al., 2007) (Munoz-Almagro et al., 2008). Similarly, the 
conjugate vaccine formulation may need to be varied based on the geographic area as 
the prevalence of serotypes in different countries may vary. Although 9 and 11 valent 
conjugate vaccines offer better protection against S. pneumoniae invasive diseases, 
nevertheless, as the number of serotypes increases, the cost of preparation increases. 
Due to this reason, there are major difficulties in introducing a conjugated vaccine to 
developing countries (Ortqvist, 2001). 
 
(d) S. pneumoniae protein vaccines and lipoproteins as vaccines 
The limitations posed by the polysaccharide and conjugate vaccines have stimulated 
research for an alternative S. pneumoniae vaccine. Targeting conserved antigens that 
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are important for survival of S. pneumoniae in the host could be a promising 
vaccination strategy and could be used as an alternative to the polysaccharide and 
conjugate vaccines. Protein based vaccines are known to induce a thymus-dependent 
immune response in young children contributing to immunological memory. Hence 
the development of a protein based vaccine can provide protection against most of the 
S. pneumoniae serotypes, thereby overcoming limitations of serotype-specific 
protection as observed in capsular polysaccharide vaccines and serotype replacement 
phenomenon observed in conjugate vaccines. Furthermore, protein based vaccines can 
be produced by relatively inexpensive recombinant DNA technology.  
Several S. pneumoniae protein antigens are being investigated and their 
efficacies as vaccines in animal models are currently under evaluation. Most of the S. 
pneumoniae proteins evaluated in animal models are cell surface proteins, although 
proteins that are secreted or cytoplasmic have also been invesitgated. Potential protein 
vaccine candidates that have shown protection in animal models are the choline 
binding proteins PspA and PspC (also called CbpA), the lipoproteins PsaA, PiaA and 
PiuA (Brown et al., 2001; Garmory and Titball, 2004; Jomaa et al., 2006), inactivated 
toxin Ply (Paton, 1998), PpmA, a putative proteinase maturation protein which is 
important during the secretion of proteins (Overweg et al., 2000), PrtA, a cell-wall 
associated precursor protein (Bethe et al., 2001) and PavA, a fibronectin binding 
protein (Swiatlo and Ware, 2003). As it is evident that these proteins contribute at 
different stages during pathogenesis, a combination of protein antigens rather than a 
single antigen may provide a superior degree of protection against nasopharyngeal 
carriage and invasive S. pneumoniae diseases (Ogunniyi et al., 2000), (Briles et al., 
2000; Brown et al., 2001; Jomaa et al., 2006). 
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(e) Live, killed and DNA vaccines 
Roche et al have used S. pneumoniae deletion mutant strains lacking capsular 
polysaccharide, pneumolysin and PspA as live attenuated vaccines. The live 
attenuated vaccine was able to colonise the upper respiratory tract, demonstrating 
significant increased levels of serum and mucosal antibody titres, and a single 
intranasal administration of the live attenuated vaccine without adjuvant was 
sufficient to induce both systemic and mucosal protection against S. pneumoniae 
challenge (Roche et al., 2007). Oliveria et al have expressed PsaA antigen in certain 
species of lactic acid bacteria such as Lactobacillus casei, L. plantarum, and L. 
helveticus. Following the intranasal inoculation of these lactic acid bacteria 
expressing PsaA in mice, increased levels of specific IgG and IgA antibodies were 
obtained. Also the intranasal immunisation with these recombinant lactic acid bacteria 
reduced the nasopharyngeal colonisation upon S. pneumoniae challenge (Oliveira et 
al., 2006). Similar experiments performed by Campos et al in L. casei expressing 
PspA as mucosal vaccine in mice induced specific anti-PspA antibodies, deposition of 
complement on the surface of S. pneumonaie and led to increased survival of 
immunized mice after a systemic challenge with S. pneumoniae (Campos et al., 
2008). Hvalbye et al demonstrated that the intranasal immunisation of mice with heat 
inactivated S. pneumoniae (serotype 4) induced specific anti-capsular polysaccharide 
antibodies in serum and mucosal secretions. Following intraperitoneal S. pneumoniae 
serotype 4 challenge, the intranasally immunised mice were protected against both 
systemic and pulmonary infection (Hvalbye et al., 1999). Lesinski et al have 
synthesised the oligodeoxynucleotides encoding the peptide mimic of the serotype 4 
capsular polysaccharide of S. pneumoniae, which was then ligated into an expression 
vector and used for the immunisation in Balb/c mice. Epidermal immunisation of this 
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DNA vaccine in Balb/c mice was able to elicit antibodies specific to serotype 4 
capsular polysaccharide of S.pneumoniae (Lesinski et al., 2001). Ferreira et al have 
shown that the DNA vaccine vectors expressing the N-terminal region of PspA confer 
systemic protection against S. pneumoniae in the intraperitoneally immunised mice, 
and that the level of protection using PspA as a DNA vaccine was similar to that of 
protection observed with PspA as protein vaccine (Ferreira et al., 2006). Moore et al 
have demonstrated protection against serotype 4 S. pneumoniae in the CBA/N mice 
immunised with PspA DNA and PspA protein using prime / boost strategy and have 
demonstrated enhanced antibody response using this method (Moore et al., 2006). 
Table 1.2 summarises the different approaches of experimental immunisation and the 
efficacy as vaccine candidates are evaluated based on the survival rate after S. 
pneumoniae challenge. 
Identifying novel conserved protein antigens and investigating the best protein 
combinations and / or alternate vaccines such as DNA, live and killed vacines may 
provide an alternative method to PPV and PCV vaccines that are effective at 
preventing S. pneumoniae nasopharyngeal carriage and invasive infection. However, 
there is lack of consensus of best method to compare the efficiency of the vaccine 
candidates due to variations in mouse strain, route of infection, bacterial strain, and 
adjuvant used. 
 
1.4 VIRULENCE FACTORS INVOLVED IN THE PATHOGENESIS OF S. PNEUMONIAE 
INFECTIONS 
As discussed above, S. pneumoniae inhabit the nasopharynx as a commensal and 
spread to different hosts as an aerosol or by mucosal contact (Hava et al., 2003). 
During invasive disease, various virulence factors of S. pneumoniae contribute to the  
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Vaccine candidates Route of immunisation /  
Whether successful 
In vivo models References 
Pneumolysin 
(Ply) 
IN (Yes), IP 
(Yes) 
Mic
e  
Briles et al. 2003, 2000, Ogunniyi et 
al. 1996   
Pneumococcal 
surface  
adhesin A (Psa A) 
IV (Yes), IP 
(No) 
Mic
e  
Seo et al. 2002, Gor et al. 2002, Talkington et 
al. 1996  
Pneumococcal 
surface  
protein A (Psp A) 
IN (Yes), IV 
(Yes),  
IP (Yes) 
Mic
e  
Briles et al. 2000, 2003, Arulanandam et 
al. 2001   
Pneumococcal 
surface  
protein C (Psp C) 
IN (No), IV 
(Yes),  
IP (Yes) 
Mic
e  
Ogunniyi et al. 2001, Balachandran et 
al. 2002   
Pneumococcal histidine 
triad  
A, B, D, E (Pht A, B, C, 
D) 
SC 
(Yes) 
Mic
e  
Adamou et al. 2001, Hamel et al. 2004, Zang et 
al. 2001  
Neuraminidase A 
(Nan A) 
IP (No), IN 
(Yes) 
Chinchilla, 
mice  
Long et al. 2004, Lock et al. 
1988  
 Table 1.2: Different approaches of immunisation against S. pneumoniae  
Autolysin A (lyt 
A) 
IN (No), IP 
(Yes) 
Mic
e  
Berry et al. 1989, Lock et al. 
1992   
Pneumococcal 
iron  
 utilisation A (Piu 
A) 
IN (Yes), IP 
(Yes) 
Mic
e  
Brown et al. 2001, Jomaa et al. 
2005 
Pneumococcal 
iron 
acquisition A (Pia 
A) 
IN (Yes), IP 
(Yes) 
Mic
e  
Brown et al. 2001, Jomaa et al. 
2005 
Novel surface proteins  
(Sp46, Sp91, Sp128, 
Sp130) 
SC 
(Yes) 
Mic
e  
Wizemann et al. 
2001   
Protein 
vaccines 
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Vaccine 
candidates 
Route of immunisation /  
Whether successful 
In vivo 
models 
Referenc
e 
DNA vaccines + protein 
boost 
psp A DNA + Psp A 
protein 
IM 
(Yes) 
Mic
e  
Moore et al. 
2006 
Mutant of cps, psp A 
and ply  
IN 
(Yes) 
Mic
e  
Roche et al. 
2007 
psa A, psp A gene 
expressed  
in lactic acid bacteria  
IN 
(Yes) 
Mic
e  
Oliveira et al. 2006, Campos et 
al. 2008 
Killed S. pneumoniae 
vaccines  
Heat inactivated 
serotype 4  
S. pneumoniae  
IN 
(Yes) 
Mic
e  
Hvalbye et al. 
1999 
IP: Intraperitoneal, IM: Intramuscular, IN: Intranasal, IV: Intravenous, SC: Subcutaneous, cps: capsular polysaccharide. Partly 
adapted from Tai,S.S., 2006. 
Live attenuated S. pneumoniae 
vaccines 
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establishment of the bacteria in different parts of the human body such as ear, lungs, 
blood and brain. Stages important for the development of invasive S pneumoniae 
disease can be divided into the following categories:  
(1) adhesion to nasopharyngeal epithelium 
(2) invasion of underlying tissue and the blood. 
(3) evasion of the host’s immune response  
(4) induction of inflammation and direct tissue damage 
(5) replication and growth in vivo 
(6) co-ordinated expression of genes responsible for S. pneumoniae growth and 
survival at different stages of infection 
Nasopharyngeal epithelial adhesion is the prerequisite for S. pneumoniae 
colonisation which may progress to invasion of the underlying tissues and further 
dissemination of the bacteria into the blood. While stages 3, 5 and 6 are essential for 
nasopharyngeal colonisation of S. pneumoniae, invasive infection also leads to stage 
4, the induction of inflammation. These stages of infection do not necessarily occur in 
a sequential manner; for example, although invasion usually follows adhesion, growth 
in vivo and coordinated expression of genes in reaction to environmental changes will 
occur continuously. 
Various S. pneumoniae virulence factors contribute to each of these stages and 
their involvement in pathogenesis is discussed in the following section (Table 1.3). 
 
1.4.1 Adhesion 
Adherence of S. pneumoniae to the mucosa of the nasopharynx is the first step to 
either remain as a commensal or to progress to cause an invasive disease. S. 
pneumoniae engages cell surface proteins, enzymes and other surface molecules to  
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Fig 1.2: Schematic diagram of various virulence factors involved in S. pneumoniae 
adherence to host cells. Adapted from Bogaert et al., 2004. 
 
successfully adhere to the host’s tissues. These virulence factors not only initiate the 
adherence but also promote the localised persistence / colonisation of S. pneumoniae, 
which would otherwise be cleared from the nasopharynx by the host’s physiological 
fluids such as mucus and saliva. S. pneumoniae virulence factors often exhibit 
specificity for the host’s cell surface receptors and mediate adhesion (Fig 1.2). Some 
of the identified S. pneumoniae virulence factors known to contribute to S. 
pneumoniae adherence including the capsule, IgA1 protease, phosphorylcholine, 
neuraminidases, exoglycosidases, pneumococcal surface adhesin, choline binding 
protein A, pneumococcal adhesion and virulence factor A, streptococcal lipoprotein 
rotamase and the newly identified streptococcal pili and are discussed below.  
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(a) Capsule 
The capsule of S. pneumoniae is the outermost covering comprised of polysaccharide. 
A possible role of the S. pneumoniae polysaccharide capsule in the nasopharyngeal 
colonisation has been recently identified by Nelson et al using both in vitro and in 
vivo methods. Histological observations of the nasal tissue of mice following 
intranasal inoculation of the S. pneumoniae wild-type and mutant unencapsulated 
strains demonstrated that the encapsulated S. pneumoniae were able to remain on the 
mucosal surface for as long as 2 weeks, suggesting the establishment of a stable 
nasopharyngeal colonisation. Unlike the wild-type strain, the unencapsulated strain of 
S. pneumoniae was agglutinated in the luminal mucus, and was unable to transit to the 
mucosal surface suggesting a role of capsule in avoiding mucus-mediated clearance of 
S. pneumoniae from the nasopharynx (Nelson et al., 2007). A probable mechanism for 
the evasion of the mucosal entrapment of encapsulated S. pneumoniae is thought to be 
the electrostatic repulsion created due to similar negative charge imparted by sialic 
acid of the mucus and the S. pneumoniae capsular polysaccharide. This electrostatic 
repulsion created between mucus and the S. pneumoniae capsule may hinder 
mucociliary clearance of S. pneumoniae in the nasal passage and thereby contribute to 
the early stages of S. pneumoniae colonisation (Nelson et al., 2007). 
 
(b) IgA1 protease 
IgA1 proteases are enzymes produced by S. pneumoniae and other bacteria residing in 
the upper respiratory tract. These enzymes cleave the IgA1 immunoglobulin which 
comprises of over 90% of IgA antibody in the respiratory secretions. IgA1 proteases 
produced by S. pneumoniae are cell wall associated (Weiser, 2006), and specifically 
cleave the proline-threonine or proline-serine peptide bonds at the hinge region of 
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human IgA1, thereby separating the Fab fragments (antigen-binding region) from the 
Fc fragment (responsible for secondary effector functions) of the IgA1 antibody. It 
has been suggested that following binding of the host’s IgA1 antibodies to S. 
pneumoniae capsular polysaccharide, secreted IgA1 protease cleaves the Fc region of 
the IgA1 antibody, and this facilitates S. pneumoniae adhesion to host cells. The 
authors have shown that the incubation of encapsulated, IgA1 protease producing S. 
pneumoniae strain with human IgA1 antibody increased the adherence of S. 
pneumoniae to the Detroit cell line (a human pharyngeal epithelial cell line), where as 
S. pneumoniae mutant strains unable to produce IgA1 protease failed to adhere to the 
Detroit cell line upon treatment with IgA1 antibody. The suggested mechanism 
behind IgA1 protease mediated S. pneumoniae adherence is that the ionic interactions 
between IgA1-Fab and the S. pneumoniae polysaccharide capsule strips the S. 
pneumoniae polysaccharide capsule from the bacteria, thereby unmasking the cell 
wall phosphorylcholine (PC) of S. pneumoniae. The cell wall PC of S. pneumoniae 
can then interact with the platelet activating factor receptor (PAFr) present on the host 
epithelial cells for the adherence (Weiser, 2006). However, the specificity of S. 
pneumoniae IgA1 protease to human IgA1 antibodies prevents effective experiments 
in mouse models of infection to support the above in vitro data (Weiser et al., 2003). 
 
(c) Phosphorylcholine (PC) 
The cell wall of S. pneumoniae plays a very important role in the adhesion of S. 
pneumoniae to the host tissues. The cell wall of S. pneumoniae is composed of 
peptidoglycan, teichoic acid (TA) and lipoteichoic acid (LTA). Although LTA is 
chemically identical to TA, LTA is attached to the cell membrane by a lipid moiety. 
Both LTA and TA contain phosphorylcholine (PC), which plays a major role in S. 
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pneumoniae adhesion and also anchors an important class of S. pneumoniae surface 
proteins called choline binding proteins (CBPs). The role of PC in the adherence of S. 
pneumoniae during asymptomatic colonisation is unknown but in vitro and in vivo 
experiments have demonstrated an important role of PC in the adherence of S. 
pneumoniae during the conversion from an asymptomatic colonisation to the onset of 
an invasive disease. Studies have demonstrated that PC of S. pneumoniae has 
increased affinity for a host cell surface receptor, PAFr which is present only on the 
activated cells, therefore enhancing S. pneumoniae adherence in the presence of 
inflammation (Prescott et al., 2000). PAFr is a G-protein coupled receptor for the 
platelet activating factor (PAF), a glycerophospholipid which is produced 
predominantly by platelets as well as epithelial cells, endothelial cells, neutrophils and 
macrophages. In vitro studies have demonstrated PC mediated adherence of S. 
pneumoniae to human endothelial, epithelial and PAFr-transfected COS-7 cells 
(Cundell et al., 1995) and human tracheal epithelial cells in vitro ((Ishizuka et al., 
2001). Furthermore, Cundell and colleagues have demonstrated the interaction of S. 
pneumoniae PC with the PAFr in an in vivo rabbit model of pneumonia. The authors 
have observed that following administration of exogenous IL-1 during the intranasal 
challenge of S. pneumoniae in rabbits, there was an increased recovery of S. 
pneumoniae from the bronchoalveolar lavage than from control rabbits, while 
administration of a PAFr antagonist reduced the colonisation and progression to 
pneumonia by >90% (Cundell et al., 1995). Further evidence for the importance of PC 
has been provided by the studies of the cell wall hydrolase, phosphorylcholine 
esterase, Pce (CbpE) which modulates the amount of PC on the S. pneumoniae cell 
wall. Inactivation of the gene encoding Pce causes an altered S. pneumoniae colony 
morphology and decreased colonisation of the nasopharynx in rats (Vollmer and 
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Tomasz, 2001). Pce has also been shown to be important for the virulence of some S. 
pneumoniae strains, such as a serotype 3 strain, possibly by increasing the choline 
residues on the cell wall thereby increasing the affinity to PAFr and hence invasion 
(Hammerschmidt, 2006). 
 
(d) Neuraminidases (NanA, NanB, NanC) 
Neuraminidase enzymes are another group of virulence factors produced by S. 
pneumoniae. These enzymes cause damage to the host tissue by cleaving the terminal 
sialic acid of glycans, mucins and glycoproteins present on the cell surface, which is 
thought to expose receptors that facilitate S. pneumoniae adherence and invasion of 
the host tissues. To date three neuraminidases have been identified, NanA and NanB 
with molecular weight of 108 and 75 kDa respectively (Camara et al., 1994) and 
NanC which is a homologue of NanB, with as yet unknown function. Both NanA and 
NanB are produced by all S. pneumoniae strains, however NanC, a homologue of 
NanB, is produced by only some strains of S. pneumoniae (Pettigrew et al., 2006). 
NanA and NanB exhibit very little homology at the amino acid level and the activity 
of NanA is much higher than NanB (Jedrzejas, 2001). Both enzymes are exported 
proteins, however NanA has a C-terminal LPXTGX motif suggesting that it is 
covalently anchored to peptidoglycan. It is unclear why S. pneumoniae produces two 
neuraminidases, but it has been suggested that they may function at different stages 
during adhesion or invasion and this is supported by the differences in their molecular 
weights and optimum pH (maximum activity of NanA at pH 5.0, and of NanB is at 
pH 7.0) (Berry et al., 1996; Jedrzejas, 2001). Both NanA and NanB have been shown 
to be important for colonisation, pneumonia and sepsis (Manco et al., 2006). 
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(e) Exogylcosidases 
Glycosylated human cell surfaces aid in functions such as cell-cell interactions and 
binding and transport of positively charged molecules. Glycosylation of human cell 
surface involves the deposition of sugar residues on the inner mannose residues with 
later elongation by linkage of N-acetylglucosamine (GlcNAc), then galactose residues 
which are further linked to sialic acid residues (King et al., 2006). S. pneumoniae 
recognises and cleaves the glycosylated surface of the host’s nasopharyngeal 
epithelium to aid its adherence. S. pneumoniae has been shown to produce cell-
surface associated enzymes, known as exoglycosidases. These include NanA (Camara 
et al., 1991), β-galactosidase (BgaA) (Zahner and Hakenbeck, 2000) and β-N-
acetylglucosaminidase (StrH) (King et al., 2006). NanA contributes to the adhesion of 
S. pneumoniae by cleaving the terminal sialic acid present on the host epithelial cells 
as discussed in an earlier section. BgaA, another S. pneumoniae exoglycosidase, 
specifically cleaves the terminal β(1-4) galactose linked to GlcNAc, and StrH cleaves 
the terminal β 1-linked N-acetylglucosamine residues on the host cell surfaces. 
Studies have shown that NanA, BgaA and StrH cleave the terminal sialic acid, 
terminal galactose and terminal N-acetylglucosamine in a sequential manner to expose 
the mannose residues necessary for the adherence of S. pneumoniae (King et al., 
2006). Although in vivo studies of colonisation in infant rats demonstrated no 
attenuation of virulence following the intranasal inoculation of the S. pneumoniae 
triple mutant strain of nanA, bgaA and strH, in vitro this triple mutant showed 
significant reduction in adherence to the Detroit cell line when compared to the wild-
type S. pneumoniae (King et al., 2006). These results suggest that although NanA, 
BgaA and StrH contribute to S. pneumoniae adherence in vitro the role in vivo of 
these exoglycosidases remains unclear. 
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(f) Pneumococcal surface adhesion (PsaA) 
PsaA is a 37-kDa surface lipoprotein component of a S. pneumoniae manganese 
uptake ATP binding cassette transporter (ABC transporter) (Berry and Paton, 1996). 
psaA
- mutants have reduced degree of adhesion to type II pneumocytes (A549 cell 
line) (Berry and Paton, 1996) and the Detroit cell line (D562) (Romero-Steiner et al., 
2003) suggesting that PsaA is important for the nasopharyngeal colonisation. PsaA 
belongs to a family of surface associated proteins called lipoprotein receptor-
associated antigen I (Lra I) and the PsaA homologues such as FimA of Streptococcus. 
parasanguis (Burnette-Curley et al., 1995), ScaA of Streptococcus gordonii 
(Kolenbrander et al., 1998) SsaB of Streptococcus sanguis (Ganeshkumar et al., 
1993) are identified to function as adhesins and some also transport manganese 
(Kolenbrander et al., 1998). It is unclear why a cation ABC transporter affects 
adhesion, and it may be that the secondary effects of loss of manganese uptake cause 
the reduced adhesion of psaA- strains to the epithelial cells. However, a recent study 
by Anderton et al. has demonstrated that the PsaA protein of S. pneumoniae 
specifically binds to the transmembrane glycoprotein, E-cadherin, in D562 
monolayers (Anderton et al., 2007). So perhaps PsaA in common with many virulence 
factors has dual functions during infection, acting as both a direct adhesin and for 
manganese uptake.  
 
(g) Pneumococcal surface protein C / Choline binding proteinA (PspC / CbpA) 
CbpA is a cell surface expressed CBP. CbpA, also known as PspC, SpsA (S. 
pneumoniae secretory IgA binding protein) and Hic (Factor H binding protein) has 
multiple functions in adhesion during carriage and lung infection (Balachandran et al., 
2002). CbpA is known to bind to the human polymeric Ig receptors (hpIgR) produced 
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by human nasopharyngeal cell lines in vitro (Zhang et al., 2000). pIgR is synthesised 
and exported to the apical surface of epithelial cells. Once at the cell surface, the 
secretory component of pIgR is released which then binds to IgA, forming secretory 
IgA (SIgA) (Phalipon and Corthesy, 2003). It has been suggested that the presence of 
excess free secretory component of IgG and secretory IgA (SIgA) in the mucosal 
cavity may lead to the binding of CbpA to SIgA or IgG, thereby aiding the adhesion 
of S. pneumoniae to the nasopharynx (Elm et al., 2004; Hammerschmidt et al., 1997). 
This has been supported by in vivo studies, where S. pneumoniae mutant strains 
deficient in CbpA have reduced colonisation of infant rats nasopharynx (Rosenow et 
al., 1997). In addition, S. pneumoniae nasopharyngeal colonisation is reduced in pIgR 
knockout mice (Zhang et al., 2000; Hammerschmidt, 2006). 
In addition to the pIgR binding, S. pneumoniae CbpA also exhibits binding to 
the complement components C3 (Smith and Hostetter, 2000) and factor H (fH, a 
glycoprotein and also functions as fluid phase regulator of host’s complement 
components). Surface bound fH on S. pneumoniae has been shown to prevent the 
complement mediated opsonophagocytosis of S. pneumoniae (Dave et al., 2001) and 
will be discussed in evasion of immunity section. A recent study has demonstrated 
that host cell surface fH bound to CbpA thereby mediating the adherence of S. 
pneumoniae to the nasopharyngeal cells (D562 cell line), lung epithelial cells (A549 
cell line) and human brain derived endothelial cells in vitro (Hammerschmidt et al., 
2007). Furthermore, microarray analysis of gene expression demonstrated an 
upregulation of CbpA by S. pneumoniae attached to the nasopharyngeal epithelial 
cells (Detroit cells) in vitro, but not by the S. pneumoniae isolated from the blood and 
CSF of mice suggesting CbpA is important for the interaction of S. pneumonaie with 
epithelium (Orihuela et al., 2004). 
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(h) Pneumococcal adhesion and virulence factor A (PavA) 
Pneumococcal adhesion and virulence factor A (PavA) is an outer cell surface protein, 
although it lacks both the typical LPXTG anchorage motif of Gram positive cell wall 
associated proteins or choline binding domains typical of CBPs. PavA binds to 
immobilized fibronectin, a mammalian glycoprotein present in either soluble or less 
soluble forms. The soluble form of fibronectin is present in body fluids such as 
plasma, CSF and amniotic fluid, whereas the less soluble form is present in the 
extracellular matrix and basement membrane (van der et al., 1995). Binding to 
fibronectin is observed for the oral bacterium, S. gordonii, which belongs to the mitis 
group of streptococci, and for other Gram positive bacteria such as S. aureus and S. 
pyogenes, and is thought to be important for adherence to epithelial cells. PavA of S. 
pneumoniae exhibits 67% amino acid identity to Fbp54, a fibronectin binding protein 
of S. pyogenes (Holmes et al., 2001). pavA- strains of S. pneumoniae exhibited 
reduced adherence to A549 and Hep-2 epithelial cells in vitro suggesting that it also 
has a role for adhesion of S. pneumoniae in the nasopharynx (Pracht et al., 2005). 
 
(i) Streptococcal lipoprotein rotamase (SlrA) 
SlrA is a S. pneumoniae lipoprotein and belongs to the family of peptidyl-prolyl 
isomerases (PPIases). Although the function of SlrA is not known, SlrA has been 
demonstrated to be important for the nasopharyngeal colonisation of S. pneumoniae in 
mice, as the mutant strains of SlrA exhibited increased clearance from the 
nasopharynx when compared to the wild-type S. pneumoniae. Moreover, in vitro 
adherence studies also demonstrated reduced adherence of the mutant strains of SlrA 
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to the Detroit cell line suggesting that SlrA may play an important role during 
adhesion of S. pneumoniae to the host cells (Hermans et al., 2006). 
 
(j) Pili 
The presence of the pili and their role in S. pneumoniae adhesion has been recently 
identified (Barocchi et al., 2006). S. pneumoniae pili are long appendages that extend 
beyond the polysaccharide capsule and S. pneumoniae capsular serotypes with better 
colonising and invasive potential such as serotype 4 and 19F have been identified to 
possess pili. The S. pneumoniae pilus is encoded by a pathogenicity island (PI), the rlr 
islet, which consist of DNA segments that differ in genetic content compared to the 
same location in strains that do not possess pili. PIs confer particular virulence traits 
on bacterial pathogens, and are often present in pathogenic but absent in non 
pathogenic strains of the same or related species (Hacker and Kaper, 2000). The rlrA 
pathogenicity islet is a cluster of 7 genes found in approximately 27% of the invasive 
S. pneumoniae isolates (Aguiar et al., 2008) . Of the 7 genes, three of them (rrgA, 
rrgB, rrgC) encode proteins with LPXTG motifs suggesting they are surface proteins, 
and 3 encode for the sortase homologues srtB, srtC and srtD which catalyse the 
covalent attachment of rrgA, rrgB, rrgC, which contain LPXTG motifs, to the 
bacterial cell wall (Hava et al., 2003). RrgA is an important pilus subunit and is 
responsible for increased adherence to the human respiratory epithelial cell line (A549 
cell line) in vitro (Nelson et al., 2007). S. pneumoniae mutant strains expressing no 
RrgA have a significant reduction in their adherence to the A549 cell line even though 
they still form pili, suggesting that the expression of RrgA on the pili is essential for 
adhesion. In support of the in vitro adherence studies, in a mouse model the rrgA- 
mutant strain was significantly reduced in its ability to colonise the nasopharynx 
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compared to the wild-type S. pneumoniae. In contrast, rrgB- and rrgC- mutant strains 
of S. pneumoniae did not exhibit any significant difference in vitro adherence studies 
or in nasopharyngeal colonisation of mice when compared to the wild-type S. 
pneumoniae (Nelson et al., 2007).  
 
(k) Phase variation 
S. pneumoniae undergoes a spontaneous but reversible phenomenon known as phase 
variation. Three different phase variants have been identified, transparent (T), 
semitransparent and opaque phase variants (O) (Weiser et al., 1994). T variants of S. 
pneumoniae are thought to be better colonisers of the nasopharynx due to the presence 
of high levels of TA and PC in the cell wall and higher expression of CbpA aiding 
adherence, whereas O variants are thought to be capable of escaping phagocytosis 
during blood stream infections or septicaemia because of the presence of more 
capsular polysaccharide (Cundell et al., 1995). The frequency of spontaneous phase 
variation is known to be strain specific among S. pneumoniae serotypes, and is 
relatively low. 
In vivo colonisation in the infant rat model demonstrated that the transparent 
variants of S. pneumonaie showed significantly higher nasopharyngeal colonisation 
than the opaque variants (Weiser et al., 1994). The in vivo observations were 
supported by the in vitro adhesion studies where the T variants of S. pneumoniae 
exhibited increased adherence compared to opaque variants to the buccal epithelial, 
cytokine-activated A549 lung epithelia (which leads to increased expression of PAFr 
on the cell surface), and vascular endothelial cell lines. In vitro adhesion assays of S. 
pneumoniae to various carbohydrate sugars, which represent the glycoconjugate 
receptors such as Gal, GalNAc, GlcNAc on the resting epithelial cell surface, 
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demonstrated increased adherence of T variants to these immobilized glycoconjugates 
compared to the O variants of S. pneumoniae (Cundell et al., 1995). These results 
suggest that phase variation of S. pneumoniae is an important phenomenon where the 
relative levels of capsule and PC expression are altered to enable better colonisation. 
Overall, a large range of virulence factors have been identified that influence 
S. pneumoniae adherence to cell lines, some of which are important for 
nasopharyngeal colonisation. Why there is such variety in adhesins and variety in 
their corresponding host ligands is not at all clear, and whether each adhesin has a role 
at different stages of infection or whether there is broad overlap in their particular 
roles and therefore a great deal of redundancy requires further investigation. 
 
1.4.2 Invasion of tissues 
Following S. pneumoniae adhesion to the nasopharynx, invasion of the underlying 
tissues to cause diseases such as pneumonia and / or meningitis occurs through the 
interaction of S. pneumoniae virulence factors with the host and probably as a 
consequence of the host inflammatory response as well. S. pneumoniae is known to 
produce enzymes and harbour surface proteins that degrade the host’s extracellular 
matrix (ECM) allowing access to deeper tissues and thus promoting invasion. 
Dissemination of S. pneumoniae into deeper tissues can occur by the paracellular 
route which involves breaking of tight junctions or by intracellular transmigration 
(transcytosis) of epithelial and endothelial cells. Intracellular transmigration requires 
the internalisation of S. pneumoniae by non-phagocytic host cells such as epithelial 
and endothelial cells and is thought to provide a survival advantage for bacteria which 
would otherwise be cleared by immune cells.  
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Some of the identified S. pneumoniae virulence factors known to contribute to 
tissue invasion include hyaluronidase, plasminogen binding proteins, PC, CbpA, 
PavA and pneumolysin are discussed below. 
 
(a) Hyaluronidase 
Hyaluronidase, an enzyme produced by S. pnemoniae degrades hyaluronic acid, a 
chemical component of the connective tissue. Degradation of the connective tissue 
helps in gaining access into the blood stream. It has been demonstrated that some S. 
pneumoniae strains with higher hyaluronidase acivity are capable of escaping into the 
blood brain barrier to cause meningitis (Kostyukova et al., 1995). S. pneumoniae 
strains isolated from patients with meningitis and meningoencephalitis have exhibited 
an increased hyaluronidase activity than strains isolated from patients with otitis 
media (Volkova et al., 1994; Gillespie and Balakrishnan, 2000). 
 
(b) Plasminogen (PLG) binding proteins 
S. pneumoniae possesses housekeeping enzymes which are involved in various 
metabolic functions, but certain housekeeping enzymes also contribute to virulence. 
Two key housekeeping enzymes of the glycolytic pathway, α-enolase (Eno) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) may have important roles for 
S. pneumoniae virulence (Bergmann et al., 2003). Both Eno and GAPDH are surface 
exposed and are displayed on the cell wall of S. pneumoniae and are proteolytic in 
nature. These enzymes lack the signal peptide and cell wall anchoring motifs and their 
mechanism of secretion is not known. Eno exhibits affinity to both plasminogen and 
plasmin and GAPDH to plasmin (Bergmann et al., 2004; Kolberg et al., 2006). 
Plasmin is an enzyme which is essential for the degradation of extracellular matrix by 
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fibrinolysis for vessel formation and angiogenesis. S. pneumoniae and other 
pathogens are known to bind to host plasmin which might facilitate invasion and 
further dissemination by leading to degradation of the extracellular fibrin matrix 
deposited at sites of infection. Plasminogen however is a pro-enzyme form of plasmin 
and its conversion to the active form is mediated by the host’s physiological 
plasminogen activators (PA) such as tissue-type PA or urokinase PA which hydrolyse 
plasminogen. However several streptococcal and staphylococal bacterial pathogens 
are known to secrete PAs which bind to plasminogen, including S. pneumoniae 
enolase and GAPDH (Ehinger et al., 2004). The inability of eno mutant strains of S. 
pneumoniae to dissolve fibrin and their attenuation in pulmonary mouse models of 
infection suggest the role of S. pneumoniae enolase in plasmin-mediated invasion of 
host tissues (Bergmann et al., 2005). 
 
(c) PC 
PC contributes to the invasion by facilitating the S. pneumoniae transmigration across 
the host cell barriers. In vitro transmigration studies were performed using 
monolayers of rat and human brain microvascular endothelial cells (BMEC) to 
understand the role of S. pneumoniae PC in tissue invasion. Transparent variants were 
able to transcytose from the apical surface to the basal surface of rat and human 
BMEC via binding of PC to the PAFr, even though both the transparent and opaque 
variants of S. pneumoniae were able to enter into the endothelial cells. This study 
demonstrates the selective preference of the S. pneumoniae transparent variants which 
exhibit higher levels of PC, therefore specific binding to the host’s cell-surface 
associated PAFr during tissue invasion when compared to S. pneumoniae opaque 
variants (Ring et al., 1998). 
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The in vivo models of S. pneumoniae invasion demonstrated reduced mortality 
and delayed progression to pneumonia in PAF-/- mice than the wild-type mice, 
following the intranasal inoculation of S. pneumoniae, suggesting the PAFr is 
exploited by S. pneumoniae to progress from adhesion to invasion (Rijneveld et al., 
2004).  
 
(d) Pav A  
Pav A has been shown to contribute not only to the adhesion but also invasion, as the 
PavA
- strains were attenuated in virulence both in murine pulmonary and also 
septicaemia models of S. pneumoniae infection. In vitro invasion studies 
demonstrated decreased internalisation of PavA- strains of S. pneumoniae by human 
brain-derived microvascular endothelial cells and human umbilical vein derived 
endothelial cells. These results suggest that PavA could be necessary for translocation 
of S. pneumoniae across cellular layers, although the mechanisms involved are not 
described (Pracht et al., 2005).  
 
(e) Pneumolysin (Ply) 
Pneumolysin is a toxin present in the bacterial cytoplasm with a molecular weight of 
35 kDa, produced by all the clinically important serotypes of S. pneumoniae. 
Pneumolysin belongs to the thiol-activated cytolysin family, which are cholesterol 
binding toxins that permeabilize the cell membrane, aggregate and fuse the cells to 
form a large vacuole (Tilley et al., 2005). Pneumolysin lacks the N-terminal signal 
sequence required for secretion and is known to be secreted during the late 
logarithmic growth phase and the release of pneumolysin is dependent on autolysin 
causing S. pneumoniae autolysis (Cockeran et al., 2002). Contradictory reports have 
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shown that the pneumolysin is also produced during the early logarithmic growth 
independent of autolysin and the mechanism may vary between strains of S. 
pneumoniae (Balachandran et al., 2001). 
Pneumolysin contributes to the host tissue invasion by disrupting the alveolar 
capillary boundary and cell junctions in the lungs. This in turn provides the required 
nutrients for S. pneumoniae and helps the penetration of the bacteria into the 
epithelium to obtain access to the blood stream (Jedrzejas, 2001). During acute otitis 
media, the hair cells of cochlea are highly sensitive to the cytotoxic effects of 
pneumolysin (Tuomanen, 2000). In vitro studies have demonstrated that exogenous 
pneumolysin and S. pneumoniae secreting pneumolysin causes severe damage to the 
human brain microvascular endothelial cell line representing an in vitro blood brain 
barrier suggesting its possible role during meningitis (Zysk et al., 2001). In vitro 
studies have also demonstrated that S. pneumoniae culture filtrates containing 
pneumolysin and pneumolysin alone are both capable of damaging the respiratory 
epithelium and slowing its ciliary function (Feldman et al., 1990). 
 
1.4.3 Evasion of host immunity 
For successful colonisation of the nasopharynx and / or the invasion of host’s tissue 
and blood S. pneumoniae will also have to evade the host’s immune response to 
infection. Clearance of bacterial pathogens from the host requires the innate and 
adaptive immune responses and the components of complement system are important 
in both these responses. The complement system consists of around 30 serum and cell 
surface proteins organised into three different enzyme cascades termed the classical, 
alternative and mannose binding lectin (MBL) pathways. Each pathway is activated 
by different mechanisms but all result in opsonisation of bacteria with breakdown 
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products (C3b and iC3b) of the central complement component C3 (Walport, 2001). 
Complement, in particular (Alper et al., 1970; Gross et al., 1978; Winkelstein, 1981; 
Sampson et al., 1982; Mold et al., 2002) the classical and alternative pathways, and 
phagocytosis (Giebink et al., 1977) are both vital for immunity to S. pneumoniae, and 
it is not surprising that S. pneumoniae has several mechanisms which affect these 
elements of host immunity as discussed below. 
 
(a) Polysaccharide capsule and cell wall 
The polysaccharide capsule is an important virulence determinant of S. pneumoniae 
and is thought to aid the bacterium by inhibiting complement activity and 
phagocytosis, thereby allowing the S. pneumoniae to multiply in the blood stream and 
possibly cause septicaemia. The capsule consists of high molecular weight polymers 
made up of repeating units of oligosaccharides containing 2-8 monosaccharides. 
Oligosaccharides such as glucuronic acid, arabinitol, ribitol and phosphorylcholine 
may be present in the capsule. More than 90 capsular serotypes have been identified 
based on the sugar composition and the linkages (Hardy et al., 2000). The degree of 
virulence of a particular serotype is dependent on the chemical composition rather 
than the thickness of the capsule, and perhaps reflects the varying ability of different 
serotypes to evade complement-dependent and independent opsonophagocytosis and 
hence to establish invasive infection (AlonsoDeVelasco et al., 1995). 
As well as conferring protection against phagocytosis and complement 
deposition, the capsule of S. pneumoniae inhibits neutrophil extracellular traps 
(NETs)-mediated killing. NETs are extracellular fibrous structures consisting of DNA 
backbone, histones and neutrophil granular proteins produced by activated neutrophils 
in the host as the first line defense against bacterial pathogens (Wartha et al., 2007). It 
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has been demonstrated that NETs capture S. pneumoniae thereby confining the 
infection, and reducing the spread of the bacteria to other parts of the host (Beiter et 
al., 2006). However encapsulated S. pneumoniae serotypes have reduced trapping by 
NETs and also exhibited resistance to NET-mediated killing. In addition to the 
polysaccharide capsule, D-alanylation of another surface- exposed polymer, the LTA 
of S. pneumoniae also confers resistance to NET-mediated killing. Incorporation of D-
alanine residues into LTA imparts positive charge on the bacterial surface thereby 
repelling the antimicrobial peptides (AMPs) secreted by neutrophils which are used to 
recognise and kill the bacteria. D-alanylation of LTA has been shown to contribute to 
the virulence of S. pneumoniae during the early stages of invasive infection when 
capsule expression is low (Wartha et al., 2007) 
 
(b) Pneumococcal surface protein A (PspA) 
Pneumococcal surface protein A (PspA) is a CBP which is anchored to the S. 
pneumoniae cell wall and has a molecular weight of 84 KDa. PspA is immunogenic 
and elicits protective antibodies (McDaniel et al., 1994). PspA prevents both classical 
and alternative pathway mediated C3b deposition on S. pneumoniae (Tu et al., 1999) 
and pspA- strains are reduced in virulence during systemic infection (Yuste et al., 
2005; Briles et al., 2000). Addition of anti-PspA antibodies enhanced the deposition 
of C3 on the surface of PspA+ strains of S. pneumoniae.  
PspA also interacts with human lactoferrin, an iron-binding glycoprotein 
present in milk and mucosal secretions that is also released by polymorphonuclear 
leukocytes during inflammation. Lactoferrin is bactericidal in nature and inhibits 
cytokine and complement activation, as well as potentially inhibiting bacterial growth 
by sequestering iron. Lactoferrin is formed of hololactoferrin, containing the binding 
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site for Fe2+ or Fe3+, and apolactoferrin. Apolactoferrin, is thought to be bactericidal 
by membrane destabilisation upon interaction with S. pneumoniae, and PspA is 
known to bind and prevent apolactoferrin-mediated killing of S. pneumoniae. 
Interaction of PspA with human lactoferrin has been demonstrated in fresh human 
saliva suggesting that PspA may contribute to carriage by preventing apolactoferrin-
mediated killing of S. pneumoniae (Shaper et al., 2004). 
 
(c) Pneumolysin  
In addition to the inhibition of the mucocliliary clearance (ie physical defences) by 
pneumolysin which has been discussed in the invasion of host tissues, pneumolysin 
also contributes to the evasion of host’s immunity. Pneumolysin is known to activate 
C1q directly or indirectly by binding to the Fc receptor of IgG in vitro thereby 
activating the complement by classical pathway (Rossjohn et al., 1998; Mitchell et al., 
1991). Using unvaccinated human sera and mice sera with no prior exposure to S. 
pneumoniae Yuste and collegues have demonstrated an increased in vitro C3 
deposition on the ply- mutant compared to wild-type S. pneumoniae. The above 
mentioned in vitro result was supported by in vivo mixed infection experiments in 
wild-type and complement-deficient mice demonstrating that pneumolysin affects 
classical pathway-mediated complement immunity against S. pneumoniae. Yuste and 
collegues have also showed that the PspA and pneumolysin interactions with 
complement are synergistic and allows the progress of infection from lungs to the 
blood (Yuste et al., 2005). However, it is not clear how pneumolysin prevents the 
complement deposition on S. pneumoniae. Extracellularly released pneumolysin may 
divert complement activity away from the bacterial surface and also consume the 
available C3 upon binding to C1q (Paton, 1996).  
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As well as preventing complement activity, pneumolysin has been shown to 
have direct inhibitory effects on white cells. In vitro results have shown that highly 
purified pneumolysin is capable of interfering with the bactericidal function of 
polymorphonuclear leukocytes (PMNL) and is shown to inhibit the PMNL 
antimicrobial function at an extremely low dose thereby enhancing the virulence of S. 
pneumoniae (Paton and Ferrante, 1983).  
 
(d) CbpA 
S. pneumoniae
 evades complement-mediated innate immunity by recruiting 
complement factor H (FH), a complement alternative pathway inhibitor. S. 
pneumoniae CbpA and its allelic variants (Janulczyk et al., 2000; Dave et al., 2001) 
have been demonstrated to bind to human FH. FH is a 155-kDa plasma glycoprotein, 
which inhibits the alternative pathway of the complement system by preventing the 
binding of factor B to C3b, enhancing the decay of the C3-convertase (C3bBb) and 
acting as a cofactor for the cleavage of C3b by complement factor I (Lu et al., 2006). 
Deposition of FH on host tissue and cellular surfaces prevents nonspecific damage and 
avoids the wasteful consumption of complement components (Lu et al., 2006). 
Interaction of CbpA with FH leads to the degradation of C3b, which further prevents 
the opsonisation of S. pneumoniae by the components of the alternative complement 
pathway (Shaper et al., 2004; Tai, 2006). Receptors similar to CbpA are expressed in 
other pathogenic bacteria that bind to FH such as M6 of group A streptococci 
(Kotarsky et al., 1998), YadA of Yersinia enterocolitica ((Roggenkamp et al., 1996), 
Por1A of N. gonorrhoea (Ram et al., 1998), and CRASP1 of Borrelia burgdorferi 
(Rossmann et al., 2007). Using an in vivo mouse model, mice intranasally infected 
with S. pneumoniae preincubated with FH had increased bacteraemia and lung 
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invasion compared to that of mice challenged with D39 alone (Quin et al., 2007). As 
discussed above, using in vitro adherence assays, Quin and collegues have also 
demonstrated that S. pneumoniae preincubated with FH showed increased adherence 
to human cell lines such as endothelial (HUVEC) and lung epithelial cells (SK-MES-
1).  
 
(e) Endonuclease A 
One of the characteristic features of S. pneumoniae pneumonia is the neutrophil 
infiltration to the site of infection. Recently it has been shown that the activated 
neutrophils release neutrophil extracellular traps (NETs) which are antimicrobial 
proteins bound to DNA scaffold. NETs not only function by killing the bacteria 
extracellularly but may confine the trapped bacteria in lungs during pneumonia 
thereby reducing the possible spread of the pathogen to cause septicaemia. Bacterial 
pathogens such as S. enterica, serovar Typhimurium, Shigella flexneri, S. aureus and 
the yeast Candida. albicans are trapped and killed by NETs. Although NETs are 
unable to kill S. pneumoniae, they prevent the rapid dissemination of S. pneumoniae 
to other compartments of the host. EndA produced by S. pneumoniae have the ability 
to degrade the extracellular DNA present in NETs (Beiter et al., 2006). endA mutant 
strains of S pneumoniae are unable to degrade NETs and after intranasal challenge in 
mice are out-competed by wild-type S. pneumoniae both in the lungs and the 
bloodstream (Beiter et al., 2006). 
 
1.4.4 Inflammation, tissue damage and the induction of septic shock 
Powerful inflammatory response may be mediated by immune cells such as 
macrophages during the bacterial clearance from the host or may also be triggered 
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directly by S. pneumoniae virulence determinants upon interaction with host cells. 
The inflammatory response consists of the release of cytokines in response to 
cytotoxic metabolites released upon recognition of the S. pneumoniae virulence 
determinants which are also called as pathogen associated molecular patterns 
(PAMPs). Inflammatory response may also occur as the result of S. pneumoniae 
mediated injury to host cells, activation of complement cascade, and the release of 
nitric oxide and H2O2 produced by the host and / or S. pneumoniae. The inflammatory 
response may lead to tissue injury and have detrimental effects on the host like septic 
shock. S. pneumoniae virulence determinants such as pneumolysin, cell wall 
components, autolysin and pyruvate oxidase that are known mediators of 
inflammation and tissue injury are discussed in this section. 
 
(a) Pneumolysin 
Pneumolysin by itself can reproduce the acute lung injury associated with fatal S. 
pneumoniae pneumonia (Feldman et al., 1991). Treatment of  a mouse model of 
disease with exogenous pneumolysin can cause increased lung vascular permeability, 
decreased resident alveolar macrophage population and recruitment of neutrophil and 
monocytes in the alveolar space (Maus et al., 2004). Pneumolysin is known to injure 
immune (Paton and Ferrante, 1983; Nandoskar et al., 1986) and respiratory cells 
(Rubins et al., 1993; Rubins et al., 1992) in vitro and is shown to activate the 
phospholipase A in the pulmonary artery endothelium. The activated phospholipase A 
breaks down different phospholipids present in the cell membrane and releases free 
fatty acids and lysophosphatides. The metabolites released due to lysophosphatides 
are cytotoxic and recruit activated neutrophils causing more lung injury and 
inflammation. The inflammation is further enhanced by pneumolysin as it is capable 
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of activating the classical complement pathway without the need of specific antibody 
(Paton et al., 1984). Pneumolysin is also known to induce the release of nitric oxide 
and inflammatory cytokines such as tumour necrosis factor-α (TNF- α), interleukin-6 
(IL-6) (Malley et al., 2003), and IL1β (Shoma et al., 2008; Malley et al., 2003; 
Houldsworth et al., 1994) by macrophages. Pneumolysin in combination with H2O2 
induces apoptosis of brain cells during experimental S. pneumoniae meningitis (Braun 
et al., 2002). Protection against S. pneumoniae infections is mediated by TLR-4 
mediated pneumolysin induced apoptosis (Srivastava et al., 2005; Malley et al., 
2003). Recently it has been demonstrated that S. pneumoniae pneumolysin activates 
nuclear factor of activated T cells (NFAT) signalling pathway independently of TLR 
which in turn upregulates the expression of inflammatory mediators (Koga et al., 
2008). Overall, pneumolysin has a variety of mechanisms which induce inflammation 
and seems to make a significant contribution to the strong pro-inflammatory nature of 
S. pneumoniae infection. 
 
(b) Cell wall and cell wall polysaccharides and Autolysin (LytA) 
Cell wall components of S. pneumoniae are mainly composed of peptidoglycan, TA 
and LTA induce acute inflammation during S. pneumoniae otitis media, septicaemia, 
pneumonia and meningitis. Cell wall components have been shown to mimic the 
symptoms of infection in animal models of otitis media (Ripley-Petzoldt et al., 1988), 
pneumonia (Tuomanen et al., 1987) and meningitis (Tuomanen et al., 1986). The 
majority of the inflammation associated with host defence could be driven by TA and 
LTA, which also can activate the alternative complement pathway (Winkelstein and 
Tomasz, 1978). LTA and TA bind to the acute phase reactant C-reactive protein 
(CRP) via their PC component and so can also activate the classical complement 
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pathway (Winkelstein and Tomasz, 1978). TA containing cell wall fragments have 
been shown to induce leukocytosis and increase vascular permeability in pneumonia 
(Tuomanen et al., 1987) and meningitis (Tuomanen et al., 1985) in animal models of 
infection. The S. pneumoniae cell wall is also responsible for the induction of 
cytokines such as IL-1, IL-6, TNFα and PAF upon binding to epithelia, endothelia and 
macrophages (Riesenfeld-Orn et al., 1989; Heumann et al., 1994; Cabellos et al., 
1992) and induce procoagulant activity on the surface of endothelial cells (Geelen et 
al., 1992). 
Autolysin (Lyt A) is an enzyme that lyses S. pneumoniae by degrading the cell 
wall components. Autolysin is a surface protein and belongs to CBPs anchored non-
covalently to the choline present in the cell wall instead of the usual type of anchorage 
using the LPXTG motif. Autolysin is produced during the late logarithmic growth 
phase and contributes to the inflammation by cell wall degradation and S. pneumoniae 
lysis as this releases LTA- and TA-containing cell wall products as well as 
pneumolysin (Gillespie and Balakrishnan, 2000). 
 
(c) Pyruvate oxidase (Spx) 
S. pneumoniae is a facultative anaerobe and due to its inability to produce catalase 
fails to neutralise reactive oxygen intermediates (ROI) and so produces large amounts 
of hydrogen peroxide (H2O2). In addition to the production of H2O2, S. pneumoniae 
infection also induces the production by host cells such as phagocytes, eosinophilic 
granulocytes and mononuclear phagocytes of anti-bacterial reactive nitrogen 
intermediates (RNI) and nitric oxide (NO). Although ROI and RNI produced by host 
cells are antimicrobial in nature, they also damage host cells and peroxynitrite, a toxic 
oxidant produced by combination of ROI and RNI compounds, cause cell death. 
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Although cytotoxicity due to the production of reactive intermediates by host cells is 
not completely understood, H2O2 produced by S. pneumoniae is apoptotic in nature 
(Hoffmann et al., 2006). 
 
1.4.5 Replication and growth in vivo 
As well as adhering to host tissues and avoiding immune responses, all pathogenic 
bacteria have to be able live and replicate in the physiological conditions found in the 
host, that is at a temperature of 37°C, an osmolality of approximately 290 
milliosmolality per kg, high oxygen tension, low availability of iron and other 
micronutrients and restricted nutritional opportunities. This has been emphasised by 
signature tagged mutagenesis (STM) screens for identifying genes involved in the 
virulence of micro-organisms, which usually identify large numbers of genes involved 
in growth and replication under stress conditions (Polissi et al., 1998; Lau et al., 2001; 
Hava and Camilli, 2002). One such group were sugar uptake and metabolism genes 
which included phosphotransferase system (PTS) and ABC transporters (Tettelin et 
al., 2001) 
Investigation of PPI1 (pathogenicity island 1) by Brown et al led to the 
identification of a three gene operon phgABC also required for the full virulence both 
in pulmonary and systemic models of infection. The disruption of this operon impairs 
the growth of S. pneumonaie under high osmotic and oxidative conditions (Brown et 
al., 2004). Alkyl hydroxyl peroxidase D (ahpD) is important for resistance to killing 
by H2O2 in vitro, suggesting that the operon is responsive to oxidative stress, and is 
required for S. pneumoniae virulence in pneumonia and bacteraemia models of 
infection in mice (Paterson et al., 2006). PcsB is an essential hydrolase which aids in 
the separation and cell division of S. pneumoniae and the in vitro results have 
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demonstrated that the pcsB expression is upregulated during stress such as the 
presence of high temperature and osmolarity. However, in vivo data to demonstrate 
the role of S. pneumoniae PcsB in virulence is not yet available (Mills et al., 2007). 
Another large group of proteins that are important for the replication and 
survival of S. pneumoniae in vivo are ABC transporters which will be discussed in 
detail in the section on ATP binding cassette transporters. 
 
1.4.6 Regulation of S. pneumoniae virulence  
STM screening of 3 different serotypes of S. pneumoniae (serotypes 3, 4, 19F) have 
identified transcriptional regulators necessary for the regulation of virulence genes 
during various stages of disease establishment and also in response to the host’s 
(external) stimuli. Progression from colonisation to invasive disease involves the 
adaptation of S. pneumoniae to different environmental niches in the host, during 
which many virulence factors are differentially expressed. It is therefore likely that 
S.pneumoniae undergoes controlled changes in the expression of various virulence 
factors during different stages of disease development and in different sites of 
infection. This hypothesis is supported by microarray data of transcriptional factors 
from mice models showing variations in gene expression (Orihuela et al., 2004). 
There are 33 identified S. pneumoniae transcriptional regulators 20 transcription 
factors (Tettelin et al., 2001) (Hava et al., 2003) and 13 two-component signal 
transduction systems (TCSTS) (Throup et al., 2000) (Lange et al., 1999) whose role 
in the regulation of virulence were either demonstrated or described as putative based 
on the sequence data. However, unlike other major pathogens such as S. pyogenes, as 
yet no regulator has been shown to control an invasive virulence phenotype for S. 
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pneumoniae. Several regulators are known to influence virulence and are discussed 
below but the exact mechanisms involved are often not clear. 
CtsR is a transcription factor that negatively regulates the expression of the S. 
pneumoniae Clp ATP-dependent protease, which in turn regulates the expression of 
LytA, CbpA, CbpE, CbpF and CbpJ and also contributes to the genetic transformation 
of S. pneumoniae (Chastanet et al., 2001), colonisation in the nasopharynx and 
survival in the lungs after intranasal challenge thereby contributing towards S. 
pneumoniae virulence (Kwon et al., 2004). Another transcriptional regulator termed 
carbon catabolite repression (CCR) allows the utilisation of preferred sugars by 
silencing the genes specific for nonpreferred sugars. Catabolite control protein A 
(CcpA), another regulator, regulates sugar metabolism and is required for S. 
pneumoniae colonisation and survival in lungs (Iyer et al., 2005). RegM, which is a 
homologue of CcpA, is required for the growth of S. pneumoniae in blood and hence 
contributes to virulence. Mutation of RegM results in the reduced transcription of the 
capsular polysaccharide biosynthesis locus (Giammarinaro and Paton, 2002). RegR, 
another transcriptional regulator has been shown to regulate hyaluronidase activity of 
S. pneumoniae and controls competence. It also regulates the S. pneumoniae 
adherence to A459 epithelial cells in vitro and also contributes to S. pnemoniae 
virulence in vivo (Chapuy-Regaud et al., 2003).  
TCSTS or TCS of S. pneumoniae consists of 13 histidine kinases (HK) paired 
with response regulators (RR) and an orphan unpaired RR. Of the 13 TCS, 10 have 
been shown to play role in the virulence of S. pneumoniae including the orphan RR. 
TCS12 consists of a HK encoded by comD and an RR encoded by comE and responds 
to competence-stimulating peptide (CSP), activates competence and also contributes 
to S. pneumoniae virulence. TCS05 also called CiaRH, was the first TCS to be 
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identified and is known to affect virulence, competence and antibiotic resistance. 
TCS13 (also called blpTCS for bacteriocin-like peptide) controls a 16-gene quorum-
sensing regulon which regulates the synthesis and export of bacteriocin-like peptides 
and immunity proteins. Bacteriocins are bacterial products which inhibit the growth of 
related strains or species of bacteria and immunity proteins protect the bacteriocin-
producing bacteria. The role of the blp product of S. pneumoniae in lung is unclear but 
they might be cytotoxic to host cells as well as other bacteria (Paterson et al., 2006).  
In conclusion, there is some evidence for several regulators that are important for 
virulence but little is understood about the role of different transcriptional regulators 
within specific sites during infection such as lungs and blood. At present the research 
into the regulation of S. pneumoniae gene expression is confused as various regulators 
have significant differences in their regulons when two different strains have been 
investigated. Further studies are required to understand the regulation of virulence-
associated genes in S. pneumoniae (McCluskey et al., 2004). 
 
1.5 ATP BINDING CASSETTE TRANSPORTERS (ABC TRANSPORTERS) 
ATP binding cassette transporters are proteins that are widespread among both 
prokaryotic and eukaryotic organisms. In bacteria, ABC transporters are involved in 
the import of wide variety of substrates such as sugars, amino acids, peptides, 
polyamines, sulphate and metal ions such as iron, molybdate. They are also 
responsible for the export of capsular polysaccharide in Gram-negative bacteria, 
secretion of antibiotics by antibiotic resistant bacteria and drug -resistant bacteria and 
secretion of extracellular toxins, role in translational regulation and DNA repair. 
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Class                 Virulence factor                                                          Role in vivo   
Adhesion        Invasion     Immune     Inflammation    
Replication 
                                          evasion Carbohydrate            Capsule 
                                  PC     
                                  LTA, 
TA CBPs                        CbpA 
                                 PspA   
Cell wall                  
PavA 
proteins                    Pili 
Enzymes /               IgA1 protease 
Toxins                     Nan A, B, C 
                                Exoglycosidases 
                                Hyl 
                                PLGs-α enolase 
                                    -GAPDH 
                                Ply 
                                EndA 
                                LytA 
                                Pyruvate 
oxidase 
Lipoproteins            PsaA            
                                PiuA 
                                PiaA 
                                PitA 
                                SlrA 
                                Adc 
                             
Table 1.3: Role of S. pneumoniae virulence factors in 
pathogenesis 
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Class                Virulence factor                                                        Role in vivo      
Adhesion        Invasion     Immune     Inflammation    Replication / 
                                          evasion                                 survival 
Others          PhgABCD 
                                 AhpD 
                                 PcsB 
Transcriptional         CcpA  
regulators of             RegM 
virulence             RegR 
gene expression        Lsp 
Two-component       TCS02 
systems                     TCS04 
                                  TCS05 
                                  TCS06 
                                  TCS09 
                                  TCS12 
                                  TCS13   
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Approximately 5% of the E. coli and B. subtilis genomes are encoded by the 
components of ABC transporters (Garmory and Titball, 2004). 
 
1.5.1 Structure of ABC transporters 
The structure of ABC transporters differ in both Gram positive and Gram negative 
bacteria. A typical ABC transporter consists of four membrane-associated domains also 
known as transmembrane domains or integral membrane domains. Integral membrane 
domain consists of two ATP binding domains (ATPase) and two membrane spanning 
domains (MSD / permeases) which may be fused in many ways to form multidomain 
polypeptides. A typical MSD consists of six putative α-helical transmembrane segments 
which act as a channel through which the substrates are transported into the cell. 
Permeases or MSDs are also known as bacterial importers and are bound to the solute 
binding proteins (SBPs) in both Gram positive and Gram negative bacteria. In Gram 
negative bacteria, SBPs are also known as periplasmic solute binding proteins as they 
bind to the substrates and import them into the inner membrane. Outer membrane 
proteins (OMPs), such as porins, import the substrates across the outer membrane from 
the external environment. In contrast, as the Gram positive bacteria lacks the 
periplasmic space and outer membrane, the solute binding proteins are anchored to the 
outer surface of the cell with the help of lipid moiety (lipoproteins) aiding in the 
transport of substrates (Garmory and Titball, 2004; Davidson et al., 2008) (Fig 1.3). 
 
1.5.2 Processing of lipoproteins 
Lipoproteins are a group of surface proteins performing important functions such as 
antibiotic resistance, substrate binding, adhesions, protein secretion, sensing, spore  
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Figure 1.3: Schematic diagram of Gram positive ABC transporter. 
 
formation, conjugation etc (Sutcliffe and Russell, 1995). The annotated genome 
sequence of S. pneumoniae has 47 lipoproteins in TIGR4 strain (Bergmann and 
Hammerschmidt, 2006). Lipoproteins in various Gram positive and Gram negative 
bacterial pathogens are known to be important during infection (Pennini et al., 2006; 
Reglier-Poupet et al., 2003), while some of them can induce protective immune 
responses by the host (Sadziene and Barbour, 1996). The investigated S. pneumoniae 
lipoproteins that are important in virulence and known to induce protection against S. 
pneumoniae are PiuA, PiaA (Jomaa et al., 2006; Brown et al., 2001) and PsaA (Seo et 
al., 2002; Miyaji et al., 2001).  
Lipoprotein processing in bacteria is of ‘Braun’ type and is conserved among 
prokaryotes (Sutcliffe and Harrington, 2002). Three different enzymes are required for 
the processing of the lipoproteins: Lgt (prolipoprotein diacylglyceryl transferase), Lsp 
(prolipoprotein signal peptidase) and Lnt (apolipoprotein N-acyltransferase) in Gram 
negative bacteria such as E. coli and S. typhimurium  Lgt and Lsp are known to be 
involved in the lipoprotein processing of low G+C content Gram positive bacteria such 
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as Bacillus subtilis (Fig 1.4) (Sutcliffe and Russell, 1995; Sankaran et al., 1995). 
Various bioinformatics analyses have been used to predict bacterial lipoproteins 
(G+LPP (Sutcliffe and Harrington, 2002), LipoP (Juncker et al., 2003) and DOLOP 
(Madan and Sankaran, 2002). In Gram positive bacteria, the N-terminal amino acid 
sequence of the unmodified prolipoprotein (signal peptide sequence) is followed by a 
lipobox which is a unique amino acid sequence [LVI] [ASTVI] [GAS] C where leucine 
is highly conserved and cysteine is strictly conserved. It is to this cysteine residue that 
the cell membrane lipid is anchored through a disulphide bridge (prolipoprotein). 
Following the lipid attachment, the enzyme Lsp cleaves the prolipoprotein removing the 
signal peptide amino acid sequence. In E. coli it has been shown that the localization of 
lipoproteins in the inner membrane is directed by aspartic acid at the +2 position 
(Masuda et al., 2002) and the translocation of the processed lipoprotein is known to 
occurs through the SRP/Sec/YidC secretory pathway (Froderberg et al., 2004). 
However, the mechanisms controlling the lipoprotein localization and translocation in 
Gram positive bacteria are not known and need to be investigated. Recent studies in 
Listeria monocytogenes, Streptococcus agalactiae and S. uberis have identified that Lsp 
can still cleave the unlipidated prolipoprotein (Baumgartner et al., 2007; Henneke et al., 
2008; Denham et al., 2009) indicating that the processing of lipoproteins may not 
follow a sequential pattern. However, Denham et al have identified that the full length 
unprocessed prolipoproteins were shed from the S. uberis cells independent of Lsp 
(Denham et al., 2009).  
 
1.5.3 Roles of ABC transporters in S. pneumoniae and other bacterial pathogens 
ABC transporters in pathogenic bacteria are known to play important roles in the 
nutrient acquisition, antibiotic resistance and other functions essential for the survival in 
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the host, thereby contributing to the virulence of the bacteria. Such ABC transporters 
from various pathogenic bacteria have been identified by in vivo screening techniques 
such as signature tagged mutagenesis (STM) which allows the large scale identification 
of attenuated phenotype of mutant strains. STM of S. pneumoniae has revealed the 
virulence associated ABC transporter genes homologous to polyamine transport in E. 
coli (potA and potF), glutamine transport in Bacillus subtilis (glnH and glnQ) and sugar 
transport in S. mutans (msmK) (Polissi et al., 1998). Similarly, STM performed in 
Yersinia spp. identified phosphate and nitrogen uptake ABC transporters (Darwin and 
Miller, 1999). In Staphylococcus aureus, STM identified oligopeptide transporter genes 
which formed the largest class of genes required for full virulence (Coulter et al., 1998). 
Other ABC transporters known to contribute to the virulence in the infection models are 
metal ion ABC transport systems such as iron, zinc, manganese as metal ions act as 
important cofactors for various metabolic pathways. Iron-binding siderophores, 
haemoproteins or glycoproteins used to acquire iron have been identified in Yersinia. 
pestis. These are also known as yersiniabactin (Ybt) (Fetherston et al., 1999), FeoABC 
(Boyer et al., 2002), iron uptake ABC transporter, SitABCD which transports both 
manganese and iron are required for the full virulence in Salmonella enterica serovar 
Typhimurium (Janakiraman and Slauch, 2000). Piu and Pia are iron uptake ABC 
transporters required for the full virulence of S. pneumoniae (Brown et al., 2001). The 
PsaABC manganese transporter is known to transport manganese and is also acts as an 
adhesin 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Processing of the lipoproteins in Gram positive bacteria described by 
(Garcia-del and Cossart, 2007; Sutcliffe and Harrington, 2002) 
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for pneumocytes (Berry and Paton, 1996). MtsABC of Streptococcus pyogenes 
(Janulczyk et al., 2003) and SloABC of Streptococcus mutans transport both iron and 
manganese (Paik et al., 2003).  
The annotated S. pneumoniae TIGR 4 genome contains 73 ABC transporters 
(Harland et al., 2005) of which 33 genes encode putative lipoproteins, 24 of which are 
organised as operons with genes encoding other components of ABC transporter 
proteins (ATPases, permeases and or additional lipoproteins). Eleven of these have been 
previously described, (Table 1.4). However the roles of the remaining ABC transporters 
in S. pneumoniae virulence need to be investigated.  
 
1.5.4 Role of components of bacterial ABC transporters as vaccine candidates 
Components of ABC transporters have shown to be protective in animal models as 
protein vaccine candidates against various pathogenic bacteria. In S. pneumoniae, solute 
binding components (SBP / lipoproteins) that have been demonstrated to be protective 
against both systemic and pulmonary infections are pneumococcal iron acquisition (Pia) 
and pneumococcal iron uptake (Piu) ABC transporters. PsaA is a  
 
Table 1.4: ABC transporters investigated before. 
 
Operon Given name Function Reference 
Sp0042 comABCDE Competence Havarstein et al 
Sp0241-243 pitADBC Iron uptake J.S.Brown et al. 
Sp0366 aliA Oligopeptide A.R.Kerr 
Sp0601-604 vex123-pep27-vncRS Vancomycin tolerance E.I. Toumanen et al 
Sp1032-35 piuA Iron uptake J.S.Brown et al 
Sp1396-1400 pstSCAB Phosphate uptake E.I.Toumanen et al 
Sp1648-50 psaABC Manganese uptake J.P.Claverys et al 
Sp1869-72 piaA  Iron uptake J.S.Brown et al. 
Sp1887-91 amiACDEF Oligopeptide  A.R.Kerr et al 
Sp2169-71 adcABC Zinc uptake J.P.Claverys et al 
Sp1526-27 aliB Oligopeptide  A.R.Kerr et al 
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manganese uptake ABC transporter present in S. pneumoniae. Although, the degree of 
protection afforded by PsaA against systemic infection is not good, it does provide 
protection against the nasopharyngeal carriage of S. pneumoniae. The vaccine against 
Lyme disease caused by Borrelia burgdorferi is based on the outer-surface lipoprotein 
A (Steere et al., 1998). Three conserved lipoproteins identified from the genome 
sequence of serogroup B of Neisseria meningitidis were able to induce bactericidal 
activity (Pizza et al., 2000), and active immunisation with 5 S. pyogenes lipoproteins are 
protective (Lei et al., 2004). PstS, a surface exposed SBP of phosphate transport system 
on mycobacteria is highly immunogenic when administered to mice through the 
intramuscular route as DNA vaccine and exhibits protection against intravenous 
challenge with M. tuberculosis (Garmory and Titball, 2004).  
 
1.5.5 Lipoprotein components of ABC transporters investigated as vaccine 
candidates in S. pneumoniae 
Immunisation of lipoprotein components of S. pneumoniae ABC transporter proteins 
such as PsaA, PiaA, PiuA and PotD, lipoprotein component of the polyamine ABC 
transporter have been shown to protect against S. pneumoniae infections. Anti-PsaA 
antibodies naturally developed in humans or elicited by recombinant PsaA in animals 
reduce the adherence of S. pneumoniae to nasopharyngeal epithelial cells in vitro. 
(Romero-Steiner et al., 2003) and Intranasal (IN) immunisation with recombinant PsaA 
provides protection against the nasopharyngeal carriage of S. pneumoniae and has little 
effect on the remaining microflora (Pimenta et al., 2006). IN immunisation with 
combination of PsaA with other proteins such as PspC has shown to protect against 
naopharyngeal carriage in mice (Briles et al., 2000). PiaA and PiuA are the lipoprotein 
components of two separate iron uptake ABC transporters required for the full virulence 
 86 
of S. pneumoniae. Systemic immunisation (intraperitoneal, IP) (Brown et al., 2001) and 
mucosal immunisation (IN) (Jomaa et al., 2006) with PiuA and PiaA induced protective 
antibody response in mice against IP and IN challenge with S. pneumoniae. Flow 
cytometry analysis of in vitro opsonophagocytosis demonstrated that anti-PiaA and anti-
PiuA aids in the complement-dependent and complement-independent clearance of S. 
pneumoniae (Jomaa et al., 2005). Amplification of piaA and piuA genes have shown 
that piaA is strictly conserved among typical S. pneumoniae and completely absent in 
oral streptococci and S. mitis group whereas piuA is conserved in typical S. pneumoniae, 
and it is also present in atypical S. pneumoniae plus closely related species of S. mitis 
and S. oralis group. PotD is yet another lipoprotein component investigated as potential 
vaccine candidate and has demonstrated protection against S. pneumoniae septicaemia 
in mice upon immunisation with the recombinant PotD and S. pneumoniae challenge 
intraperitoneally (Shah and Swiatlo, 2006). Recently Shah and collegues have also 
demonstrated that the IN immunisation with recombinant PotD (rPotD) protects against 
nasopharyngeal carriage of S. pneumoniae serotypes (TIGR4 and 19F) in mice, and that 
the rPotD immunised mice clear S. pneumoniae from target organs such as brain, lungs, 
olfactory bulbs compared with the control mice (Shah et al., 2009). Although other 
groups of surface exposed proteins such as putative proteinase maturation protein A 
(PpmA) and streptococcal lipoprotein rotamase A (SlrA) are known to be immunogenic, 
their efficacy as vaccine candidates needs to be investigated (Bergmann and 
Hammerschmidt, 2006). 
Of the S. pneumoniae lipoproteins investigated, PsaA (Sampson et al., 1997) 
PiaA and PiuA (Whalan et al., 2006) have been demonstrated to be conserved between 
S. pneumoniae strains. However, these lipoproteins are less likely to be surface exposed 
probably because the lipoproteins are likely to be membrane bound underneath the 
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peptidoglycan and capsule layers (Tai et al., 2003; Lawrence et al., 1998). Nevertheless 
their functional importance in the acquisition of nutrients and therefore survival of S. 
pneumoniae in the host makes it less likely for these genes to be lost by mutation as a S. 
pneumoniae adaptation to vaccine-induced immunity. 
 
1.5.6 Conclusion 
S. pneumoniae is a major worldwide cause of morbidity and mortality especially 
amongst children and the elderly. Currently, capsular polysaccharide vaccines and 
conjugate vaccines are administered to prevent S. pneumoniae diseases. The most 
unconjugated capsular polysaccharide vaccines does not stimulate adequate immunity in 
infants, elderly and immunocompromised patients, and this drawback has been 
overcome by conjugating the capsular polysaccharide antigens to a protein carrier to 
make a vaccine that is effective in infants. However the conjugated vaccine has only 
limited serotype coverage and is expensive. Therefore conserved S. pnemoniae surface 
proteins such as ABC transporter lipoproteins are being evaluated for their potential role 
in future vaccination against S. pneumoniae diseases. PsaA, PiaA, PiuA and PotD are 
among the many lipoproteins of the S. pneumoniae ABC transporters that have been 
successfully investigated as potential vaccine candidates. However these are only a 
handful of the S. pneumoniae ABC transporter SBP components identified by genome 
sequencing, and the uninvestigated lipoprotein components may be important for the S. 
pneumoniae virulence and could be additional potential vaccines candidates.  
 
 
 
 
 88 
 
1.6                                                                      HYPOTHESIS 
 
‘Previously uninvestigated ABC transporters may be required for the in vivo growth and 
full virulence of S. pneumoniae, and their lipoprotein components could be potential 
novel vaccine candidates’. 
 
AIMS 
 To identify previously uninvestigated S. pneumoniae ABC transporters required 
for S. pneumoniae in vivo growth and virulence in mouse models 
 To characterise the function of previously uninvestigated ABC transporters that 
are important for S. pneumoniae virulence 
 To investigate the potential of the corresponding lipoprotein(s) components of 
ABC transporters found to be important for virulence as vaccine candidates using 
mouse models of S. pneumoniae septicaemia and pneumonia. 
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    Chapter 2 
   Materials and methods 
 
2.1 BACTERIAL STRAINS 
The E. coli strains DH5α, Novablue competent cells (Novagen), JM109 (Promega) and 
M15 (Qiagen) were used for cloning procedures. The capsular serotype 3 S. pneumoniae 
strain 0100993, originally isolated from a patient with pneumonia and obtained from 
Smithkline Beecham PLC (Lau et al., 2001), was used to construct S. pneumoniae 
mutant strains for the in vitro and in vivo phenotype analysis. While most of the in vitro 
and in vivo phenotype analyses were performed in 0100993 strain, some experiments 
such as radioactive uptakes assays were performed using capsular serotype 2 strain D39 
since mucoid colonies of 0100993 strain prevented effective pelleting of bacteria. 
Vaccination studies were mostly performed using the capsular serotype 2 strain D39 
since this strain has been previously used for these experiments (Brown et al., 2001b). 
S. pneumoniae, E. coli mutant strains and plasmids constructed and primers used for 
this thesis are listed in the tables 2.2, 2.3 and 2.4.  
 
2.2 MEDIA AND GROWTH CONDITIONS 
E. coli DH5α was cultured using Luria Bertani (LB) medium (Sambrook J. et al., 1989) 
at 37ºC. Liquid cultures were grown with continuous shaking at 200 rotations per 
minute (rpm) and colonies were grown on LB agar plates. Plasmids pID701 was 
selected using chloramphenicol (10 μg ml-1) and pST-1, pGEM-Teasy, pQE30, 
pQE30UA plasmids were selected using appropriate antibiotics according to 
manufacturer’s instructions. For long term storage, strains were cultured overnight in 
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LB broth with appropriate antibiotic selection and stored at -70ºC in 10% glycerol. S. 
pneumoniae strains were cultured at 37ºC in the presence of CO2 on Columbia agar 
(Oxoid) supplemented with 5% horse blood (TCS Biosciences), or in Todd-Hewitt 
broth supplemented with 0.5% yeast-extract (Oxoid). Mutant strains were grown on 
blood agar plates in the presence of appropriate antibiotic (10 µg ml-1 chloramphenicol 
and 0.2 µg ml-1 erythromycin). Broth culture growth was monitored by measuring 
optical density (OD) at 580nm. Single use 0.5 ml aliquots of THY broth culture (O.D580 
0.3 - 0.4) of different S. pneumoniae strains were stored at -70ºC in 10% glycerol. 
 
2.3 DNA METHODS 
2.3.1 Extraction of plasmid DNA from E. coli 
Plasmid DNA was isolated from E. coli using the Qiaprep® Spin Miniprep kit (50 μl at 
400 ng ul-1) or the Eppendorff Fast PlasmidTM Miniprep kit (50 μl at 400 ng ul-1). 
Plasmid concentrations were quantified by comparing band intensity to the Bioline 
Hyperladder 1 after electrophoresis in a 0.8-1% agarose gel. 
 
2.3.2 Extraction of genomic DNA from S. pneumoniae 
4-6 ml of S. pneumoniae culture (OD580 ~ 0.4) was resuspended in 200 μl of 50 mM 
EDTA and 0.1% deoxycholate and the genomic DNA extracted using Wizard genomic 
DNA kit (Promega) according to the manufacturer’s instructions. 
 
2.3.3 Gel extraction and purification of DNA 
Specific DNA fragments obtained by restriction digestion or PCR were fractionated 
using 1% agarose gels and purified using the QIAquick gel extraction kit. Restriction 
digests or PCR were purified by using Qiagen® QIA quick columns. 5 volumes of PB 
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buffer (Qiagen®) were added to the reaction product, mixed and transferred to Qiagen® 
QIAquick columns and centrifuged at 13000 rpm for 1 minute. The membrane bound 
DNA was washed 2 times with 750 µl of PE buffer (Qiagen®) and centrifuged for 2 
minutes to remove traces of PE buffer, then eluted in 30 µl of distilled water or EB 
buffer (10 mM Tris-Cl  pH8.0) (Qiagen®). 
 
2.3.4 PCR 
Templates for PCR were either genomic DNA, plasmid DNA or E. coli colonies picked 
directly from transformation plates. In a reaction volume of 200 µl, 100 pmoles of 
primers (Invitrogen), 200 µM of dNTPs (Promega) and 0.5 units (U) of Taq DNA 
polymerase (Sigma) were used. The standard PCR cycle was an initial denaturing step 
at 94ºC for 4 minutes, 94ºC for 30 seconds, followed by an annealing step at 50ºC for 30 
seconds and an extension step at 72ºC for 45 seconds, for 35 cycles, with a final 
extension at 72ºC for 10 minutes. PCR products were purified by Qiagen® QIAquick 
columns (see above) and visualised on 1% agarose electrophoresis gels. 
 
2.3.5 Restriction digestion 
When necessary, PCR products and plasmids were digested with appropriate restriction 
enzymes. 4 µl of PCR products / plasmid preparations were digested by 2-4 µl of 
restriction enzymes at 37ºC. For ligations, the digested plasmid products were 
dephosphorylated by the addition of 5 U of calf intestinal alkaline phosphatase (MBI 
Fermentas, 10 U µl-1) and incubating for up to 30 minutes at 37ºC. Once digested and 
dephosphorylated, PCR products and plasmids were cleaned using a Qiagen® spin kit 
(see above) and eluted in 20 µl or 40 µl of distilled water or EB buffer respectively (10 
mM Tris-Cl pH 8.0) respectively. 
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2.3.6 Ligation 
Ligations were performed in a total volume of 20 µl of 1x ligation buffer (50 mM Tris-
Cl pH 7.6, 1 mM ATP, 1 mM DTT, 5% w/v PEG 8000) with 1 U of T4 DNA ligase 
(Gibco RL). Ligation reactions were performed overnight at 16ºC with variable ratios of 
prepared plasmid DNA and insert DNA (3:1 to 1:3). Negative controls included 
plasmids ligated without insert DNA and reactions with no added T4 DNA ligase. 
 
2.3.7 Overlap extension PCR (OEP) 
The deletion construct of Sp0149 was obtained by flanking the erythromycin gene 
(antibiotic resistance) between Sp0148 and Sp0150 genes which are upstream and 
downstream to Sp0149 respectively. To obtain the Sp0149 deletion construct, fragments 
of Sp0148 and Sp0150 genes were amplified from the genomic DNA of S. pneumoniae 
(0100993 strain). The erm gene was amplified from the erm cassette of pACH74 (a 
suicide vector carrying erm for selection in S. pneumoniae, a kind gift from J. Paton). 
Similarly the deletion construct of Sp0750-53 was obtained by flanking the 
erythromycin gene (antibiotic resistance) between Sp0749 and Sp0754 genes which are 
upstream and downstream of Sp0750-53 respectively. To obtain the Sp0750-53 deletion 
construct, fragments of Sp0749 and Sp0754 genes were amplified from the genomic 
DNA of S. pneumoniae (0100993 strain). All the primers (table 2.2) were designed from 
5’to 3’ direction but the reverse primer of the Sp0148 and Sp0749 and the forward 
primer of the Sp0150 and Sp0754 had linkers that were complementary to the 5’ and 3’ 
portion of the erm gene at their 5’ ends (Shevchuk et al., 2004). 
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(a) Initial PCR 
The individual PCR products were amplified in a reaction volume of 200 µl, 100 
pmoles of primers, 200 µM of dNTPs (Bioline) and 0.5 U of Taq DNA polymerase 
(Sigma) using a PCR cycle of an initial denaturing step at 94ºC for 4 minutes, 94ºC for 
30 seconds, followed by an annealing step at 55ºC for 45 seconds and an extension step 
at 72ºC for 1 minute, for 30 cycles, with a final extension at 72ºC for 10 minutes. PCR 
products were purified by Qiagen® QIAquick columns (see above) and visualised on 
1% agarose gels. 
 
(b) Fusion of the initial PCR products without primers 
Purified individual PCR products were pooled in a reaction volume of 20 µl which 
contained 8.7 µl of nuclease free water, 1 µl of buffer, 1 µl of 2 mM dNTPs, 0.4 µl of 
50 mM MgSO4, 2 µl (approximately 50 ng) of fragment 1 and 3, 5 µl (approximately 50 
ng) of fragment 2 and 0.2 µl of Taq polymerase (Bioline). The PCR cycle was an initial 
denaturing step at 94ºC for 2 minutes, 94ºC for 20 seconds, followed by an annealing 
step at 50ºC for 30 seconds and an extension step at 72ºC for 1 minute, for 10 cycles, 
and a final hold at 4ºC. 
 
(c) Amplification of fused PCR products 
Final amplification was performed in a reaction volume of 100 µl which contained 68.2 
µl of nuclease free water, 10 µl of buffer, 10 µl of 2 mM dNTPs, 4 µl of 50 mM 
MgSO4, 100 pmoles of forward primer of the fragment 1 and reverse primer of fragment 
3, 3 µl of unpurified PCR product from the step (b) and 0.8 µl of Taq polymerase. The 
PCR cycle was an initial denaturing step at 94ºC for 2 minutes, 94ºC for 20 seconds, 
followed by an annealing step at 50ºC for 30 seconds and an extension step at 72ºC for 
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2.30 minutes, for 35 cycles, with a final extension at 72ºC for 3 minutes and a final hold 
at 4ºC. The fusion PCR products were then analysed on 1% agarose gel, desired DNA 
bands excised and purified using Qiagen® QIAquick columns and the resulting deletion 
constructs were used to transform S. pneumoniae serotype 3 strain (0100993). 
 
2.3.8 Transformation of E. coli 
Transformation of E. coli was performed by mixing 5 µl of ligation reaction with 100 µl 
of competent E. coli DH5α cells (prepared by the rubidium chloride method, Sambrook 
et al. 1989) and using heat shock at 42ºC (Sambrook et al. 1989). The transformation 
mix was then plated on LB agar containing the required antibiotic. (10 µg ml-1 
chloramphenicol or 100 µg ml-1 carbenicillin) and incubated overnight at 37ºC. Correct 
inserts in the plasmids from the transformants were confirmed by colony PCR, 
restriction digests and / or sequencing. 
 
2.3.9 Transformation of S. pneumoniae 
A single S. pneumoniae colony from an overnight incubation on a blood agar plate was 
inoculated into THY pH 6.8 broth and cultured until the O.D580 reached 0.015. The 
culture was pelleted at 15,000 rpm at 4ºC for 10 minutes and the pellet resuspended in 1 
ml of pre-warmed THY pH 8.0 broth containing 1 mM CaCl2 and 0.2% BSA. The 
resuspended solution was transferred into Falcon tubes and competence stimulating 
peptide-І (CSP1) (kind gift from D. Morrison) was added to a final concentration of 200 
ng ml-1 (Håvarstein et al., 1995; Lau et al., 2001). The transformation mix was 
incubated at room temperature for 5 minutes before the addition of transforming DNA 
(circular plasmid or linear constructs) followed by incubation at 37ºC for 2 hours in the 
presence of CO2. 200 µl of the above transformation mixture was spread onto antibiotic 
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containing blood agar plates and the identity of successful transformants confirmed by 
PCR and / or sequencing. 
 
2.3.10 Nucleotide sequencing 
Mutant identities were confirmed by PCR followed by sequencing of the PCR products 
obtained using mutant genomic DNA, a target gene specific forward primer and a vector 
specific reverse primer. DNA sequencing was performed by Lark Technologies Inc. UK 
or UCL sequencing services using the Big Dye™ Terminator technique and gene 
specific PCR primers. 
 
2.4 RNA METHODS 
2.4.1 RNA extraction from S. pneumoniae 
RNA was extracted from S. pneumoniae using the SV total RNA extraction kit 
(Promega). S. pneumoniae colonies from overnight grown blood agar were inoculated 
into 20 ml of THY and incubated at 37ºC in the presence of CO2. Once OD580 reached 
0.2-0.3, 2-5 ml of the culture was centrifuged at 13,000 rpm for 10 minutes at room 
temperature. The pellet was resuspended in 100 µl of TE (50 mM Tris, 5 mM EDTA) 
and 0.01% DOC (deoxycholate) and incubated for 10 minutes. Further steps of the 
extraction were performed according to the manufacturer’s instructions. To inhibit RNA 
degradation, 0.5-1 µl of RNAsin was added to the completed RNA preparation and 
aliquots of 5-8 µl were made and stored at -70ºC until use. 
 
2.4.2 RNA extraction from S. pneumoniae by acid-phenol method 
Total RNA from S. pneumoniae grown in human and mouse blood was extracted as 
described by Ogunniyi et al, (2002). S. pneumoniae was harvested from the human and 
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mouse blood by brief centrifugation at 825 g at 4ºC for 5 minutes to pellet the 
erythrocytes and leucocytes. The resulting supernatant which is a mixture of plasma and 
thrombocytes along with the bacteria was centrifuged further at 15500 g at 4ºC for 5 
minutes. The supernatant was discarded and the bacterial pellet was then used to extract 
the total RNA. 
The bacterial pellet was resuspended in 300 µl of pre-warmed (65ºC) acid-
phenol (Ambion) and incubated for 5 minutes at 65 C followed by further addition of 
300 µl of pre-warmed NAES buffer and incubation at 65 C for 5 minutes with 
intermittent mixing. The mixture was cooled on ice for 1 minute and centrifuged at 
15500 g for 1 minute to separate the phases. The aqueous phase was re-extracted twice 
with acid-phenol and NAES buffer and later extracted twice with 300 µl of chloroform. 
To this mixture, sodium acetate was added at a final concentration of 300 mM followed 
by addition of 2 volumes of ethanol and RNA was precipitated at -20 C overnight. The 
precipitated RNA was centrifuged at 6000 rpm for 5 minutes and the resulting pellet 
was washed in 70% ethanol and resuspended in 50 µl of nuclease-free water. To the 
resulting RNA, recombinant RNasin ribonuclease inhibitor (Promega N251A) was 
added to a final concentration of 1 U µl-1 and then treated with 0·5 U µl-1 RQ1 RNase-
free DNase (Promega M610A) at 37 C for 40 minutes. Aliquots of this RNA were 
stored at -70 C until use. An aliquot was used to check the purity by RT-PCR as 
described in section 2.4.3 with and without reverse transcriptase using gene specific 
primers.  
 
2.4.3 RT-PCR 
RT-PCR was performed using the Access RT-PCR system (Promega). In the final 
volume of 25 µl, 5 µl AMV buffer, 0.5 µl of 5 mM dNTPs (Promega), 1 µl of 25 mM 
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MgSO4, 1.5 U each of AMV reverse transcriptase and Tfl DNA polymerase, 1 µl of 
RNA with 0.1 µl stop solution and primers at 120 nanomoles final concentration were 
added and the volume was made up with nuclease free water. Amplification of target 
specific DNA was performed at 48ºC for 45 minutes, followed by PCR amplification of 
the cDNA with the following parameters of 94ºC for 2 minutes, 94ºC for 30 seconds, 
55ºC for 30 seconds, 72ºC for 45 seconds, 72ºC for 10 minutes for 35 cycles. 
 
2.5 PROTEIN METHODS 
2.5.1 Induction of positive clones for protein expression 
Protein induction was performed according to The QIAexpressionistTM manual. 
Colonies of E. coli M15 strain were confirmed for the insert and the orientation of the 
lipoprotein gene by colony PCR using the vector specific forward primer (pQE30F) and 
insert specific reverse primers (Sp0149Rev, Sp0749Rv, PiaARv and PiuARv). These 
colonies were picked and inoculated in 1.5 ml LB broth containing carbenicillin (100 µg 
ml-1) and kanamycin (25 µg ml-1). An extra culture was inoculated to serve as a non-
induced control. These cultures were grown overnight at 37ºC at 220 rpm (rotations per 
minute). 500 µl of the above overnight culture was inoculated into 10 ml LB containing 
carbenicillin (100 µg ml-1) and kanamycin (25 µg ml-1) and grown at 37ºC at 220 rpm 
until the OD580 reached 0.5-0.7. Protein expression by the cultures was induced by 
adding isopropyl ß thiogalactosidase (IPTG) to a final concentration of 1 mM and 
incubation for an additional 4-5 hours. The cells were harvested by centrifugation at 
4800 g for 5 minutes and supernatant was discarded. The harvested cells were 
resuspended in 400 µl of buffer B (appendix) and lysed by gentle vortexing until the 
solution became translucent. The lysate was centrifuged to remove the cell debris 
(termed pellet), and the supernatant was transferred to a fresh tube. 2.5 µl of 5x SDS-
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PAGE sample buffer (appendix) was added to 10 µl of the supernatant and boiled at 
95ºC for 5 minutes to denature the proteins for analysis by SDS-PAGE. 
 
2.5.2 Purification of 6xHis-tagged lipoproteins by Ni-NTA affinity 
chromatography under native conditions 
Purification of His-tagged lipoproteins was performed according to the 
QIAexpressionistTM manual. 10 ml of LB containing 100 µl ml-1 of carbenicillin and 25 
µl ml-1 of kanamycin was inoculated with a positive clone cultured on LB agar 
containing 100 µl ml-1 of carbenicillin and cultured at 37ºC with vigorous shaking at 
220 rpm overnight. 100 ml of pre-warmed LB medium with 100 µl ml-1 of carbenicillin 
and 25 µl ml-1 of kanamycin was inoculated with 5 ml of the overnight culture and 
cultured until the OD580 reached 0.6. The culture was then induced with IPTG at a final 
concentration of 1 mM and cultured for an additional 4-5 hours. The bacteria were 
pelleted by centrifugation at 4000 g for 20 minutes and the pellets stored at -20ºC until 
use. The cell pellets were thawed for 15 minutes on ice and resuspended in 2-5 ml per 
gram of wet weight in cell lysis buffer (appendix) and sonicated on ice using six 10 
second bursts at 200-300W, with 10 seconds cooling between each burst. The lysates 
were centrifuged at 10,000 g for 20-30 minutes at 4ºC to pellet the cellular debris and 
the supernatant (CL) was saved for further use. 5 µl of 2x SDS-PAGE sample buffer 
was added to 5 µl of cell lysate and stored at -20ºC for analysis. 1 ml of 50% Nickel 
tagged Nitrilotriacetic acid (Ni-NTA) agarose slurry was added to 4 ml of the cleared 
cell lysate and mixed by shaking at 200 rpm at 4ºC for 1 hour. The lysate-Ni-NTA 
slurry was then loaded into the protein purification columns with the bottom outlet 
capped. After loading, the outlet caps were removed to collect the flow-through (FT). 5 
µl of 2x SDS-PAGE sample buffer was added to 5 µl of flow-through (FT) and were 
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stored at -20ºC for the analysis by SDS-PAGE. The columns were washed twice with 4 
ml of wash buffer (appendix) and the successive fractions (W1 &W2) were saved for 
SDS-PAGE analysis. Finally the protein was eluted with four 0.5 ml volumes of elution 
buffer (appendix), and the eluate collected in 4 tubes and analysed by SDS-PAGE. 
 
2.5.3 Preparation of dialysis tubing 
Dialysis tubings were prepared as follows. The tubings were first boiled in 500 mls of 
2% w/v sodium bicarbonate and 1 mM EDTA pH 8.0 for 10 minutes, rinsed in distilled 
water, boiled again in 1 mM EDTA pH 8.0 for 10 minutes, cooled and finally stored 
submerged in ethanol at 4ºC. The tubings were washed with distilled water before use. 
 
2.5.4 Dialysis of purified lipoproteins 
One end of the treated dialysis tubing was tied with a thread, the purified protein sample 
was loaded carefully and then the other end was also tied. The tubing was tied to a rod, 
placed in 10 mM NaH2PO4 and dialysed extensively overnight at 4
 ºC. The dialysed 
protein samples were removed and transferred into a fresh tube and an aliquot was used 
to determine the protein concentration. The proteins were mixed in a final concentration 
of 50% sterile glycerol and stored at -20ºC. 
 
2.5.5 Protein concentration determination by Bicinchonic acid (BCA) method 
(Pierce) 
2 mg ml-1 bovine serum albumin (BSA) was diluted in 10 mM NaH2PO4 to 25, 125, 
250, 500, 750, 1000, 1500 and 2000 µg ml-1 and used as protein standards. The negative 
control consisted of 10 mM NaH2PO4. BCA working reagent was prepared by mixing 
50 parts of BCA reagent A with 1 part of BCA reagent B. 10 µl of each diluted standard 
 100 
and the unknown samples were added into a microtitre well and 200 µl of BCA working 
reagent added to each well and mixed for 30 seconds. The plate was incubated for 30 
minutes at 37ºC and cooled after incubation to room temperature. Absorbance was 
measured at 562 nm on a plate reader. The protein concentration was determined by 
plotting a standard curve with the BSA values on the X-axis and the absorbance at 562 
nm on the Y-axis. The concentrations of the unknown protein samples were determined 
using the albumin values as standard. 
 
2.5.6 Whole cell lysate preparation from S. pneumoniae 
Different serotypes of S. pneumoniae were grown in THY medium until the OD580 
reached 0.6 and the cells were centrifuged for 10 minutes at 4800 g. The supernatant 
was discarded and the pellet resuspended in sterile phosphate buffered saline (PBS) and 
sonicated on ice using six 10 second bursts at 200-300W with 10 seconds of cooling 
between each burst. The cell lysate was centrifuged for 30 minutes at 4800 g, the 
supernatants saved for further analysis and the pellet containing cell debris discarded. 5 
µl of SDS-PAGE sample buffer (appendix) was added to 30 µl of the supernatant and 
boiled at 95ºC for 5 minutes to denature the proteins for analysis by SDS-PAGE and 
Western blotting. 
 
2.5.7 Extraction of S. pneumoniae membrane proteins by Triton X-114 
Membrane proteins were extracted from S. pneumoniae according to Khandavilli et al. 
(2008). S. pneumoniae grown in THY to mid-logarithmic phase were pelleted at 3000 g 
for 20 minutes at 4ºC and then resuspended in 0.1% DOC. This mixture was cooled for 
2 minutes and then sonicated for 15 seconds with 10 seconds cooling between each 
sonication. 800 µl of PBS and 100 µl of 10% Triton X-114 was added to this mixture 
 101 
and incubated at 4ºC for 2 hours, and then centrifuged at 13,000 rpm for 10 minutes at 
4ºC. The resulting supernatant was incubated at 37ºC for 30 minutes, followed by 
centrifugation at 13,000 rpm for 5 minutes at room temperature to separate the phases. 
The upper phase was removed and 1 ml of PBS was added to the lower phase (Triton X-
114 phase) and incubated at 4ºC for an hour, followed by incubation at 37ºC for 30 
minutes and further centrifugation at 13,000 rpm for 5 minutes at room temperature. 
The upper phase was removed and the Triton X-114 phase was then diluted at 1:2 with 
PBS and stored at -20ºC until use. 
 
2.5.8 SDS-PAGE 
SDS-PAGE gels were prepared using SDS-PAGE cassettes (Invitrogen) according to 
Sambrook et al. 5 µl of SDS-PAGE sample buffer (appendix) was added to 30 µl of the 
supernatant, heated at 95ºC for 5 minutes before loading and electrophoresis using 1x 
Tris-glycine electrophoresis buffer (appendix) at a constant 120 volts for 11/2 hours. The 
gels were stained with 0.1% Coomassie Brilliant Blue R250 stain (appendix) for 2 
hours, and then destained using 40% methanol and 10% acetic acid until the 
background staining had disappeared. 
 
2.5.9 Western blotting 
After electrophoresis, the SDS-PAGE gels were transferred to HyBond Nitrocellulose 
membranes (Amersham Biosciences) using a constant current of 40 mA per membrane 
for 2 hours and the semi-dry blotting method (Sambrook et al). Transferred membranes 
were washed for 5 minutes in 1x transfer buffer (appendix), and stained in Ponceau S 
solution (Sigma) to confirm the transfer of proteins. After washing to remove the stain, 
the membranes were incubated overnight at 4ºC in 5% milk in 1x TBS-TWEEN (TBS-
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T, appendix) to block any non-specific binding of antibodies. The membranes were 
incubated with primary antibody (polyclonal mouse serum at 1/2000 dilution) at room 
temperature for 2 hours, washed 2-3 times with 1x TBS-T for one hour, and then 
incubated with secondary antibody (goat anti-mouse IgG conjugated with HRP [Dako 
Cytomation] at 1/2000 dilution) at room temperature for 2 hours. After washing 3 times 
with 1x TBS-T for 10 minutes, the membranes were analysed using the ECLTM Western 
blotting analysis system according to the manufacturer’s instructions and exposed to 
photographic film for up to 2 minutes before developing. 
 
2.5.10 Tryptophan fluorescence spectroscopy 
The protein concentration of purified lipoprotein was estimated and the protein dialysed 
in 10 mM NaH2PO4 and then used for the tryptophan fluorescence spectroscopy. The 
assay was performed using a Hitachi F-2500 spectrofluorimeter at an excitation 
wavelength of 280 nm (slit width 3 nm) and an emission wavelength of 309 nm (slit 
width 3 nm). Ligands (individual amino acids) were solubilised in 10 mM NaH2PO4. 
The assay was performed by mixing 0·5 µM protein in 1·5 ml 50 mM Tris/HCl pH 8 in 
the sample cuvette maintained at 25ºC in the spectrofluorimeter with continous stirring. 
The slit width of the spectrofluorimeter was adjusted to avoid photobleaching of the 
protein and fluorescence changes upon addition of ligands were recorded (Thomas et 
al., 2006). 
 
2.5.11 Radioactive substrate binding assay 
100 µl of purified lipoprotein was first incubated on ice for 15 minutes. A mixture of 
14C-labelled and non-radioactive ligand (GE Healthcare, United Kingdom) at 5 µM 
concentration was added to the protein and further incubated on ice for 10 minutes. To 
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this mixture, 1 ml of saturated ammonium sulphate was added and incubated on ice for 
20 minutes, then filtered using glass fibre filter papers (GF/F; Whatman, United 
Kingdom), the filters washed with 4 ml of saturated ammonium sulphate and dried for 5 
minutes. The filters were allowed to dissolve in the Ready safe scintillation cocktail 
(Beckman Coulter, United Kingdom) for 20 minutes and the radioactivity was 
determined using Wallac 1214 RackBeta liquid scintillation counter after brief 
vortexing of the samples. 
 
2.5.12 Streptonigrin assay 
For streptonigrin assay (Brown et al., 2001a), frozen S. pneumoniae strains were thawed 
and pelleted by centrifugation at 13,000 pm at 4ºC, then resuspended in 2.5 µg ml-1 or 5 
µg ml-1 of streptonigrin (Sigma) and incubated at 37ºC. The reaction culture was serially 
diluted and appropriate dilutions were plated for cfu before (0 minute) and after (20 and 
40 minutes) the addition of streptonigrin. Results are represented as the percent survival 
of wild-type and mutant strains of S. pneumoniae on exposure to streptonigrin. 
 
2.5.13 Radioactive substrate uptake assays 
Radioactive uptake assays were performed as described by (Webb et al., 2008) with 
some modifications. Wild-type and mutant strains of S. pneumoniae were inoculated in 
THY medium until the O.D620 reaches 0.2-0.4. Bacteria were harvested at 6000 rpm for 
20 minutes and resuspended in potassium phosphate buffer (appendix) to an 
approximate O.D620 between 0.8-1.1. The radioactive uptake assay was performed in a 
total volume of 1 ml which contained 0.85 ml of bacteria, 50 µl of 0.5 mM non-
radiolabelled test substrate and 100 µl of 2.5 µCi radiolabelled test substrate. 150 µl of 
sample was taken immediately after the addition of non-radiolabelled substrate followed 
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by the addition of radiolabelled substrate at time 0. Equal volumes of samples were 
taken at 1, 2 and 3 minutes, and immediately filtered through glass fibre filters, then 
washed with potassium phosphate buffer. 50 µl of total isotope control was directly 
added into a scintillation vial immediately after the 3rd minute. Washed filters were 
placed in scintillation vials, 5 ml of Ready safe scintillation cocktail (Beckman Coulter) 
was added to all the vials and radioactivity was counted using a Wallac 1214 RackBeta 
liquid scintillation counter.  
 
2.8 IN VIVO METHODS 
2.8.1 In vivo studies of S. pneumoniae in mouse models 
Male outbred white mice (strain CD1; Charles River Breeders) which were 4-8 weeks 
old were used for the in vivo experiments as they have been previously used in our 
laboratory for competitive indicies experiments. The use of different mouse strains for 
different in vivo experiments is listed in Table 2.1. The colony forming units per ml 
(cfu) from the frozen stocks of S. pneumoniae were first determined by plating serial 
dilutions, and diluted in 0.9 ml PBS to the cfu concentration required for inoculation. 
For mixed infections, equivalent numbers of bacteria from the wild-type and mutant 
strains were used. To determine the equivalent numbers of bacteria from the wild-type 
and mutant strains, the frozen THY stocks of the wild-type and mutant strains whose 
cfu has been previously determined were thawed, calculated to obtain equivalent 
numbers and mixed. The mixed strains were then centrifuged to remove THY and 
resuspended in sterile PBS, serially diluted and appropriate dilutions were plated on 
plain media and media containing appropriate antibiotic to enumerate the wild-type and 
mutant bacterial cfu. For the systemic models of infection, 100 µl containing 1x103 cfu 
of bacteria were injected intraperitonially (IP) per mouse. For pneumonia models of 
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infection, mice were deeply anaesthetized by inhalation of halothane and 40 µl 
containing 5 x 106 cfu of bacteria per mouse inoculated intranasally (IN). After 24 hours 
(IP) or 48 hours (IN), mice were sacrificed and the target organs (spleens for IP 
inoculations, and lungs and spleen for IN inoculations) were homogenised in 0.5 ml of 
PBS. Appropriate dilutions of organ homogenates were plated on plain and antibiotic 
blood agar plates and incubated overnight (Brown et al., 2001). Bacterial cfu were 
enumerated and the competitive index (CI) calculated using the formula: ratio of mutant 
to wild-type strain recovered from mice divided by the ratio of mutant to wild-type 
strain in the inoculum. The CI technique is useful in analysing the role of surface 
proteins such as ABC transporters, however this technique cannot be used to analyse the 
role of secreted proteins (Holden et al, 2000). All the in vivo CI and survival 
experiments using the wild-type and mutant strains were performed using 0100993 S. 
pneumoniae strain. To recover blood, mice were deeply anaesthetized by IP injection of 
pentobarbital (100 µl) and the blood obtained by cardiac puncture or from the femoral 
artery. The blood was stored on ice during transport and allowed to clot for 2-3 hours at 
4ºC and then centrifuged for 10 minutes at 10,000 rpm to obtain serum. Aliquots of sera 
were stored at 4ºC for ELISAs and the remaining aliquots stored at -70ºC for C3 
binding and opsonophagocytosis assays. 
 
2.8.2 IP vaccination schedule and challenge experiment 
Purified proteins were prepared for vaccination at 100 µg ml-1 in 50% glycerol and 10% 
alum (Pierce) as adjuvant. Alum alone was used as the negative control. For the 
vaccination experiments, proteins were mixed with 10% alum at room temperature for 2 
hours, and 100 µl (10 µg of protein) injected intraperitonially into groups of 24 mice. 2 
booster doses of proteins were prepared as above and were given at 7 to 10 day intervals 
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after the initial vaccination. After 2 weeks, serum was recovered from 5 mice from 
each group, and the remaining 19 mice challenged intraperitonially with 100 µl 
containing 1 x 105 or 1 x 103cfu of S. pneumoniae D39 strain. Mice were routinely 
observed every 3-4 hours from 2 days to 5 days post-challenge and then twice a day 
for a further 9 days. When they exhibited hunched posture and poor mobility, mice 
were sacrificed and the survival rates of each vaccination group recorded (Brown et 
al., 2001).  
 
2.8.3 IN vaccination schedule and challenge experiment 
Intranasal vaccination was performed by mixing the purified proteins and cholera 
toxin (CT) (Sigma) as the adjuvant at 2.5 µg ml-1 in a final volume of 10 µl. Groups 
of 20 mice were deeply anaesthetized by inhalation of halothane and 10 µl of the 
Table 2.1: Mouse strains used for different in vivo experiments 
during this study 
Mouse strain Reasons 
CD1 
 
 
 
 
 
 
 
BALB/C 
 
 
CBA/Ca  
CI, survival studies 
 
 
IP and IN 
immunisation 
 
 
 
IP immunisation 
 
 
IN immunisation 
Established model for phenotype 
analysis 
 
Less expensive, greater relevance if 
positive results were obtained as this 
mouse strain is outbred and genetically 
variable 
 
Inbred mouse strain and therefore 
immunologically less variable  
 
Inbred mouse strain, susceptible to 
intranasal infection and 
immunologically less variable 
Experiment 
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prepared proteins were intranasally administered. 2 booster doses of proteins were 
prepared as above and were given at 7 intervals after the initial vaccination. After 2 
weeks, serum, bronchoalveolar lavage fluid (BALF) and lungs was recovered from 5 
mice from each group for immune assays, and the remaining 15 mice challenged 
intranasally with 50 µl of PBS containing 1 x 105 or 1 x 106 cfu of S. pneumoniae D39 
or 0100993 strain. Mice were routinely observed every 3-4 hours from 2 days to 5 
days post-challenge and then twice a day for further 9 days. When they exhibited 
hunched posture and poor mobility, mice were sacrificed and the survival rates of 
each vaccination group recorded (Jomaa et al., 2006). 
Survival curves were further refined by quantitative analysis of the S. 
pneumoniae cfu from the target fluids and organs such as bronchoalveolar lavage 
fluid, lungs and blood after IN immunisation and S. pneumoniae challenge. 
 
 
2.8.4 Immune cell surface marker staining recovered from target organs 
Immune cell surface markers such as CD4, CD8, B220, CD45RB, macrophage 
surface markers such as CD80 and I-A-I-E (MHC class II antigens) were stained on 
the recovered cells from the lungs and BALF of mice. Aseptically the lungs were 
homogenised by passage through a nylon sieve and washing with 3 ml of RPMI 
(containing L-glutamine) directly into a Falcon tube and centrifuged at 1200 rpm for 5 
minutes. The resulting supernatant was discarded and the pellet was resuspended in 3 
ml RBC lysis buffer (appendix) for 3 minutes at room temperature, followed by 
addition of 3 ml RPMI to gently resuspend the pellet, which was then centrifuged at 
1200 rpm for 5 minutes. The resulting pellet was resuspended in 1 ml RPMI and an 
aliquot of 50 µl of cells was stained with trypan blue (Sigma) and total cell counts 
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were determined using a haemocytometer. Approximately 500,000 cells were added 
into each well of a round bottomed microdish plate (Nunc) based on the total cell 
counts, centrifuged for 2 minutes at 2000 rpm and the supernatant aspirated. To the 
pellet, 30 µl of antibody solution (appendix) prepared in PBS / 1% BSA / 0.1% azide 
(appendix) was added and incubated in dark for 20 minutes at room temperature. This 
incubation was followed by addition of 100 µl of PBS / 1% BSA / 0.1% azide, 
centrifuged at 2000 rpm for 2 minutes. The supernatant was aspirated and the pellet 
washed with 200 µl of PBS followed by another wash in PBS / 1% BSA / 0.1% azide. 
The pellet was fixed in 100 µl of 3% paraformaldehyde (appendix) and finally 
analysed by flow cytometry (Brown et al., 2002). Immune cell surface marker 
staining in mice BALF was performed by determining the total cell counts in an 
aliquot of 50 µl stained with trypan blue using a haemocytometer followed by staining 
the immune cell surface marker as described above. 
 
2.8.5 Cytological analysis of BALF 
500,000 cells from the BALF were centrifuged onto poly-l-lysine microscope slides 
(Cytospin 3; Shandon, UK). The slides were air dried overnight and then stained 
using DiffQuik (DADE AG, Switzerland). 100 cells per sample were counted and the 
number of macrophages, monocytes and neutrophils were recorded based on the 
cellular morphology (Hodges et al., 2004). 
 
2.8.6 Histological analysis of lung sectioning 
The degree of inflammation of lungs before and after the intranasal vaccination was 
analysed by histological observation. The left lung from each mouse was fixed in 4% 
neutral buffered formalin, processed to paraffin wax, and stained using haematoxylin 
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and eosin. The degree of inflammation during S. pneumoniae infection was 
determined by a previously described scoring system (Bergeron et al., 1998;Yuste et 
al., 2007b). Microscopic observation of the lung cross section at x10 magnification 
was first estimated to determine the extent of inflammation. Later, at x200 
magnification, six fields were scored as: 1 (no visible inflammatory change), 2 
(minimal swelling of alveolar walls with slight change in architecture), 3 (increased 
swelling with presence of erythrocytes and inflammatory cells and an increase in type 
II pneumocytes), and 4 (considerable haemorrhage with inflammatory cell influx, 
widespread alveolar disorganisation with interstitial swelling and pneumocyte 
proliferation). A total score for each mouse was obtained by multiplying the 
percentage of the involved lung by the mean score for the areas analysed, and data 
presented as medians with IQRs (Yuste et al., 2007). 
 
2.9 IMMUNE ASSAYS 
2.9.1 Enzyme Linked Immunosorbant assay (ELISA) 
Microtitre ELISA plates were coated with 100 µl of antigen at a concentration of 5 µg 
ml-1 in TSA buffer (appendix) and incubated overnight at 4ºC. The plates were 
washed 5 times with ELISA wash buffer (appendix) and soaked in 150 µl of 2% 
BSA-Tween (appendix) for 2-4 hours at 37ºC and washed again for 3-4 times with 
ELISA wash buffer. A 1/1000 dilution of mouse serum was made in BSA-Tween 
diluent buffer and added to the first well, and then 2 fold dilutions transferred to 
subsequent wells and incubated at 37ºC for 4 hours. The wells were then washed 6 
times with ELISA wash buffer and incubated overnight at 4ºC in 100 µl of 1/15000 
dilution of goat anti-mouse IgG conjugated to alkaline phosphate (Sigma) diluted in 
enzyme diluent (appendix). The ELISA plate was then washed 5 times in ELISA 
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wash buffer and 100 µl of dinitrophenol (dNP) substrate solution added to each well 
and incubated for 1 hour at 37ºC (dNP substrate solution was prepared by adding 1 
tablet of dNP (Sigma) in 5 ml of water). The absorbance was read at 405 nm and 
antibody titre was calculated as the lowest dilution at 405 nm giving an OD equal to 
or greater than 0.3. 
 
2.9.2 C3 deposition and IgG binding assay 
To analyse C3 deposition on S. pneumoniae, stocks were thawed and washed with 
PBS to remove THY and glycerol and the bacteria diluted in PBS to obtain 5 x 106 
cfu in 50 µl. To these aliquots of bacteria, 10 µl of mouse serum was added and the 
mix incubated for 20 minutes at 37ºC, washed twice with 300 µl of ice cold PBS-
Tween 20 (0.1%) by centrifugation at 10,000 rpm for 5 minutes and resuspending the 
bacterial pellet in 50 µl of 1:300 dilution of fluorescein isothiocyanate-conjugated 
polyclonal goat anti-mouse C3 antibody (ICN Cappel) followed by incubation on ice 
for 30 minutes. The labelled bacteria were then washed twice in 500 µl of PBS-Tween 
20 (0.1%), the bacterial cells were fixed using 3% paraformaldehyde and finally 
analysed by flow cytometry. IgG binding to the bacteria in different sera was analysed 
using the same method but incubating the bacteria with a 1:100 dilution of 
phycoerythrin-conjugated goat anti-mouse IgG (Jackson Immunoresearch). 
 
2.9.3 Opsonophagocytosis 
Opsonophagocytosis assay is a method to determine the serum opsonic activity 
following immunisation. However, in this assay the functional ability of anti-Sp0149 
and anti-Sp0749 antisera to aid in S. pneumoniae association with the phagocytes is 
analysed using flow cytometry. 
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(a) FAMSE labelling of S. pneumoniae for opsonophagocytosis 
The frozen bacterial stocks were streaked on to plain blood agar and incubated 
overnight at 37ºC in the presence of 5% CO2. A loopful of bacteria was inoculated in 
15 ml THY and cultured until the OD600 reached 0.6-0.7. The bacteria were 
centrifuged at 4000 rpm for 10 minutes, washed once with 0.1 M sodium bicarbonate 
buffer and 50 µl of 10 mg ml-1 FAM-SE solution (5,6-carboxyfluorescein-succinidyl 
ester; Molecular Probes, Eugene, Oreg.) prepared in DMSO was added. After 
incubation at 37ºC for 1 hour without shaking, the labelled bacteria washed 5 times in 
opsonophagocytosis buffer (HBSS + Ca + Mg) (Invitrogen) until no free dye was 
present. Aliquots of labelled S. pneumoniae were prepared containing 10% glycerol 
and serial dilutions of an aliquot were plated on plain blood agar plate to determine 
the bacterial counts and the remaining aliquots stored at -70ºC until use. 
 
(b) Tissue culture of HL60 for opsonophagocytosis 
HL60 (Human promyelocytic leukemia cells; CCL240; American Type Culture 
Collection, Rockville, Md.) were cultured in RPMI medium (Invitrogen) containing 
20% foetal bovine serum (Invitrogen), 1% glutamine (Invitrogen) and 1% penicillin / 
streptomycin (Invitrogen) to a cell density of 5 x 105 cells ml-1. Addition of 100 mM 
N,N-dimethylformamide (Sigma) and culturing for 5 days stimulated differentiation of 
the HL60 cells into granulocytes. The undifferentiated HL60 cell line was passaged 
daily for maintenance and propagation. Differentiated HL60 cells were washed twice 
by centrifuging at 1000 g for 7 minutes with HBSS (Hanks balanced salt solution) 
with 0.1% BSA, without Ca2+ and Mg2+. Cells were washed once in 
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opsonophagocytosis buffer (HBSS + Ca2+ + Mg2+), resuspended in 5 ml of 
opsonophagocytosis buffer and counted using haemocytometer. 
 
(c) Opsonophagocytosis 
Different dilutions of mouse sera were prepared in opsonophagocytosis buffer and 10 
µl of the diluted serum was added to a 96 well plate. To obtain a multiplicity of 
infection (MOI) of 10 bacteria per HL60, 106 cfu of FAM-SE labelled bacteria were 
added to each well and the plate was incubated for 20 minutes at 37ºC with gentle 
shaking at 150 rpm. When necessary 10 µl of 1/300 dilution of baby rabbit serum 
(Sigma) was added as a source of exogenous complement and the plate was incubated 
at 37ºC with gentle shaking at 150 rpm for 15 minutes. 105 washed and differentiated 
HL60 cells were added to each well and the plate incubated at 37ºC with gentle 
shaking at 150 rpm for 30 minutes. The cells were fixed by adding 50 µl of 3% 
paraformaldehyde to all the wells and analysed by flow cytometry. 
 
2.10 FLUORESCENCE-ACTIVATED CELL SORTING (FACS) ANALYSIS 
A minimum of 25,000 bacteria and 6,000 HL60 cells were analysed for the C3b 
deposition, IgG binding and opsonophagocytosis asays using a FACSCalibur flow 
cytometer (BD Biosciences). Cell Quest/Pro software (BD Biosciences) was used to 
acquire and analyse the data. Bacteria and the cells that were positive or negative for 
the above mentioned assays were sorted using FL-1 histogram, with the X-axis 
representing the intensity of fluorescence and the number of cells of varying intensity 
represented in the Y-axis. The left peak in the histogram determines the bacteria and 
cells with negative results, while the right peak determines the bacteria and cells with 
positive results for the assays. The percentage of positive bacteria and cells were 
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determined by creating a gate (M1 marker) around the positive peak which represents 
the proportion of bacteria positive for C3b / iC3b or IgG and the proportion of HL60 
cells associated with FAMSE-labelled bacteria. For the immune cell surface marker 
staining from BALF and lungs, lymphocytes were determined using their forward and 
side scatter properties and the identity and proportion of different sub-populations 
confirmed using antibodies to the cell surface markers CD4, CD8 (T cell subsets) and 
B220 (B cells).  Activated T cells were identifed by double staining with anti-CD4 
and -CD8 and anti-CD45RB, with activated cells recognised by loss of the CD45RB 
expression. Lymphocyte counts are presented as  the percent of CD4, CD8 and B220 
positive cells present in the lymphocyte gate, with a minimum of 10,000 (lungs) or 
1000 (BALF) cells counted (Thorpe et al., 2007). 
 
2.11 COMPUTER ANALYSIS 
The genomic DNA sequence of S. pneumoniae serotype 4 strain was obtained from 
The Institute for Genomic Research website (http://www.tigr.org). Blast searches and 
alignments of the available complete and incomplete bacterial nucleotide and protein 
databases were performed using NCBI website (http:// www.ncbi.nlm.nih.gov/blast). 
Primers for both PCR and RT-PCR were designed using ARTEMIS software. 
 
2.12 STATISTICAL ANALYSIS 
Competitive indices of the mutant strains were compared to a theoretical value of 1.0 
and the significance were determined using Student’s t-test. All the in vitro growth 
curves were performed in triplicates and represented as means and standard 
deviations. Results of growth curves, radioactive uptakes, radioactive substrate 
binding assays, ELISA, OP assay, C3b deposition and IgG binding assays and 
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cytospins were analysed using two-tailed t-tests. Results of survival experiments were 
compared using the log rank method. Non-parametric data (eg target organ CFU, 
proportions of lymphocyte and macrophages and lung histology results) were 
analysed using the Kruskal Wallis (if three or more groups) or Mann Whitney U (if 
only two groups) tests.  
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Table 2.2: Primers used during this study 
 
Primer name   Sequence 
 
Sp0090.1 GCT CTA GAC ATT GAG AGA GAC AAC TGG 
Sp0090.2 CGC TCT AGA CAA GAA GTA AGG GAA C 
Sp0149.1 GCT CTA GAG GCT CTT GCA GCT TGC GG 
Sp0149.2 CGC TCT AGA GGC TTT CGT TTG TAG CGT C 
Sp0610.1 GCT CTA GAT TAC GGA GAC TAC CAC G 
Sp0610.2 CGC TCT AGA TCC ACC AGA TAG CAT GCC 
Sp0710.1 GCT CTA GAT TGG GCG TTA CGA TTG 
Sp0710.2 CGC TCT AGA GTG CCT GTC CAC TTT C 
Sp0750.1 GCT CTA GAC GCG CTG TTA GCC CTA GG 
Sp0750.2 GCT CTA GAT GAT ACT GCA CGC ATG GC 
Sp846.1 GCT CTA GAT GTT AGC AGG CCT TCT TG 
Sp846.2 CGC TCT AGA GCC CCT GCA ATT TCA AC 
Sp1690.1 GCT CTA GAT TGC GCT AGC GGC TGT TG 
Sp1690.2 GCT CTA GAG CTT CCT CCA CCA CTA CG 
Sp1798.1 GCT CTA GAT GAC TGT CCC CGG TTT AG 
Sp1798.2 CGC TCT AGA TTG TTG ATT GGT CCT CCC 
Sp1826.1 GCT CTA GAC GAC TGC TTC TTC ATC TG 
Sp1826.2 CGC TCT AGA ATT GCC CGT CCT GTA CC 
Sp2084.1 GCT CTA GAT TTG GGC TTG TTG CCT G 
Sp2084.2 CGC TCT AGA TGT GAC CAC TTG TTG ACC 
Sp2108.1 GCT CTA GAA CTG CTA CAC TTG CTA G 
Sp2108.2 CGC TCT AGA ACC AAG GCT ACC TAC 
Cm.1  GCT CTA GAT TAT AAA AGC CAG TCA AT 
Cm.2  GCT CTA GAT TGA TTT TTA ATG GAT AA 
Sp1  TCG AGA TCT ATC GAT GCA 
Sp3  GGA TCC ATA TGA CGT CGA  
R-20  CAG CTA TGA CCA TGA TTA CG 
Sp0090.3 CCT GCA AAT AGG AGT ATA C 
Sp0149.3 GGT TTC TCA GTT TTT AGG 
Sp0610.3 GAT TTG ACT GTC CCG ATC G 
Sp0610.4 GCT CTA GAG AGG AGG AGT TCC GGA TG  
Sp0710.3 CTC CGC CAT GCA GGA TTC 
Sp0710.4 GCT CTA GAG GTC AGG CGA TTG CTA TCG 
Sp0750.3 GTG AGG GAA AAC CCT CGG 
Sp0846.3 GTG GAT TTG TTG CCA ACG 
Sp1690.3 CGT GCG AAT GCC TCA TCA C 
Sp1798.3 GGA GGT TGC TAT GAA TAG 
Sp1826.3 CCA ACT ATT ACT GTA AAC 
Sp2084.3 GTA GTA AGC CTA CAC AAG 
Sp2108.3 CTA TTC TTT AGG AGG AAT AC 
Sp090RT1 GAG TGA CGC CAT CAC TGG 
Sp090RT2 GAC CAT CCT TGC AGT CGG 
Sp091RT1 CCG TGA AAT AGC GTA GGC 
Sp091RT2 GCC AAA GCG GTC GGC TTG 
Sp092RT1 GAG CGA CTA CAC TAG CAG 
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Primer name   Sequence 
 
Sp092RT2 CAC TGG TAC TGT AGA CCC 
Sp95RT1 GTG GTC TGC AGC AAA TTG 
Sp095RT2 CGA GTG CCG TGT TCA CCC 
Sp096RT1 CAA ACC GTC TAG CAA GGC 
Sp0090RT1.1 CAC ACA ATG CTG GTC AGC  
Sp0091RT2.1 CCA TTG GAA CAA TCA AGG C 
90rt1.2  CTG GGC ATC TGG CCC TAT C 
91rt2.2  GGT AGG ATA CAA GAG AGG 
Sp148RT1 GCT CAG GGT CAA GAT GAG 
Sp149RT1 GGT TGT GAG TAG TCT GTG 
Sp149RT2 GGG AAA CAT CAC CTA AGG 
Sp150RT1 GTG CCA TGA CAA AGG GCG 
Sp150RT2 CCA CAG GGC GTT TCA GTC 
Sp151RT1 CCT CTG CTG TCT TTT GGC 
Sp151RT2 CAG CGT TGG CAG GTG CCC 
Sp152RT1 CTG ACG GGC AAA GAA GGC 
Sp152RT2 GTG ACG ACT GTG ACC TTG 
Sp153RT1 GCG CCC AAA GCC TAT ATG 
Sp0151RT1.1 CGC TGG AGC TTC AAC AGA C 
Sp0152RT2.1 CAG AAA GTC GCT CCG CTC 
Sp606RT1 GCT AGT CCT GGA ATC TAG 
Sp607RT2 CTC TAC TCT GTT ATC GCC 
Sp607RT1 CCA GAG AAG GTT GGG AAC 
Sp608RT2 CTC CCT CCA TTG ACC AAC C 
Sp608RT1 GGT CAC TGA TAA GAG GTA G 
Sp609RT2 CTT CCC TGC ACG CTC ATC 
Sp609RT1 CCA GAA TAA GTA CCG GTC 
Sp610RT2 CCT CCT CTT TGA TGA ACC 
Sp610RT1 CAG GAC AAC AAC TTG TCC 
Sp611RT1 CAA TAG CCT GAC GAA TCC 
Sp0749RT1 CGA TGC AGA CCA CAA CAC 
Sp750RT2 CCT AGG GCT AAC AGC GC 
Sp0750RT1 GGT GCG GCT CTT GGT GG 
Sp0751RT2 CAC CAA TCG CCA TGA AAC C 
Sp751RT1 GAC CAG GTG GAC TCC TTG G 
Sp0752RT2 GTC CAA GTC CCA AAG AGG 
Sp0752RT1 GGC CGT TTA ATC GCT CAA G 
Sp0753RT2 GGG CGC GTC CCA TGG CAA G 
750RT1.1 GAT GGG GGT TAC TCC AGG 
751RT2.1 CCC AGA GTT GCT ACC GC 
751RT1.1 GGT GCG ATT GTT TCG G 
752RT2.1 GGT TCC GTA GCA AGG G 
753RT1.1 GGA GAA TCG TCC TAT CAG 
754RT2.1 CAG GCA GACGGT GCA AAC C 
Sp845RT1 CCC TGG CGG TCA AGT GAT C 
Sp846RT2 CAC CTT GGT ATT ATC ACG C 
 117 
 
Primer name   Sequence 
 
Sp846RT1 GTG GGT TGG ATG TCG GTG 
Sp847RT2 GCA GAC TGC CAA AGG CTG 
Sp847RT1 GGT ATT TCT GCC AAG CGG 
Sp848RT2 GTA AAG ATG AGA GGT GCT G 
Sp1686RT2 CGC ATC TAC CAT CTC GCG AC 
Sp1687RT1 GAA GTG GCC GCA AGG GAG 
Sp1687RT2 CAG TTG ATA TGA ACC TCC 
Sp1688RT1 GTT GTG CTA CCG ATT GTA G 
Sp1688RT2 CTG CAA CGA TGG TCG CAC 
Sp1689RT1 GGT GCT TCA AGT TGG CAG 
Sp1689RT2 GGC GTA CTC TGT GAA GAG 
Sp1690RT1 GGG CCA AGT GTA CAA GCT G 
Sp1690RT2 CCT TGA GTA AAG GAG TGC C 
Sp1691RT1 CCA TGG CTG TTA CAT CGC C 
Sp1794RT1 GGC AAT TGC CGG GCA ACG 
Sp1795RT1 CCA AGA ACA CAA GTG GGC  
Sp1795RT2 CAA GTG CTC CCA AGT CAC 
Sp1796RT1 CCA AAT GGC GTT TGG ATC 
Sp1796RT2 GGA GAT AAC GGT GAA CTG 
Sp1797RT1 GCT TTT GTA GGA CAG TGG 
Sp1797RT2 GCT GGT AAC CTT CTA CAG 
Sp1798RT1 GCT TCA ACG CTC TAC ACG 
Sp1798RT2 GTG CGT ATA AAA TGA GCT G 
Sp1799RT1 GCA AAC GTA TTC CTC ATG 
Sp1822RT1 CAG GAG GTA AAT GAA AGG C 
Sp1823RT1 GCA TTT GGG CTT CGG CAG 
Sp1823RT2 CCA GCG CCT AGA AAA CCC 
Sp1824RT1 GGA AGA TGC AGC AAG AAG 
Sp1824RT2 CAG TCG CTA AAA CCA CTC 
Sp1825RT1 GTC GGT ACA CCA GTA GAG 
Sp1825RT2 CCA CGC TTT TCA GGT TCC 
Sp1826RT1 GGG GTT CTG GTG CAT TAG 
Sp1826RT2 CAC GGT CTG CTA ATT GAG C 
Sp1827RT1 GAA GAG GAG GAA GAA GAG 
Sp1827RT2 CTC CGT TTC ACG ATT TTC 
Sp1828RT1 GAC ATG TGT AGA GAT ACA TG 
Sp1824RT2.1 GAT GTA CAG CAT CAA GGG 
Sp1825RT1.1 GAC CGA TGA AAC AGT CCA CG 
Sp1825RT1.1 CCA CGC TTT TCA GGT TCC 
Sp1826RT2.1 GCC CTC AAA GAT CTA CCT G 
Sp1827RT1.1 GCT ACA ACT GTA TTC CCA G 
Sp1828RT2.1 CTA GGC TCG GGA GAA GGC 
Sp1825RT1.2 ACC ACA TCC TGA AGG CCA 
Sp1826RT2.2 GAA TGA TGT GGG GTT CTG 
Sp2108RT1 GTC TGC AGT TTG GGA TCC AG 
Sp2109RT2 GGA ATG ATA GAC AGC AGG G 
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Primer name   Sequence 
 
Sp2109RT1 CAA TGG CGG CAG CTG TTA C 
Sp2110RT2 GTT GAG GTA CCA AGT ACC G 
2107RT1.1 CAA CGA AGT CGT AAG CAC 
2108RT2.1 CCA AGC ACC GCA GCG CTC 
2108RT1.1 CCC AGC TAA TAC TGA GGC 
2109RT2.1 GGT TGC TCA ATT CAG GGG 
2110RT1.1 CCG TAG GTC TCC AAA CC 
2111RT2.1 GGA TAG GTC TCC TGG GAG 
16s.1  GGT GAG TAA CGC GTA GGT AA 
16s.2  ACG ATC CGA AAA CCT TCT TC 
PsaA.1  CGT TCC GAT TGG GCA AGA C 
PsaA.2  GCA CTT GGA ACA CCA TAG 
Sp0149.1 G GCT CTT GCA GCT TGC GG 
Sp0149.2 GGC TTT CGT TTG TAG CGT C 
Sp0749.1 T GTG GAG AAG TGA AGT CTG GA 
Sp0749.2:        GCA CGG TAA GCG TCA AGG AAGG 
Sp0148F CAC CAA TTG CCC AAA ATC C 
Ery-Sp0148R TATT TTAT ATT TTT GTT CAT GAT TCT TTC TCC TTA AAA 
ATA 
Ery-Sp0150F ATT ATT TAA CGG GAG GAA ATA A TAA GAA ACA GGG 
AGG TGG GAG 
Sp0150R CCA AGG CAT TTT TGG TCC C 
Sp0749F CAC TGA CAA TGC CAG TGA CTA TGC 
Ery-Sp0749R TAT TT TAT ATT TTT GTT CAT AAG ATT CAC TCT TTC TAT 
TTA TAA 
Ery- Sp0753F ATT ATT TAA CGG GAG GAA ATA A AAC ATT CCA GTG 
GAT TGT TTT AG 
Sp0754R GC GGA ATA TTG ACT GTA TGG GAG 
Sp0149 For TGC GGA AAC TCA GAA AAG AAA GCA 
Sp0149 Rev TTA CCA AAC TGG TTG ATC CAA ACC A 
Sp0749Fwd CGG GAT CCT GTG GAG AAG TGA AGT CTG GA 
Sp0749Rv CGG GAT CCT TAT GGT TTT ACA ACT TCT GC 
Sp1032 (piaA) Fwd TGT TCT TCT AAT TCT GTT AAA AAT G 
Sp1032 (piaA) Rv TTA TTT CGC ATT TTT GCA TG 
Sp1872 (PiuA) Fwd TGT AGT ACA AAC TCA AGC AC  
Sp1872 (PiuA) Rv TTA TTT CAA AGC TTT TTG TAT G  
pQE30F  CCC GAA AAG TGC CAC CTG 
 
 
 
 
 119 
Table 2.3: Plasmids constructed during the study 
 
Abcr : Antibiotic resistance  
 
Ampr : Ampicillin resistant  
 
Kanr : Kanamycin resistant  
 
a No restriction enzyme utilized during ligation. 
 
 
Plasmid  
name  
E. coli 
strain 
Target  
gene (bp) 
Insert 
size 
Restriction site Plasmid 
backbone 
Abc r  
pPC110.1 DH5α |Sp0090 337 5’ XbaI 3’ pID701 Cmr 
pPC111.1 DH5α Sp0149 392 5’ XbaI 3’ pID701 Cmr 
pPC112.1 DH5α Sp0610 315 5’ XbaI 3’ pID701 Cmr 
pPC114.1 DH5α Sp1798 357 5’ XbaI 3’ pID701 Cmr 
pPC115.1 DH5α Sp1826 425 5’ XbaI 3’ pID701 Cmr 
pPC116.1 DH5α Sp0750 462 5’ XbaI 3’ pID701 Cmr 
pPC117.1 DH5α Sp1690 657 5’ XbaI 3’ pID701 Cmr 
pPC118.1 DH5α Sp0846 590 5’ XbaI 3’ pID701 Cmr 
pPC119.1 DH5α Sp2084 500 5’ XbaI 3’ pID701 Cmr 
pPC120.1 DH5α Sp2108 450 5’ XbaI 3’ pID701 Cmr 
ΔSp0149 
 
ΔSp0750-53 
 
pPC749 
JM109 
 
JM109 
 
Novablue 
Sp0149 
 
ΔSp0750-53 
 
Sp0749 
2040 
 
2454 
 
1200 
5’a ; 3’a 
 
5’a ; 3’a 
 
5’ BamHI; 3’ SalI 
pGEM-T 
easy 
pGEM-T 
easy 
pST-1 
Ampr 
 
Ampr 
 
Ampr 
 
pPc138 
 
 
M15 
 
Sp0149 
 
800 
 
5’a ; 3’a 
 
pQE30UA 
 
Ampr / 
Kanr 
 
pPC139 
 
Sp1032-
pQE30UA 
 
Sp1872-
pQE30UA 
 
M15 
 
M15 
 
 
M15 
Sp0749 
 
Sp1032 
 
 
Sp1872 
1200 
 
969 
 
 
900 
5’ BamHI ; 3’ SalI 
 
5’a ; 3’a 
 
 
5’a ; 3’a 
pQE30 
 
pQE30UA 
 
 
pQE30UA 
  Ampr /  
  Kanr 
  Ampr /  
  Kanr 
 
  Ampr /  
  Kanr 
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Table 2.4: S. pneumoniae mutant strains constructed during the study 
 
Strain                  Target  
                             gene 
   ABC    
transporter 
                                  Description 
 
110.1    
 
 
111.1 
 
 
111.1
D39
  
 
 
112.1 
 
 
114.1 
 
 
115.1 
 
 
116.1 
 
 
116.1
D39
 
 
 
117.1 
 
 
118.1 
 
 
119.1 
 
 
120.1 
 
 
ΔSp0149 
 
 
ΔSp0750-53 
 
 
ΔSp0149D39 
 
 
ΔSp0750-53D39 
 
 
 
Sp0090 
 
 
Sp0149 
 
 
Sp0149 
 
 
Sp0610 
 
 
Sp1798 
 
 
Sp1826 
 
 
Sp0750 
 
 
Sp0750 
 
 
Sp1690 
 
 
Sp0846 
 
 
Sp2084 
 
 
Sp2108 
 
 
Sp0149 
 
 
Sp0750-53 
 
 
Sp0149 
 
 
Sp0750-53 
 
Sp0090-92 
 
 
Sp0149-152 
 
 
Sp0149-152 
 
 
Sp0607-610 
 
 
Sp1796-98 
 
 
Sp1824-26 
 
 
Sp0749-753 
 
 
Sp0749-753 
 
 
Sp1689-90 
 
 
Sp0844-848 
 
 
Sp2084-87 
 
 
Sp2108-10 
 
 
Sp0149-53 
 
 
Sp0749-53 
 
 
Sp0149-53 
 
 
Sp0749-53 
 
 
0100993 containing an insertion made with  
plasmid pPC 110.1:  Cmr 
 
0100993 containing an insertion made with  
plasmid pPC 111.1: Cmr 
 
D39 containing an insertion made from 111.1  
genomic DNA 
 
0100993 containing an insertion made with  
plasmid pPC 112.1: Cmr 
 
0100993 containing an insertion made with  
plasmid pPC 114.1: Cmr 
 
0100993 containing an insertion made with  
plasmid pPC 115.1: Cmr 
 
0100993 containing an insertion made with  
plasmid pPC 116.1: Cmr 
 
D39 containing an insertion made from  
116.1 genomic DNA 
 
0100993 containing an insertion made with  
plasmid pPC 117.1: Cmr 
 
0100993 containing an insertion made with  
plasmid pPC 118.1: Cmr 
 
0100993 containing an insertion made with  
plasmid pPCPC 119.1: Cmr 
 
0100993 containing an insertion made with  
plasmid pPC 120.1: Cmr 
 
0100993 containing the Sp0149 deletion construct:  
ermr 
 
0100993 containing the Sp0750-53 deletion  
construct: ermr 
 
D39 containing the Sp0149 deletion construct  
from 0100993: ermr 
 
D39 containing the Sp0750-53 deletion construct  
from 0100993: ermr 
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    Chapter 3 
   Screening of S. pneumoniae ABC transporters 
 
Eleven S. pneumoniae ABC transporters were chosen from the annotated completely 
sequenced genome of serotype 4 strain (TIGR4) for the investigation. Amino acid 
homologies of the chosen TIGR4 ABC transporters with other bacterial species were 
identified using the Basic Local Alignment Search Tool (BLAST). Genetic 
organisation studies of the chosen ABC transporters were analysed by RT-PCR in the 
serotype 3 (0100993 strain) using the available TIGR4 genome information. Nine 
disruption mutants were then constructed in 0100993 strain and their in vitro and in 
vivo phenotypes were analysed. These results are presented in this chapter. 
 
3.1 IDENTIFICATION AND SELECTION OF ABC TRANSPORTER GENES 
The ABC transporters chosen for these studies were identified from the annotated 
completely sequenced genome of the capsular serotype 4 strain of S. pneumoniae 
(TIGR4) (Tettelin et al., 2001). The genome contains 73 ABC transporters (Harland 
et al., 2005), 33 genes encoding putative lipoproteins, 24 of which are organised as 
operons with genes encoding other components of ABC transporter proteins 
(ATPases, permeases and or additional lipoproteins). Eleven of these have been 
previously described, (Table 1.3). Of the remaining 13 candidates, we selected 11 
ABC transporters from the TIGR4 genome of S. pneumoniae for further investigation 
(Sp0090-0092, Sp0149-52, Sp0607-10, Sp0707-11, Sp0749-53, Sp0846-48, Sp1689-
90, Sp1796-98, Sp1826-28, Sp2084-87 and Sp2108-2110). The genetic organisation 
of these selected ABC transporters are shown in figure 3.1. 
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3.2 AMINO ACID HOMOLOGY OF TIGR4 ABC TRANSPORTER GENES WITH OTHER 
BACTERIAL SPECIES 
To identify the close homologues of the S. pneumoniae ABC transporters, the derived 
amino acid sequence of each gene within the putative ABC transporter operons of 
TIGR4 genome were aligned against the amino acid sequence of completely 
sequenced R6 genome (an avirulent serotype 2 strain of S. pneumoniae) and other 
bacterial genomes using BLAST and the NCBI website (http://www.tigr.org). Six of 
the TIGR4 ABC transporter proteins (Sp0090-92, Sp0148-52, Sp0707-11, Sp0749-53, 
Sp0846-48, Sp2108-10) had >90% identity to the proteins encoded by genes in the R6 
strain. The exceptions were: Sp0607 with 85% identity and 86% similarity; Sp1826 
with 89% identity and 90% similarity and Sp0610, Sp1796, Sp1797, Sp1798, whose 
amino acid sequences were completely absent in the R6 strain of S. pneumoniae. 
Other bacterial species which contained genes encoding proteins exhibited homology 
of at least 50% identity and 60% similarity to the genes encoding proteins present in 
the TIGR4 genome included S. suis, S. agalactaie, S. pyogenes, S. mutans and S. 
thermophilus. In contrast, proteins encoded by the Sp1688-90, Sp1824-26 and 
Sp2084-87 operon had no close homologues amongst streptococci probably 
suggesting that these genes may not be horizontally transferred. Analysis of the S. 
pneumoniae ABC transporter genes, their homology to other bacterial species and 
their probable function according to BLAST similarities are listed in the Table 3.1. 
 
3.3 CONSTRUCTION OF THE DISRUPTION MUTANTS OF S. PNEUMONIAE BY 
INSERTIONAL DUPLICATION MUTAGENESIS 
To investigate the role of these ABC transporters in virulence in mouse models of  
Sp0090-92 :  Putative ABC transporter
Sp0090                  Sp0091                           Sp0092
Permease Permease Lipoprotein
Sp0149-0153 : Metal ion ABC transporter, unknown function
Sp0148              Sp0149               Sp0150                    Sp0151                 Sp0152         Sp0153
Lipoprotein        Lipoprotein Peptidase                  ATPase Permease Hypothetical
Sp0607-0610 : Putative amino acid ABC transporter 
Sp0607                   Sp0608                  Sp0609                 Sp0610
Permease Permease Lipoprotein               ATPase
Sp0708-711: Putative glutamine ABC transporter 
Sp0707 Sp0708 Sp0709 Sp0710 Sp0711
PermeaseATPase ? ATPase
Sp0749            Sp0750              Sp0751               Sp0752             Sp0753
Lipoprotein            Permease Permease ATPase ATPase
Sp0749- 0753 : Putative branched chain amino acid ABC transporter
Permease
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Sp0846                          Sp0847                 Sp0848 
ATPase Permease Permease
Sp0846-0848 : Putative sugar ABC transporter
Sp1688                         Sp1689                                Sp1690
Permease Permease Lipoprotein
Sp1688-90 :  ABC transporter, unknown function
Sp1824                          Sp1825                             Sp1826
Permease ATPase Lipoprotein
Sp1824-26 : Putative iron uptake ABC transporter
Sp1796-98 :  ABC transporter, unknown function
Sp1796                         Sp1797                         Sp1798
Permease Permease Permease
Sp2084                          Sp2085               Sp2086                Sp2087
Lipoprotein                 Permease Permease ATPase
Sp2084-87 : Putative phosphate ABC transporter     
Sp2108                          Sp2109                  Sp2110
Lipoprotein                     Permease Permease
Sp2108-10 : Putative maltodextrin ABC transporter     
Fig 3.1 The genetic organisation of TIGR4 S. pneumoniae ABC transporters chosen for the 
phenotype studies. Shaded arrows indicate the genes disrupted by insertional duplication
mutagenesis 124
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Table 3.1 BLAST alignments of the derived amino acid sequences of the investigated 
S. pneumoniae (TIGR4) ABC transporters. 
 
Genea Size 
(amino 
acids) 
Protein name Organism % Identity / 
Similarity 
Possible 
substrate 
(transport 
classification)
b
 
Sp0090 
Sp0091 
Sp0092 
319 
307 
491 
EfaeDRAFT_2526 
EfaeDRAFT_2527 
EfaeDRAFT_2538 
Enterococcus faecium 
E. faecium 
E. faecium 
61/80 (311) 
60/79 (300) 
53/70 (486) 
Sugar 
(CUT1 3.A.1.1) 
Sp0148 
Sp0149 
Sp0150 
Sp0151 
Sp0152 
276 
284 
457 
353 
230 
SMU.1942c 
SPs1626 
SMU.1940c 
SsiuDRAFT_0064 
SPs1624 
Streptococcus mutans 
Streptococcus pyogenes 
S. mutans 
Streptococcus suis 
S. pyogenes 
55/76 (237) 
67/81 (278) 
70/85 (457) 
80/90 (352) 
71/89 (230) 
Methionine 
(MUT 3.A.1.24) 
Sp0607 
Sp0608 
Sp0609 
Sp0610 
219 
219 
254 
252 
SMU.1522 
SMU.1521 
StheL01000593 
StheL01000592 
S. mutans 
S. mutans 
Streptococcus thermophilus 
S. thermophilus 
74/85 (213) 
62/81 (222) 
60/73 (232) 
82/90 (251) 
Amino acid 
(PAAT 3.A.1.3) 
Sp0707 
Sp0709 
Sp0710 
Sp0711 
215 
252 
225 
206 
SsuiDRAFT_0032 
SGO_0983 
SGO_0984 
SGO_0985 
S. suis 
Streptococcus gordonii 
S. gordonii 
S. gordonii 
60/77 (213) 
88/94 (252) 
89/95 (225) 
87/94 (226) 
Amino acid 
(PAAT 3.A.1.3) 
Sp0749 
Sp0750 
Sp0751 
Sp0752 
Sp0753 
386 
289 
318 
254 
236 
SAG1582 
SAK_1597 
gbs1630 
SsuiDRAFT_0078 
SsuiDRAFT_0077 
Streptococcus agalactiae 
S. agalactiae 
S. agalactiae 
S. suis 
S. suis 
53/73 (390) 
83/93 (289) 
73/88 (252) 
85/93 (254) 
87/96 (236) 
BCAAc 
(HAAT 3.A.1.4) 
Sp0846 
Sp0847 
Sp0848 
511 
352 
318 
Spy1227 
SAK_1051 
Spy0928 
S. pyogenes 
S. agalactiae 
S. pyogenes 
81/91 (508) 
77/88 (353) 
80/92 (318) 
Ribonucleoside 
(CUT2 3.A.1.2) 
Sp1688 
Sp1689 
Sp1690 
277 
294 
445 
PM1760 
PM1761 
PM1762 
Pasteurella multocida 
P. multocida 
P. multocida 
80/91 (277) 
79/93 (291) 
70/85 407 
Sugar 
(CUT1 3.A.1.1) 
Sp1796 
Sp1797 
Sp1798 
538 
305 
305 
SsuiDRAFT_0524 
SsuiDRAFT_0525 
SsuiDRAFT_0526 
S. suis 
S. suis 
S. suis 
78/89 (537) 
82/94 (294) 
84/95 (303) 
Sugar 
(CUT1 3.A.1.1) 
Sp1824 
Sp1825 
 
Sp1826 
563 
336 
 
355 
Lxx14070 
STH2752 
 
Lxx14040 
Leifsonia xyli 
Symbiobacterium 
thermophilum 
L. xyli 
31/48 (539) 
45/59 (343) 
 
30/48 (323) 
Cation 
(BIT 3.A.1.20) 
Sp2084 
Sp2085 
Sp2086 
Sp2087 
291 
287 
271 
250 
RUMOBE_00498 
Cthe_1604 
DORLON_00312 
BACCAP_00261 
Ruminococcus. obeum 
Clostridium thermocellum 
Dorea longicatena 
Bacteroides capillosus 
46/65 (287) 
61/98 (284) 
59/80 (287) 
72/86 (253) 
Phosphate 
(PhoT 3.A.1.7) 
Sp2108 
Sp2109 
Sp2110 
423 
435 
280 
M_28Spy1048 
Spy1301 
SsuiDRAFT_0440 
S. pyogenes 
S. pyogenes 
S. suis 
53/67 (420) 
66/82 (430) 
85/93 (280) 
maltodextrin 
(CUT1 3.A.1.1) 
aTIGR4 genome Sp number. 
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bTransport classification and subfamily and number according to the transport 
classification system based on sequence similarity (32,45) (http://www.tcdb.org/). 
cBCAA  Branched-chain amino acid. 
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S. pneumoniae septicaemia and pneumonia, and to identify their growth defects in in 
vitro conditions,, mutant strains were constructed containing a disrupted copy of one 
of the genes encoding each of the ABC transporters using insertional duplication 
mutagenesis (IDM) in 0100993 strain of the capsular serotype 3 S. pneumoniae. The 
0100993 strain was used to construct IDM mutants of the chosen ABC transporters 
because previous virulence studies of S. pneumoniae ABC transporters were 
performed by constructing IDM mutants in 0100993 strain in our laboratory. In 
general, the first gene of the probable operon was disrupted to prevent the 
transcription of the downstream genes and therefore ensure the maximum loss of 
function of the putative ABC transporter operon. 
To construct S. pneumoniae mutant strains by IDM, forward and reverse 
primers were designed (Table 2.1) to amplify an internal portion of the target gene, 
which was amplified by PCR using 0100993 strain of serotype 3 genomic DNA as the 
template (Fig 3.2 A). An Xba1 restriction enzyme site was linked to the primers at 
5’and 3’end and the amplified PCR products were digested with XbaI and ligated into 
pID701 (Fig 3.2 B). pID701 is a suicide vector derived from pEVP3 which carries 
chloramphenicol for selection in S. pneumoniae and E. coli (Claverys et al., 1995; 
Lau et al., 2001). After transformation into E. coli DH5α, positive clones of were 
identified by colony PCR using insert specific forward and reverse primers and 
plasmid DNA was extracted. The 0100993 strain of S. pneumoniae was then 
transformed with recombinant pID701 containing the target gene as described in 
chapter 2, plasmid constructs were confirmed by sequencing the PCR products 
generated by plasmid specific primer Sp1 or Sp3, upstream and downstream primers 
from the target region using the genomic DNA extracted from the mutant strains of S. 
pneumoniae as the template (Fig 3.3 A and B). Of the chosen 11 ABC transporters, 
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mutants were successfully constructed for 10 of them (Table 3.2) Despite repeated 
attempts and confirmation by sequencing that the plasmid was correctly constructed, 
no corresponding mutants were obtained for Sp0710 possibly because some regions 
of S. pneumoniae genome may be resistant to transformation or because the disruption 
of this gene may prove to be lethal for the bacteria. The Sp0090-, Sp0149-, Sp0610-, 
Sp1796
- and Sp1824- mutant strains were constructed by Suneeta Khandavilli.  
 
Table 3.2: List of mutants constructed in 0100993 strain with the Sp number, possible 
substrate specificity and disruption site. 
 
 
aBranched chain amino acids 
 
3.4 STABILITY OF THE MUTATION 
All the isogenic mutants listed in the table 3.2 were checked for the stability of the 
Mutant 
name 
Plasmid name ABC transporter 
gene 
Putative 
substrate 
Site of disruption 
Sp0090
-
 pPC110.1 Sp0090-92 Sugar Sp0090 
Sp0149
-
 pPC111.1 Sp0149-152 Metal ion Sp0149 
Sp0610
-
 pPC112.1  Sp0607-610 Amino acid Sp0610 
Sp0750
-
 pPC116.1 Sp0749-753 BCCAa Sp0750 
Sp0846
-
 pPC118.1 Sp0846-848 Sugar Sp0846 
Sp1690
-
 pPC117.1 Sp1689-90 Sugar Sp1690 
Sp1796
-
 pPC114.1 Sp1796-98 Sugar Sp1798 
Sp1824
-
 pPC115.1 Sp1824-26 Iron Sp1826 
Sp2084
-
 pPC119.1 Sp2084-87 Phosphate Sp2084 
Sp2108
- pPC120.1 Sp2108-2110 Maltose Sp2108 
 A
 
 
 
 
Xba1
Xba1 Xba1
PCR product
Cat gene
Ori
pID701
2906 bp
B
Figure 3.2 Schematic diagram of pID701 plasmid used to construct S. pneumoniae mutants 
in 0100993 strain using insertional duplication mutagenesis.
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1. PCR amplification of an 
internal portion of target gene
2. Ligation into suicide vector
3. Transformation in S. pneumoniae
Sp1
Sp3
P3 P1
P2P2 P4
P1
P1
P2
pID701
Sp1
Sp3
P2 P4
P3 P1
target gene
Sp0749.3            Sp0749.3
+ Sp1                  +Sp3          Kb ladder
B
A
Fig 3.3 Diagram of insertional duplication mutagenesis, showing the integration of the
entire plasmid into the target gene flanked by a duplication of the insert targeting DNA.
(1 and 2) Successful ligation of the PCR product into pID701 was confirmed by PCR
with primers Sp1 and P1 or P2 (depending on the insert orientation). (3 and B)
Successful transformation into S. pneumoniae (0100993 strain) was confirmed by PCR using P3
or P4 and Sp1 or Sp3 (depending on the orientation of the insert).
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mutation by culturing the mutant strains in THY broth in the absence of antibiotic 
(and therefore with no selective pressure for the mutation) for two 8 hours growth 
cycles followed by plating onto plain and antibiotic containing Columbia agar plates. 
S. pneumoniae mutant strains Sp0090-, Sp0149-, Sp0610-, Sp0750-, Sp0846-, Sp1690-, 
Sp1796
-, Sp1824 -, and Sp2108- had similar number of colonies on the antibiotic-free 
and antibiotic-supplemented plates confirming the mutation was stable over these 
time periods. However, Sp2084- had an unstable mutation, as the number of colonies 
recovered from these mutant strains were very low on the blood agar containing the 
antibiotic (19 cfu) compared to the number of colonies recovered on the 
unsupplemented blood agar (>1000 cfu) when a 10-4 dilution of the second 8 hour 
THY culture was plated. 
 
3.5 GROWTH CURVES IN THY 
The in vitro phenotypes of the mutants strains were investigated by comparing the 
growth rates of the mutant strains to the wild-type strains in the undefined complete 
medium (THY). Equal numbers of the wild-type and the mutant bacteria obtained 
from thawed stocks were inoculated into THY, cultured at 37°C in the presence of 5% 
CO2 and the optical density recorded at one hourly intervals for 8 hours. All the 
mutant strains exhibited good growth in THY, similar to the wild-type strain (Fig 3.4 
and 3.5), suggesting that the disruption of the target genes of the ABC transporters 
had little effect on the growth of S. pneumoniae in a complete laboratory medium. 
 
3.6 PHENOTYPE ANALYSIS BY COMPETITIVE INDEX 
To investigate the role of the selected ABC transporters in mouse models of 
pulmonary (IN inoculation) and systemic (IP inoculation) infection, mixed inocula of 
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wild-type and mutant strains were inoculated into mice by either intraperitoneal or 
intranasal routes and the competitive indices (CI) determined by plating the bacteria 
recovered from the target organs (spleen and lungs) on plain and chloramphenicol 
containing medium. The in vitro phenotypes of the mutant strains were also 
investigated using CIs to identify any subtle growth defects in complete medium 
(THY), high osmotic stress medium (THY + 100mM NaCl) and normal physiological 
fluid (human blood) and relate these to the in vivo phenotype. The cfu of wild-type 
and mutant strains of bacteria recovered from various target organs and media were 
enumerated by plating and CIs calculated using the formula described in Chapter 2. A 
CI of 1 shows there is no difference in virulence or growth between wild-type and 
mutant strains whereas CIs less than 1 suggest a degree of attenuation in virulence or 
growth. The CIs of the mutants in different in vitro growth conditions and mouse 
models of septicaemia (IP) and pneumonia (IN) infection are shown in the table 3.3. 
Most of the mutants had CIs close to 1.0 in both complete medium (THY) and 
high osmotic stress medium (THY + 100mM NaCl), suggesting that the disruption 
performed in the target gene of the ABC transporters had no effect on growth in rich 
laboratory medium or in the presence of high osmotic stress. The exceptions were 
Sp0610
-which had impaired growth in high osmotic media and Sp0750- which had 
mildly impaired growth in THY. In contrast, in normal physiological fluid, that is 
human blood, several mutants (Sp0090-, Sp0149-, Sp1824-, Sp0750-), and to a lesser 
extent Sp0610-, exhibited decreased CIs. This suggests these mutants have a particular 
problem growing under the greater stress conditions (presence of immune cells, 
restricted nutrient availability) found in physiological fluid compared to THY. In both 
systemic and pulmonary infection, Sp0149- and Sp0750- were markedly attenuated in  
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Fig 3.4 Growth of mutant strains (squares) of ABC transporters and the wild-type (diamonds) 
of S. pneumoniae,ST3 (0100993 strain) measured in THY medium. Results presented are the 
mean of triplicate samples for each strain.   133
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Fig 3.5 Growth of mutant strains (squares) of ABC transporters and the wild-type (diamonds) 
of S. pneumoniae,ST3 (0100993 strain) measured in THY medium. Results presented are the 
mean of triplicate samples for each strain.   
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Strain THY THY + 100mM 
NaCl
Blood IP IN
Sp0090- 1.06 ± 0.31
n=7
0.40 ± 0.08
n=6
0.50 ± 0.10
n=5
0.43 ± 0.13
n=4
1.17 ± 0.21
n=3
Sp0149- 0.80 ± 0.27
n=13
0.85 ± 0.26
n=6
0.46 ± 0.13
n=6
0.067 ± 0.028
n=5
0.023 ± 0.019
n=6
Sp0610- 0.94 ± 0.32
n=17
0.65 ± 0.13
n=6
0.71 ± 0.12
n=6
0.70 ± 0.13
n=5
0.64 ± 0.30
n=4
Sp0750- 0.68 ± 0.17
n=9
0.94 ± 0.30
n=3
0.38 ± 0.15
n=6
0.17 ± 0.12
n=10
0.016 ± 0.018
n=8
Sp0846- 1.07 ± 0.22
n=8
0.88 ± 0.26
n=8
0.93 ± 0.17
n=6
0.61 ± 0.37
n=6
0.45 ± 0.18
n=4
Sp1690- 0.97 ± 0.23
n=12
1.27 ± 0.52
n=3
1.61 ± 0.35
n=6
0.89 ± 0.39
n=5
ND
Sp1796- 0.91 ± 0.28
n=7
0.91 ± 0.30
n=3
0.99 ± 0.29
n=6
1.34 ± 0.48
n=6
ND
Sp1824- 0.95 ± 0.23
n=7
0.85 ± 0.14
n=3
0.49 ± 0.008
n=6
0.59 ± 0.10
n=3
0.40 ± 0.17
n=3
Sp2108- 1.06 ± 0.076
n=4
0.81 ± 0.18
n=8
0.94 ± 0.14
n=6
0.37 ± 0.18
n=8
3.33 ± 3.5a
n=5
Table 3.3 In vitro and in vivo phenotype analysis of S. pneumoniae ABC transporter 
mutant strains (0100993) by competitive index (CI).
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ND: Not Done
a: Highly variable results were obtained even after the experiment was repeated several times 
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virulence, while Sp0090-, Sp0610-, Sp1824- and Sp2108- had partial attenuation of 
their virulence. Sp1796- and Sp1690- did not show any impairment in virulence. 
Sp0750
- showed a greater attenuation of virulence in pulmonary infection than in 
systemic infection suggesting a possible greater role for the corresponding ABC 
transporters during pneumonia compared to septicaemia These in vivo CIs mirrored 
the CIs for blood for most mutant strains, with those strains showing no impairment in 
blood also being fully virulent after IP inoculation (Sp0846-, Sp1690- and Sp1796-) 
and those strains with impaired CIs in blood having a similar CI or lower during 
infection. Sp2108- is an exception as this particular mutant strain exhibited attenuation 
in systemic models of infection although there was no impairment in human blood. 
Even though the CIs of the mutant strains in human blood mirrored the CIs in in vivo 
infection models, there was no marked attenuation as observed in IP and IN models of 
infection. One explanation could be that the natural exposure of the humans to S. 
pneumoniae would have elicited antibodies and therefore may have cleared both the 
wild-type and mutant strains of bacteria. The CI for pulmonary infection for Sp2108- 
was too variable for easy interpretation. The similar CI for the Sp0610- strain in 
THY+NaCl, blood and in vivo suggests the mildly impaired virulence of this strain is 
due to poor growth under the osmotic conditions found in vivo. The impairment in 
virulence of Sp0090-, Sp0610-, Sp1824- and Sp2108- were relatively mild and these 
strains were not investigated further. However, as the Sp0149- and Sp0750- were more 
significantly attenuated in virulence they were chosen for further investigation and as 
potential vaccine candidates. 
 
3.7 ANALYSIS OF THE GENETIC ORGANISATION OF THE ABC TRANSPORTER 
OPERONS BY RT-PCR 
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To confirm the operon structure of the ABC transporters and identify genes whose 
transcription will be disrupted in the mutant strains, RT-PCR was performed with 
primers designed to amplify a product that spans the junctions of the genes present in 
the possible operon. Total RNA from 0100993 strain of S. pneumoniae serotype 3 was 
used as the template for RT-PCR, its purity being demonstrated by the absence of 
DNA contamination using appropriate RT-PCR negative control reactions containing 
no reverse transcriptase. As controls for the target specific PCR, the same primers 
were used with the genomic DNA as the template. Since the ABC transporters were 
selected using the TIGR4 genome sequence, cDNA products obtained from the RT-
PCR not only gave the information about the organisation of genes, but also, 
confirmed that the genes were organised in the serotype 3 strain in an identical way to 
the TIGR4 genome. In addition, deducing the genetic organisation of these operons in 
serotype 3 genetic background will also provide information on the possible polar 
effect due to IDM. Amplification of cDNA failed if the primers spanned junctions of 
genes of the ABC transporter operon were not co-transcribed. 
 
(a) Sp0090-0092: 
RT-PCR analysis of the transcriptional structure for these three genes suggested that 
Sp0090, Sp0091 and Sp0092 are all co-transcribed with transcription terminating after 
Sp0092 in serotype 3 (Table 3.4).  
 
(b) Sp0148-0152 
Using serotype 3 RNA, RT-PCR analysis of the transcriptional structure for Sp0148-
0152 suggested that Sp0148, Sp0149 and Sp0150 are not transcriptionally linked in 
serotype 3. However, Sp0150, Sp0151 and Sp0152 are all co-transcribed with 
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transcription terminating after Sp0152 (Fig 3.6). Hence the RT-PCR results of 
Sp0148-52 region in serotype 3 strain correlated with the operon structure of the 
TIGR4 genome sequence. 
 
(c) Sp0607-10 
RT-PCR across the junction of Sp0607/Sp0608, Sp0609/610 and Sp0610/611 
suggested that these junctions may be linked in serotype 3. However the junction of 
Sp0608/Sp0609 is not transcriptionally linked in serotype 3(Table 3.4). 
 
(d) Sp0749-53 
RT-PCR analysis of the transcriptional structure for Sp0749-53 suggested that Sp0749 
and Sp0750 are not transcriptionally linked in serotype 3. However, Sp0750, Sp0751 
and Sp0752 are all co-transcribed with transcription terminating after Sp0753 (Fig 
3.7).  
 
(e) Sp0846-48 
RT-PCR analysis of the transcriptional structure for Sp0846-48 suggested that 
Sp0846, Sp0847 and Sp0848 are co-transcribed (Fig 3.8) in serotype 3 genome.  
 
(f) Sp1686-90 
RT-PCR analysis of the transcriptional structure for Sp1686-90 suggested that 
Sp1686, Sp1687 and Sp1688 are co-transcribed. However, from the RT-PCR results it 
was not clear if Sp1688, Sp1689 and Sp1690 are transcriptionally linked (Table 3.4) 
in serotype 3.  
 
Sp0148              Sp0149             Sp0150                 Sp0151               Sp0152                Sp0153
830 bp 854 bp 1373 bp 1053 bp 692 bp 569 bp
98 bp gap 7 bp overlap 1 bp gap 28 bp gap
Gene 
length
148rt1/
149rt1
149rt2/
150rt1
150rt2/
151rt1
151rt1.1/
152rt2.1
152rt1/
153rt1
B
DNA cDNA DNA  cDNA DNA  cDNA DNA  cDNA DNA  cDNA
C
Primer 
pairs
152 bp gap
A
Fig 3.6 (A) Operon structure of Sp0148-0153. Open arrows: ORFs of genes present in the operon
(Sp0148: lipoprotein, Sp0149: lipoprotein, Sp0150: hypothetical protein, Sp0151: ATPase,
Sp0152: permease, Sp0153: hypothetical protein) in the chromosomal DNA of S. pneumoniae.
Diagonally hatched arrow: site of disruption in the mutant strain using IDM. (B) Horizontal line:
PCR products generated using the primer pairs. (C) Ethidium bromide stained agarose
gel containing PCR products generated by primer pairs (mentioned in B) using S. pneumoniae
genomic DNA as the template and RT-PCR products generated using S. pneumoniae RNA as
the template.
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Sp0749               Sp0750          Sp0751            Sp0752             Sp0753              Sp0754
DNA  cDNA DNA  cDNA DNA  cDNA DNA cDNA DNA  cDNA
749rt1/
750rt2
750rt1.1/
751rt2.1
751rt1.1/
752rt2.1
753rt1.1/
754rt2.1
752rt1/
753rt2
266 bp gap 3 bp gap No gap No gap
1160 bp 869 bp 956 bp 763 bp 709 bp
A
Gene 
length
B
C
656 bp
306 bp gap
Primer 
pairs
Fig 3.7 (A) Operon structure of Sp0749-0753. Open arrows: ORFs of genes present in the operon
(Sp0749: lipoprotein, Sp0750: permease, Sp0751: permease, Sp0752: ATPase, Sp0753: ATPase,
Sp0754: putative acetion utilization protein) in the chromosomal DNA of S. pneumoniae.
Diagonally hatched arrow: site of disruption in the mutant strain using IDM. (B) Horizontal
line: PCR products generated using the primer pairs. (C) Ethidium bromide stained agarose
gel containing PCR products generated by primer pairs (mentioned in B) using S. pneumoniae
genomic DNA as the template and RT-PCR products generated using S. pneumoniae RNA as
the template. cDNA band generated from the junction of Sp0751/Sp0752 was sequenced and
then aligned against TIGR4 genome which matched the Sp0751 gene.
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Sp0845                          Sp0846                           Sp0847                 Sp0848 
1052 bp 1535 bp 1050 bp 956 bpGene 
length
A
B
845rt1/
846rt2
846rt1/
847rt2
847rt1/
848rt2
Primer 
pairs
DNA  cDNA DNA  cDNADNA  cDNA
142 bp gap 8 bp overlap 2 bp gap
C
Fig 3.8 (A) Operon structure of Sp0846-0848. Open arrows: ORFs of genes present in the operon
(Sp0845: lipoprotein, Sp0846: ATPase, Sp0847: permease, Sp0848: permease) in the
chromosomal DNA of S. pneumoniae. Diagonally hatched arrow: site of disruption in the mutant
strain using IDM. (B) Horizontal line: PCR products generated using the primer pairs.
(C) Ethidium bromide stained agarose gel containing PCR products generated by primer
pairs (mentioned in B) using S. pneumoniae genomic DNA as the template and RT-PCR products
generated using S. pneumoniae RNA as the template.
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Sp2107                       Sp2108                   Sp2109               Sp2110               Sp2111
A
Gene 
length
1271 bp 842 bp1307 bp
96 bp gap 1 bp gap
B
Primer 
pairs
2108rt1.1/
2109rt2.1
2109rt1/
2110rt1
C DNA  cDNA DNA  cDNA
1517 bp
549 bp gap 250 bp gap
2107rt1.1/
2108rt2.1
2110rt1.1/
2111rt12.1
DNA  cDNA DNA  cDNA
800 bp
Fig 3.9 (A) Operon structure of Sp2108-2110. Open arrows: ORFs of genes present in the
operon (Sp2107: 4-alpha-glucanotransferase, Sp2108: lipoprotein, Sp2109: permease, Sp2110:
permease, Sp2111: malA protein ) in the chromosomal DNA of S. pneumoniae. Diagonally
hatched arrow: site of disruption in the mutant strain using IDM. (B) Horizontal line: PCR
products generated using the primer pairs. (C) Ethidium bromide stained agarose gel
containing PCR products generated by primer pairs (mentioned in B) using S. pneumoniae
genomic DNA as the template and RT-PCR products generated using S. pneumoniae RNA as
the template.
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Operon Junction 
between genes
Gap / overlap 
between junction
in base pairs (bp)  
Primer pairs 
used
DNA (bp)
Expected Obtained
cDNA (bp)
Expected Obtained
Sp0090-96 Sp0090 / 
Sp0091
13 bp Sp0090RT2 / 
Sp0091RT1
Sp0090rt1.2 / 
Sp0091rt2.2
605 bp ~600 bp NP 600 bp 
Sp0091 /
Sp0092
256 bp 467 bp ~500 bp NP Sp0091RT2 /  
Sp0092RT1
~500 bp 
Sp0092 /
Sp0095
600 bp 600 bp NP NPSp0092RT2 /  
Sp0095RT1
Sp0095 /
Sp0096
500 bp 500 bp NP NPSp0095RT2 /  
Sp0096RT1
Sp0607-11 Sp0607 / 
Sp0608
9 bp Sp0607RT1 / 
Sp0608RT2
509 bp 500 bp   NP ~500 bp 
Sp0608 / 
Sp0609
12 bp Sp0608RT1 / 
Sp0609RT2
415 bp ~400 bp NP NP
Sp0609 / 
Sp0610
38 bp Sp0609RT1 / 
Sp0610RT2
436 bp ~400 bp NP ~400 bp 
Sp0610 / 
Sp0611
575 bp Sp0610RT1 / 
Sp0611RT2
578 bp ~600 bp NP ~600 bp 
Sp1686-91 Sp1686 / 
Sp1687
11 bp Sp1686RT2 / 
Sp1687RT1
540 bp >500 bp   NP >500 bp
Sp1687 / 
Sp1688
17 bp Sp1687RT2 / 
Sp1688RT1
400 bp 400 bp   NP 400 bp + other bands 
Sp1688 / 
Sp1689
No gap Sp1688RT2 / 
Sp1689RT1
350 bp 350 bp   350 bp NP
Sp1689 / 
Sp1690
77bp  Sp1689RT2 / 
Sp1690RT1
600 bp 600 bp   NP NP
270 bp 
273 bp 
Table 3.4 Analysis of ABC transporter operon structure in serotype 3 by RT-PCR 
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Operon Junction 
between genes
Gap / overlap 
between junction
in base pairs (bp)  
Primer pairs 
used
DNA (bp)
Expected Obtained
cDNA (bp)
Expected Obtained
Sp1690 / 
Sp1691
18 bp  Sp1690RT2 / 
Sp1691RT1
350 bp 350 bp   NP Non-specific bands
Sp1794-99 Sp1794 / 
Sp1795
400 bp  Sp1794RT1 / 
Sp1795RT1
714 bp 700 bp NP NP 
Sp1795 / 
Sp1796
9 bp  Sp1795RT2 / 
Sp1796RT1
544 bp NP NP ( obtained 544 bp DNA 
from TIGR4)
NP 
Sp1796 / 
Sp1797
27 bp  Sp1796RT2 / 
Sp1797RT1
485 bp 485 bp NP NP 
Sp1797 / 
Sp1798
13 bp overlap Sp1797RT2 / 
Sp1798RT1
583 bp >550 bp 583 bp NP 
Sp1798 / 
Sp1799
149 bp  Sp1798RT2 / 
Sp1799RT1
734 bp >700 bp NP NP 
Sp1822-28 Sp1822 / 
Sp1823
95 bp  Sp1822RT1 / 
Sp1823RT1
626 bp ~600 bp NP ~600 bp 
Sp1823 / 
Sp1824
2 bp  Sp1823RT2 / 
Sp1824RT1
571 bp ~600 bp ~600 bp 571 bp 
Sp1824 / 
Sp1825
11 bp  Sp1824RT2.1 / 
Sp1825RT1.1
431 bp ~400 bp NP NP 
Sp1825 / 
Sp1826
101 bp  Sp1825RT1.1 / 
Sp1826RT2.1
514 bp NP NP NP 
Sp1826 / 
Sp1827
23 bp  Sp1826RT2 / 
Sp1827RT1
426 bp ~400 bp NP NP 
Sp1827 / 
Sp1828
179 bp  Sp1827RT1.1 / 
Sp1828RT2.1
469 bp NP NP NP 
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NP: No product
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(g) Sp1796-98 
RT-PCR analysis of the transcriptional structure for Sp1796-98 was not clear as the 
expression level of this region was poor in serotype 3 (Table 3.4).  
 
(h) Sp1824-26 
RT-PCR analysis of the transcriptional structure for Sp1824-26 suggested that 
Sp1823, Sp1824 may be transcriptionally linked in serotype 3. However It is not clear 
from the RT-PCR if other genes of this region are transcriptionally linked as the 
expression level of this region was poor (Table 3.4).  
 
(i) Sp2108-10 
RT-PCR analysis of the transcriptional structure for Sp2108-10 suggested that 
Sp2108, Sp2109 and Sp2110 are transcriptionally linked with transcription 
terminating after Sp2110 in serotype 3 (Fig 3.9). 
 
3.8 SUMMARY 
 
For this study, 11 ABC transporters (Sp0090-0092, Sp0149-0152, Sp0607-0610, 
Sp0707-0711, Sp0846-0848, Sp1689-90, Sp1796-98, Sp1826-28, Sp2084-87, 
Sp2108-2110) were chosen for investigation from the annotated completely 
sequenced genome of serotype 4 strain (Tettelin et al., 2001). Of the 11 ABC 
transporters operons, four of the operons (Sp0090-92, Sp0148-52, Sp0846-48 and 
Sp2108-2110) from serotype 3 strain are genetically organised in a similar fashion to 
that of annotated serotype 4 strain. Mutant strains were successfully constructed in a 
serotype 3 (0100993 strain) of S. pneumoniae for 10 of these ABC transporters 
(Sp0090-, Sp0149-, Sp0610-, Sp0750-, Sp0846-, Sp1690-, Sp1798-, Sp1826-, Sp2084-, 
Sp2108
-) by disrupting the first gene of the probable operon using insertional 
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duplication mutagenesis. 9 mutant strains (Sp0090-, Sp0149-, Sp0610-, Sp0750-, 
Sp0846
-
, Sp1690
-
, Sp1798
-
, Sp1826
-
, Sp2108
-) were confirmed to have a stable 
mutation, with one mutant strain (Sp2084-) containing an unstable mutation. Despite 
the mutations generally having weak or no effect in culture media, in vivo phenotype 
analysis using CIs suggested a strong attenuation of virulence for Sp0149- and 
Sp0750
- in both systemic and pulmonary models of infection, while Sp0090-, Sp0610-, 
Sp0846
- Sp1826- and Sp2108- had partial attenuation in virulence. These data confirm 
that ABC transporters are frequently required for full virulence and identified the 
Sp0149 and Sp0749 lipoproteins for further investigation. 
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    Chapter 4 
Detailed phenotype analysis of the effects of 
mutation of Sp0149 and Sp0750-53 
 
Results from chapter 3 showed that Sp0149-52 and Sp0749-53 are important for S. 
pneumoniae survival in in vivo models of pneumonia and septicaemia. Therefore, 
detailed in vitro and in vivo phenotype analysis of the effects of deletion of Sp0149 and 
Sp0750-53 were performed mostly using 0100993 strain. However, for the ease of 
performing certain experiments such as uptake assays, the deletion mutation was 
transferred from the serotype 3 (0100993) to serotype 2 (D39) strain. These results are 
presented in this chapter.  
 
4.1 GENE EXPRESSION OF SP0149 AND SP0749 BY SEMI-QUANTITATIVE RT-PCR 
To investigate whether the Sp0149 and Sp0749 lipoprotein genes are expressed during 
infection, semi-quantitative RT-PCR was performed on total RNA extracted from S. 
pneumoniae recovered from mice, or after incubation of the bacteria in blood or THY. 
The abundance of the Sp0149 and Sp0749 lipoprotein mRNA transcripts were 
compared with the mRNA expression of lipoprotein component (Sp1386) of polyamine 
ABC transporter (ORFs 1386-89) (Shah et al., 2008) and another well-characterized 
ABC transporter lipoprotein, psaA, both of which are known to be expressed during 
infection (Ogunniyi et al., 2002; Shah et al., 2008). To analyse the relative abundance 
of Sp0149, Sp0749 and Sp1386, primer pairs (Table 2.1) were designed to amplify 
cDNA products of comparable sizes, and the amplification efficiency of the primer 
pairs was analysed using S. pneumoniae genomic DNA (0100993) as the target for  
A12 cycles 16 cycles 20 cycles 24 cycles
B
26 cycles                                               30 cycles
Fig 4.1 (A) Amplification efficiency of primer pairs using S. pneumoniae 0100993 genomic 
DNA as template for the PCR. (B) cDNA products generated by RT-PCR after 26 and 30 
cycles using S. pneumoniae 0100993 total RNA extracted from the blood of the infected mice . 
8 μl of the PCR and cDNA products were electrophoresed on the agarose gel. 
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PCR. After 12, 16, 20 and 24 cycles Sp0149, Sp0749, Sp1386 and psaA PCR products 
were electrophoresed on prestained ethidium bromide agarose gels, loading the same 
volume of the PCR reaction for each gene. Using DNA as the target, similar intensities 
of Sp0149, Sp0749, Sp1386 and psaA PCR products were obtained for each cycle 
length, indicating that the PCR primers have similar amplification efficiencies for each 
of these genes (Fig 4.1 A). 
To extract total RNA from bacteria grown in human blood and THY, the 
0100993 wild-type strain was first inoculated in THY and grown until the OD580 
reached 0.2-0.3. The culture was divided into two tubes, the resulting bacterial pellets 
were washed in sterile PBS and each pellet was resuspended in 3 mls of THY or in 
freshly extracted heparinised human blood. An aliquot from this culture was removed, 
serially diluted and plated onto blood agar plates to determine the approximate S. 
pneumoniae cfu immediately after the inoculation. The culture was incubated for an 
hour at 37ºC in the presence of CO2 followed by simultaneous extraction of the total 
RNA from S. pneumoniae grown in THY or in human blood. To extract total RNA 
from S. pneumoniae during infection, 3 to 5 CD1 mice were intraperitoneally injected 
with approximately 4 x 106 cfu/ mouse of 0100993 strain of S. pneumoniae and blood 
was obtained from the mice 12 hours later and pooled before total RNA was extracted 
using acid-phenol as described in chapter 2. Expression of the lipoprotein genes in the 
THY was used only as baseline for the comparison of gene expression in human blood 
and septicaemia model of infection. The extracted total RNA from these different 
conditions were subjected to RT-PCR with and without reverse transcriptase to ensure 
that DNA contamination was not present as described in chapter 2 and the RNA 
concentration was determined using a nanospectrophotometer. Equal quantities of total 
RNA (0.04 ng μl-1) from each condition were then used for semi-quantitative RT-PCR  
Fig 4.2 Densitometry analysis of 16S, psaA, Sp0149, Sp0749 and Sp1386 cDNA product 
generated by RT-PCR after different cycles using S. pneumoniae 0100993 total RNA 
extracted from the (A) THY, (B) human blood and (C) infected mouse blood. 
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to assess mRNA expression levels of the Sp0149, Sp0749, Sp1386 and psaA genes. To 
minimise sample variation a master mix was prepared for all RT-PCR reactions and 
these were performed simultaneously by mixing all the RT-PCR constituents except the 
primer pairs and the total RNA before aliquoting into individual tubes. cDNA products 
generated after 10, 14, 18, 22, 26 and 30 cycles for each primer pair were analysed in 
triplicate. Since the 16S rRNA level is constantly maintained under in vitro and in vivo 
conditions, 16S rRNA was used as internal control in all of these experiments. In each 
experiment 8 μl of the cDNA products generated from each triplicate sample was 
electrophoresed on agarose gel and the intensity of the bands corresponding to the 
lipoprotein genes were analysed by densitometry. The results are shown in Fig 4.2. The 
band intensities at 10, 14, 18, 22, 26 and 30 cycles demonstrated that there was 
differential expression of these genes when bacteria were grown in all three conditions. 
From the densitometry analysis (Fig 4.2 A, B, C), in THY 16S rRNA was the most 
abundantly present cDNA followed by those of psaA, Sp0149 and Sp1386 with no 
detectable levels of Sp0749 cDNA observed (Fig 4.2 A). In human blood, the cDNA 
level of Sp1386 was similar to that of Sp0149 but again both were lower than the 
cDNA levels of psaA and Sp0749 cDNA was not detected (Fig 4.2 B). However, in 
bacteria recovered from infected mice (Fig 4.2 C), the results were quite different, with 
greater expression of Sp0749 compared to Sp0149 and Sp1386. Expression of psaA was 
not investigated in this infection model. These data suggest that mRNA of Sp0749 and 
Sp1386 are differentially expressed under different conditions, with expression of 
Sp0749 specifically induced during septicaemia despite low levels of expression after 
culture in THY or incubation in blood. 
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4.2 CONSTRUCTION OF SP0149 AND SP0750-53 DELETION MUTANT STRAINS IN S. 
PNEUMONIAE 
In order to investigate the in vitro and in vivo phenotypes of the Sp0148-53 and 
Sp0749-53 ABC transporters in detail, deletion mutant strains were constructed in 
which the Sp0149 lipoprotein gene and the Sp0750-53 genes (encoding permeases and 
ATPases) were replaced with the erythromycin resistance cassette (erm) by the overlap 
extension PCR (OEP) method (Fig 4.3 A-D and 4.4 A-D) as described in chapter 2. 
The role of these two operons during in vivo virulence and in vitro growth had initially 
been investigated using IDM mutants (chapter 3), and the deletion mutants were 
designed to affect the genes disrupted within the IDM mutant strains (Fig 4.5 A-C). 
The ΔSp0149 and ΔSp0750-53 deletion constructs were then transformed in to the 
0100993 strain of S. pneumoniae. ΔSp0149 and ΔSp0750-53 deletion mutant strains 
were successfully obtained, and the deletion construct confirmed using the genomic 
DNA of the mutant strain as template to amplify the junctions of the upstream and 
downstream regions surrounding the deleted target gene (Fig 4.6 A-D). Fig 4.6 B 
shows the confirmation of Sp0149 deletion by PCR using different primer pairs. To 
demonstrate that erm gene is flanked by Sp0148 and Sp0150 genes in the ΔSp0149 
mutant strain, PCR was performed using the Sp0148F + ermR and ermF + Sp0150R 
primers. This generated correct sized products only in the mutant strain. PCR across 
Sp0148 to Sp0150 genes using Sp0148F and Sp0150R primers generated similar sized 
bands in the wild-type and ΔSp0149 mutant strain because the erm gene and Sp0149 
genes are of similar size. A non-specific band of smaller size was also obtained in the 
mutant strain. The absence of Sp0149 in the ΔSp0149 mutant strain was confirmed by 
PCR across the Sp0149 gene (Sp0149F and R) in the wild-type and ΔSp0149 mutant  
 
AB
C
Sp0148                       Sp0149                    Sp0150                 Sp0151              Sp0152            Sp0153
Sp0150
erm
Sp0150erm
D
Sp0148                     erm Sp0150                  Sp0151             Sp0152              Sp0153
PCR products generated by individual PCR
PCR on pooled gene products to obtain ΔSp0149
construct by OEP
Transformation of ΔSp0149 construct in 
S. pneumoniae wild-type
Fig 4.3 Schematic diagram of the deletion of Sp149 by overlap extension PCR (OEP). (A) 
Arrows indicate the transcription direction of genes of Sp0148-53 operon in the TIGR4 
genome. The Sp0149 gene, shaded with diagonal lines, was chosen for deletion. Small black 
arrows indicate the forward and reverse primers used for OEP. (B and C) OEP to obtain the 
Sp0149 deletion construct by replacing Sp0149 with the erythromycin gene (erm) (D) 
Representation of the product of transformation of the ΔSp0149 construct in to the 0100993 
S. pneumoniae strain.
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Sp0749                  Sp0750             Sp0751             Sp0752            Sp0753                    Sp0754
erm
erm
Sp0749 Sp0754
Sp0749 Sp0754
Sp0749 Sp0754erm
A
B
C
D
Fig 4.4 Schematic diagram of the deletion of Sp750-53 by overlap extension PCR (OEP). (A) 
Arrows indicate the transcription direction of genes of Sp0749-53 operon in the TIGR4 
genome. The Sp0750-53 genes are shaded with diagonal lines, were chosen for deletion. 
Small black arrows indicate the forward and reverse primers used for OEP. (B and C) OEP to 
obtain the Sp0750-53 deletion construct by replacing Sp0750-53 genes with the erythromycin 
gene (erm) (D) Representation of the product of transformation of the ΔSp0750-53 construct 
in to the 0100993 S. pneumoniae strain.
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A
Individual PCR products 
B
Final deletion constructs obtained after the 
fusion of the individual PCR products 
Sp0148-
erm-
Sp0150
Sp0749-
erm-
Sp0753
C
Sp0148-
erm-
Sp0150
Sp0749-
erm-
Sp0753
Gel purified deletion constructs
Fig 4.5 Generation of ΔSp0149 and ΔSp0750-53 deletion constructs. (A) Amplification of 
Sp0148 (630 bp), Sp0150 (672 bp), Sp0749 (883 bp), Sp0754 (833 bp) using S. pneumoniae
0100993 genomic DNA as the template and the erm gene (738 bp) using pACH74 plasmid 
DNA as the template (B) ΔSp0149 (2040 bp) and ΔSp0750-53 (2454 bp) deletion constructs 
generated by OEP after using the individual PCR products generated from A (C) Gel purified 
ΔSp0149 and ΔSp0750-53 deletion constructs used for S. pneumoniae transformation.
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BSp0149 F 
+ Sp0149 R
Sp0148F + 
Sp0150R
WT    Δ149 WT      Δ149 WT    Δ149WT    Δ149
ermF +
Sp0150R
Sp0148F + 
ermR
ermR
A
Sp0150R
Sp0148                                                     Sp0150                 Sp0151                     Sp0152          Sp0153
ermF
Sp0148F
erm
Sp0149 F
Sp0149 R
Sp0749F + 
ermR
ermF +
Sp0754R
Sp0750rt1.1/ 
751rt2.1
Sp0751rt1.1/ 
752rt2.1
Sp0752rt1 /       
753rt2
Sp0753rt1.1 / 
754rt2.1
WT   Δ750/3 WT    Δ750/3WT   Δ750/3 WT   Δ750/3WT   Δ750/3WT    Δ750/3
D
C Sp0749                                                                                                                       Sp0754
ermF
ermR
Sp0749F Sp0750rt1.1
Sp0751rt2.1
Sp0751rt1.1
Sp0752rt2.1
Sp0752rt1
Sp0753rt2
Sp0753rt1.1
Sp0754rt2.1
erm
Fig 4.6 (A + C) Schematic diagram showing the deletion of Sp0149 gene from the Sp0148-53
operon and Sp0750-53 genes from Sp0749-53 operon. Small black arrows indicate the forward 
and the reverse primers used for the confirmation of deletion of target gene(s) Gel pictures 
(B and D) demonstrating the confirmation of the deletion of Sp0149 and Sp0750-53 genes by 
PCR using the 0100993 wild-type, ΔSp0149, ΔSp0750-53 genomic DNA as templates. 
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strain, which generated a correct sized product only in the wild-type. Fig 4.6 D 
demonstrates the confirmation of the Sp0750-53 deletion in the ΔSp0750-53 mutant 
strain by PCR and later by sequencing. To demonstrate the replacement of Sp0750-753 
genes by erm in the ΔSp0750-53 mutant strain, PCR using Sp0749F + ermR and ermF 
+ Sp0754R primers was performed. This generated correct sized product in the mutant 
strain but no product was obtained in the wild-type. Similarly, to confirm the deletion 
of Sp0750-53 genes, primers designed to amplify the junction of genes in the Sp0749-
754 operon were used (chapter 3). PCR using these primers spanning the junction of 
Sp0750-54 did not generate a PCR product in the ΔSp0750-53 mutant strain but 
generated correct sized bands in the wild-type suggesting that Sp0750-53 genes were 
deleted in the mutant strain.  
Efforts to obtain Sp0149 and Sp0750-53 complemented mutants were not 
successful as the Sp0149 complementation construct did not transform into the 
ΔSp0149 deletion mutant and several efforts to obtain the Sp0750-53c construct failed. 
 
4.3 LOCALISATION STUDIES OF SP0149 AND SP0749 LIPOPROTEINS 
To investigate whether Sp0149 and Sp0749 lipoproteins are localised to the S. 
pneumoniae cell membrane, the Triton X-114 extracts of the membrane bound proteins 
were probed with the polyclonal mouse anti-Sp0149 and anti-Sp0749 antibodies 
(obtained as described in chapter 5) and analysed by Western blotting (Khandavilli et 
al., 2008). To demonstrate whether Sp0149 and Sp0749 are, as predicted, lipoproteins, 
extracts from the lsp mutant strain as well as the wild-type and the complemented lspc 
strain were probed. Δlsp and lspc strains were constructed by Suneeta Khandavilli 
(Khandavilli et al., 2008). Previous studies have demonstrated that lipoprotein signal 
peptidase (Lsp) is employed to process the prelipoproteins into mature lipoproteins in  
Fig 4.7 Western blots of the whole cell lysates, Triton X-114 and aqueous extracts of 
S. pneumoniae wild-type (WT), ΔSp0149, ΔSp0750-53, Δlsp and lspc strains probed with 
anti-Sp0149 and anti-Sp0749 antibodies to demonstrate the localisation of Sp0149 (A) 
and Sp0749 (B) lipoproteins. Purified His6-Sp0149 and His6-Sp0749 were used as controls. 
The sizes of Sp0149 and Sp0749 are 1-2 kDa larger in the Δlsp strain than in the wild-type, 
lspc strains and the purified lipoproteins. 
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various bacteria (Sutcliffe and Russell, 1995) (described in chapter 1). Recently, 
Khandavilli and collegues have demonstrated that Lsp (encoded by the Sp0928 gene) is 
responsible for the processing of prelipoproteins by enzymatic cleavage of the N-
terminal signal sequence from the prelipoproteins to form mature lipoproteins in S. 
pneumoniae. They have also demonstrated that the deletion of Sp0928 prevents the 
formation of the mature lipoproteins and therefore the lipoproteins in the Δ928 mutant 
strain (Δlsp) have slightly higher molecular masses. Complementation of Sp0928 in 
928c (lspc) strain restores normal processing of lipoproteins. Fig 4.7A shows that the 
molecular weight signals from the whole cell lysates of wild-type, Δlsp, and lspc strains 
probed with anti-Sp0149 or anti-Sp0749. The Δlsp gave signal at higher molecular 
weight when probed with anti-Sp0149, but it was difficult to determine the size 
difference of Sp0749 lipoprotein in Δlsp strain when probed with anti-Sp0749 as this 
antibody only gave a weak signal with this strain. Surprisingly, the band identified by 
probing with anti-Sp0149 in the lspc strains was not restored to the size found in the 
wild-type strain. However similar sized molecular weight signals were obtained when 
the whole cell lysates of lspc and wild-type strains were probed with anti-Sp0749. A 
strong signal was obtained when the Triton X-114 extracts of the wild-type and Δlsp 
strains were probed with anti-Sp0149 antibodies, where as ΔSp0149 strain did not give 
any signal due to the deletion of Sp0149 and the band obtained with the Δlsp strain had 
a slightly higher molecular weight as the result of incomplete processing of the 
lipoprotein.  
The presence of same sized signal in the aqueous extract (Fig 4.7 A) of wild-
type, Δlsp and ΔSp0149 probably occurred as a result of the contamination of Triton X-
114 extract in to aqueous extract during the extraction procedure. Alternatively it is 
also possible that the loss of lsp may result in the release of significant quantities of 
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Sp0149 lipoprotein from the cell surface into the culture medium. When probed with 
anti-Sp0749 antibodies a strong signal was obtained for the whole cell lysates of the 
wild-type and lspc strains but only a weak signal of slightly higher molecular mass for 
the whole cell lysate of the Δlsp strains. Furthermore in the Triton X-114 extracts, the 
wild-type and ΔSp0750-53 strain, but not the Δlsp strain gave a strong signal for the 
Sp0749 lipoprotein suggesting that Sp0749 lipoprotein is membrane bound but 
expression on the membrane is lost in the absence of Lsp. However, there was no 
Sp0749 signal in the aqueous extracts indicating that loss of expression of the Sp0749 
in the Δlsp strain was not accompanied by shedding of the protein from the cell surface 
(Fig 4.7 B). 
Overall the Western blots indicated that Sp0149 and Sp0749 are both 
membrane bound, and that the Sp0149 exists as a prelipoprotein that is processed by 
Lsp. The reduction of expression of Sp0749 in the absence of Lsp was unusual and 
differs from the effect of the Δlsp mutation on other lipoproteins. However the 
localisation of Sp0749 within the membrane and the fact that this is affected by Lsp 
does indicate it is also a lipoprotein. 
 
4.4 IN VITRO PHENOTYPE ANALYSIS OF THE S. PNEUMONIAE ΔSP0149 AND ΔSP0750-53 
DELETION MUTANTS 
4.4.1  Growth curve of ΔSp0149 and ΔSp0750-53 mutants in THY 
The in vitro phenotypes of the ΔSp0149 and ΔSp0750-53 mutants strains were 
investigated by comparing the growth rates of the deletion mutant strains to the wild-
type strains in the THY medium. Equal numbers of the wild-type and the mutant 
bacteria obtained from thawed stocks were inoculated into THY, cultured at 37°C in 
the presence of 5% CO2 and the optical density recorded at one hourly intervals for 8 
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hours. Both the deletion mutant strains exhibited good growth in THY, similar to the 
wild-type strain (Fig 4.8 A), suggesting that the deletion of the Sp0149 and Sp0750-53 
genes of the ABC transporters had little effect on the growth of S. pneumoniae in a rich 
laboratory medium that is THY. 
 
4.4.2  Growth curve of ΔSp0149 and ΔSp0750-53 mutants in cation depleted media  
From the BLAST search, Sp0149-52 encodes a putative metal ion ABC transporter, 
hence the role of Sp0149-52 and Sp0749-53 operon in a cation depleted environment 
was investigated by analysing growth of the mutant strain in THY that has been treated 
with Chelex-100 to remove cations from the medium (Brown et al., 2001). Fig 4.8.B 
showed no differences in the growth pattern of ΔSp0149, ΔSp0750-53 mutant strains 
and the wild-type S. pneumoniae in THY-chelex supplemented with 100 μM CaCl2 and 
2 mM MgSO4. Therefore cations such as zinc, ferric iron and cobalt were supplemented 
in THY-Chelex at a final concentration of 100 μM and the growth defect of ΔSp0149 in 
the presence and absence of these cations were compared with the wild-type. Fig 4.9 A 
demonstrates that the wild-type and ΔSp0149 strain had impaired growth in Chelex-
THY medium alone. Both the wild-type and ΔSp0149 showed better growth when 
supplemented with 100 μM ferric citrate (Fe3+) as the source of iron suggesting that the 
depletion of iron from the medium may be responsible for this growth defect, but there 
was no difference between the strains indicating iron was not a major substrate for 
Sp0149 (Brown et al., 2001). However, when the Chelex-THY medium was 
supplemented with 100 μM cobalt or 100 μM zinc chloride, the growth of wild-type 
and ΔSp0149 strains was inhibited, suggesting these concentration of cobalt or zinc 
were relatively toxic. The growth of the ΔSp0149 strain was actually better than the 
wild-type strain in zinc supplemented THY-chelex, and this may indicate that this  
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Fig 4.9 (A) Growth of wild-type and ΔSp0149 S. pneumoniae strains at 4 hours in Chelex-THY 
medium supplemented with and without individual cations (100 μM) such as cobalt, zinc and 
ferric iron. p values were obtained using Student’s-t-test by comparing the wild-type with 
ΔSp0149. (B) Sensitivity to streptonigrin of the wild-type and ΔSp0149 S. pneumoniae strains. 
Results are expressed as mean percent survival (triplicate samples) of the wild-type and 
ΔSp0149 mutant strains surviving the exposure to 5 μg ml-1 streptonigrin for 20 and 40 
minutes. 
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strain has had less toxic effects due to loss of cation transport. However this data 
requires further development before the significance of any differences in growth 
between strains can be correctly interpreted. 
 
4.4.3  Streptonigrin sensitivity test 
Streptonigrin is an antibiotic which is bactericidal in nature and requires intracellular 
iron for its activity. Mutations in iron uptake systems are associated with streptonigrin 
resistance due to the reduced levels of intracellular iron preventing streptonigrin 
activity. In S. pneumoniae, mutations in iron uptake ABC transporters such as Piu, Pia 
and Pit have demonstrated increased resistance to streptonigrin (Brown et al., 2001). 
The streptonigrin sensitivity test was performed (as described in chapter 2) to identify 
whether streptonigrin has any effect on the ΔSp0149 mutant strain of S. pneumoniae. 
Both the wild-type and the ΔSp0149 mutant strain were incubated with 5 μg ml-1 
streptonigrin and serial dilutions were plated on Columbia blood agar after 0, 20 and 40 
minutes of streptonigrin exposure. Bacterial cfu were represented as percentage 
survival after each time point and the percentage survival of the wild-type and the 
ΔSp0149 mutant strains were compared. Fig 4.9 B shows no difference between the 
wild-type and the ΔSp0149 mutant strain after 20 and 40 minutes of exposure to 
streptonigrin. The above result suggests that the intracellular concentration of iron was 
adequate for the streptonigrin activity in both the wild-type and ΔSp0149 mutant strain 
of S. pneumoniae, and that the deletion of Sp0149 gene has little or no effect on the 
streptonigrin sensitivity. Hence Sp0149 is either not involved in iron uptake or is 
redundant and can be compensated for by other iron transporters. 
 
  
Fig 4.10 Growth of S. pneumoniae wild-type, ΔSp0149 and ΔSp750-53 strains in Cden
medium in the presence and absence of branched chain amino acids, leucine, isoleucine and 
valine. ΔSp0149 mutant strain was used as negative control in these experiments. Growth of 
the wild-type and mutant strains in (A) complete Cden medium, (B) Cden medium without 
leucine, (C) Cden medium without isoleucine (D) Cden medium without valine. Results 
presented are the mean of triplicate samples.
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4.4.4  Growth curve of ΔSp0149 and ΔSp0750-53 mutants in chemically defined 
medium (Cden) 
From the BLAST search prediction, Sp0749-53 operon encodes a putative branched 
chain amino acid transporter. In order to investigate whether the deletion of Sp0750-53 
genes has any effect on the growth of the ΔSp0750-53 mutant strain, a chemically 
defined medium, Cden (Tomaz., 1964) was used to compare the growth patterns of the 
wild-type and ΔSp0750-53 strain in the absence of branched chain amino acids such as 
leucine, isoleucine and valine. ΔSp0149 was used as a negative control in these 
experiments. The ΔSp0149, ΔSp0750-53 mutant and the wild-type strains did not 
exhibit growth pattern differences in the Cden medium alone (Fig 4.10 A). Growth 
patterns of ΔSp0149, ΔSp0750-53 mutant and the wild-type strains in Cden medium 
were impaired by the absence of any of the branched chain amino acids with a 
maximum optical density attained at 6 hours of approximately 0.2 to 0.4 compared to 
0.6 for complete Cden (Fig 4.10 B, C, D). However, there were no significant 
differences in the growth of the mutant or wild-type strains in the absence of branch 
chain amino acids. 
 
4.4.5  Azaleucine toxicity test 
Azaleucine is a toxic analogue of leucine that is taken up by branched chain amino acid 
transporters. Hence the relative level of toxicity of azaleucine indicates whether a 
bacterial strain has impaired transport of branched chain amino acids. The azaleucine 
sensitivity test was performed using the wild-type and the Sp0750- IDM mutant strain 
of S. pneumoniae (0100993 strain). Azaleucine at concentrations of 10, 20, 30, 40, 50, 
60, 70, 80, 90 and 100 μg ml-1 in THY were used to grow the bacteria and the growth  
 
Fig 4.11 Growth of S. pneumoniae (0100993) wild-type and Sp0750- IDM mutant strains in 
THY medium at different concentrations of azaleucine. Growth of the wild-type and the 
Sp0750- strain in (A) THY medium, (B) THY + 10 μg azaleucine, (C) THY + 50 μg 
azaleucine and (D) THY + 100 μg azaleucine. Results presented are the mean of triplicate 
samples.
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patterns of wild-type and Sp0750- mutant strains were recorded (shown in Fig 4.11 A-
D; similar growth patterns were observed in the other concentrations tested). There was 
no evidence of toxicity due to azaleucine in the wild-type and Sp0750- IDM mutant 
strains of S. pneumoniae at all the tested concentrations. One of the reason could 
perhaps be that the azaleucine toxicity assay was performed in THY which is a rich 
undefined medium with leucine as one of the amino acid component. Therefore even in 
the presence of azaleucine, leucine may be the substrate preferred by Sp0749-0753 
ABC transporter. Therefore repeating the experiment with modifications, such as using 
chemically defined medium in which leucine could be replaced with azaleucine to 
identify the differences between wild-type and Sp0750- mutant strains may provide 
information regarding the azaleucine toxicity. 
 
4.4.6 Uptake assays 
To try and confirm that Sp0749-0753 does encode a branched chain amino acid ABC 
transporter, uptake assays of 14C-labelled leucine were performed with the wild-type and 
ΔSp0750-53 mutant strains (experiments performed under Dr Hosie’s supervision at King’s 
College London) (Webb et al., 2008). For the ease of performing the uptake assays, deletion 
mutation from the serotype 3 (0100993) was transferred into serotype 2 (D39) because the 
mucoid serotype 3 strain would prevent efficient pelleting. Preliminary 14C-labelled leucine 
uptake experiments were performed as described in chapter 2 by inoculating the wild-type 
and ΔSp0750-53 mutant strains of S. pneumoniae in CDM medium alone containing branched 
chain amino acids and CDM medium without branched chain amino acids (Fig 4.12 A, B, C, 
D). No significant detectable leucine uptake was observed in either the wild-type or 
ΔSp0750-53 S. pneumoniae strains in the presence (Fig 4.12 A) and absence (Fig 4.12 B) of  
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Fig 4.12 Radioactive leucine and maltose uptake using serotype 2 (D39) S. pneumoniae
wild-type (diamonds) and ΔSp0750-53 (triangle) strains in CDM medium containing 
isoleucine, leucine and valine (I, L, V) (A and C) and CDM without isoleucine, leucine and 
valine (B and D). (A) 14C-leucine uptake by wild-type and ΔSp0750-53 S. pneumoniae strains 
in CDM medium (B) 14C-leucine uptake by wild-type and ΔSp0750-53 S. pneumoniae strains 
in CDM medium without I, L, V (C) 14C-maltose uptake by wild-type and ΔSp0750-53 S. 
pneumoniae strains in CDM medium (D) 14C-maltose uptake by wild-type and ΔSp0750-53 S. 
pneumoniae strains in CDM medium without I, L, V. 
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branched chain amino acids. To ensure that the experimental conditions for the uptake 
were correct, 14C-labelled maltose uptake assays were also performed as a positive 
control. There was good 14C-labelled maltose uptake in the S. pneumoniae wild-type 
both in the presence (Fig 4.12 C) and absence (Fig 4.12 D) of branched chain amino 
acids and by the ΔSp0750-53 mutant strain in the CDM medium. However, in the CDM 
medium without branched chain amino acids, there was markedly reduced maltose 
uptake by the ΔSp0750-53 mutant strain, the reasons are unclear. 14C-labelled 
isoleucine, leucine and maltose uptake was also performed, and again showed 
negligible uptake both amino acids. Hence, the above results indicate that there is no 
significant detectable uptake of BCAA by S. pneumoniae under the in vitro conditions 
tested, preventing effective assessment of whether Sp0749-0753 does encode a BCAA 
ABC transporter using these assays.  
 
4.4.7  Analysis of substrate specificity by tryptophan fluorescence spectroscopy 
In order to investigate whether the Sp0749 lipoprotein binds to branched chain amino 
acids (BCAAs), tryptophan fluorescence spectroscopy was performed using purified 
and dialysed recombinant His6-Sp0749 lipoprotein (Thomas et al., 2006). Tryptophan 
fluorescence spectroscopy analyses the fluorescence emitted as a result of excitation of 
electrons by the tryptophan residues present in the protein. In the absence of tryptophan 
residues, as is the case for the Sp0749 lipoprotein, this method uses tyrosine residues to 
analyse the fluorescence in the proteins. Fig 4.13 A demonstrates that the maximum 
emission of fluorescence for the purified His6-Sp0749 lipoprotein occurs at the 
wavelength of 309 nm. To test which amino acids induce fluorescence changes in His6-
Sp0749 lipoprotein, branched chain amino acids such as isoleucine, leucine, valine and 
other amino acids such as proline, glycine, alanine and threonine were incubated with 
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the recombinant Sp0749 protein. Fig 4.13 B demonstrates that the addition of amino 
acids such as proline, glycine, alanine and threonine and valine at a concentration of 50 
μM to His6-Sp0749 lipoprotein soon after its stabilization in the spectrofluorimeter had 
minor effects on fluorescence. However, the addition of the branched chain amino acid 
isoleucine at the concentration of 3.2 μM resulted in a marked change in Sp0749 
fluorescence. Further addition of 3.2 μM isoleucine did not result in any quenching of 
the changes in fluorescence (data not shown). Therefore to identify the minimum 
concentration of the ligand required to obtain maximum fluorescence change, 
isoleucine concentrations of 0.64 μM, 0.32 μM (Fig 4.14 A) and 0.16 μM (Fig 4.14 B) 
were tested. Addition of 0.16 μM isoleucine did not induce significant changes in 
fluorescence of His6-Sp0749, whereas significant changes did occur with the addition 
of 0.32 or 0.64 μM isoleucine. No further quenching following the addition of a further 
0.64 μM of isoleucine (data not shown). These data suggest that Sp0749 binds to 
isoleucine with a high affinity. 
To investigate whether His6-Sp0749 lipoprotein binds to leucine, another 
potential branched chain amino acid ligand, fluorescence changes upon addition of 
leucine at different concentrations were measured. After the addition of leucine at the 
final concentration of 3.2 μM, change in fluorescence occurred after a small delay as 
shown in Fig 4.15 A, and addition of leucine at the final concentration of 16 μM did not 
result in further quenching of fluorescence. When a lower concentration of leucine 
(0.64 μM) was tested, only a slow change in fluorescence was observed and further 
addition of leucine at 3.2 μM did not result in any fluorescence change. These data 
suggest that the His6-Sp0749 lipoprotein binds to leucine with low affinity.  
Fluorescence changes upon addition of valine, another branched chain amino 
acid ligand was also tested. A marked fluorescence change was observed when valine 
0150000
300000
450000
50 150 250 350 450
Emission wavelength (nm)
Fl
uo
re
sc
en
ce
 (
ar
bi
tr
ar
y 
un
it
s)A 309 nm
1000
9000
17000
25000
33000
41000
0 100 200 300
Fl
uo
re
sc
en
ce
 (
ar
bi
tr
ar
y 
un
it
s)
Time (s)
50 μM ProlineB 50 μM Glycine 50 μM Alanine
50 μM Threonine 50 μM Valine
Fig 4.13 Flourescence spectroscopy analysis of the purified His6-Sp0749 lipoprotein (A) 
Emission scan of His6-Sp0749 lipoprotein (0.5 μM) demonstrating the maximum flourescence
emission at 309 nm (indicated by an arrow) when excited at the 280 nm wavelength. (B) 
Measurement of flourescence change upon addition of 50 μM proline, glycine, alanine, 
threonine and valine to 2 μM His6-Sp0749 lipoprotein (point of addition of the amino acid 
ligands are indicated by arrows).
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was added to His6-Sp0749 lipoprotein at the final concentration of 16 μM but 
additional valine at the same concentration did not quench the fluorescence change as 
shown in Fig 4.15 B. To assess the minimum concentration required for maximum 
fluorescence change, 3.2 μM valine was added to the His6-Sp0749 lipoprotein. This 
induced only a small fluorescence change. Addition of 50 μM valine in the presence of 
50 μM each of a variety of other amino acids failed to induce any changes on 
fluorescence, probably due to the large amounts of other amino acids inhibiting binding 
the His6-Sp0749 lipoprotein. Overall, the results of the fluorescence binding studies 
suggest that the His6-Sp0749 lipoprotein binds to BCAA exhibiting its highest affinity 
towards isoleucine, moderate affinity to valine and least affinity towards leucine. 
 
4.4.8  Radioactive substrate binding assay 
To further determine the specific binding affinity of the Sp0749 lipoprotein to 
isoleucine, leucine and / or valine, radioactive ligand binding assays were performed 
using the purified His6-Sp0749 putative lipoprotein. The results suggest that the His6-
Sp0749 lipoprotein bound to 14C-isoleucine, and to a lesser degree to 14C-leucine (p < 
0.05) but not to the negative control, 14C-amino isobutyric acid (AIB) (Fig 4.16 A). 
Branched chain amino acid transporters (LIV transporters) have been well 
characterised in E. coli and P. aeruginosa and have been shown to bind to amino acids 
such as L-threonine, L-alanine, L-serine in addition to L-leucine, L-isoleucine and L-
valine (Rahmanian et al., 1973; Hoshino et al., 1992). Therefore His6-Sp0749 
lipoprotein was used to investigate if Sp0749 exhibits broader specificity towards 
amino acids other than isoleucine, leucine and valine, such as L-threonine. Competitive 
ligand binding with leucine, valine, threonine and AIB (negative control) was 
performed in the presence of 14C-isoleucine. Fig 4.16 B shows that His6-Sp0749 
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lipoprotein strongly binds to 14C-isoleucine alone and does not bind to 14C-AIB. 
However, valine, leucine and threonine inhibited the 14C-isoleucine binding to His6-
Sp0749 lipoprotein and that the His6-Sp0749 lipoprotein bound to valine and threonine 
inhibited the 14C-isoleucine binding at similar affinities than leucine. These results 
confirm that His6-Sp0749 lipoprotein has greatest affinity towards isoleucine and also 
indicates that His6-Sp0749 lipoprotein probably exhibits preferential binding to amino 
acid ligands in decreasing order of isoleucine > valine > threonine > leucine. Although 
the preferential binding experiment should have been performed with other amino acids 
such as serine and alanine in the presence of 14C-isoleucine, it could not be done due to 
the lack of purified His6-Sp0749 lipoprotein and time constraints. 
 
4.5 IN VIVO PHENOTYPE ANALYSIS OF THE S. PNEUMONIAE ΔSP0149 AND ΔSP0750-53 
DELETION MUTANTS 
4.5.1 Competitive index 
To investigate the effect on the virulence of S. pneumoniae as the result of Sp0149 and 
Sp0750-53 deletion during the pulmonary (IN) and systemic (IP) infection in mouse 
models, CIs were performed. Mixed inocula of S. pneumoniae wild-type, ΔSp0149 and 
ΔSp0750-53 strains were inoculated in mice by IN and IP routes and the CIs were 
determined as described in chapters 2 and 3. Deletion of Sp0149 and Sp0750-53 
affected the S. pneumoniae virulence with markedly reduced CIs for the ΔSp0149 and 
ΔSp0750-53 strains in both pulmonary (median CIs in lungs: ΔSp0149: 0.028, 
ΔSp0750-53: 0.109) and systemic (median CIs in spleen: ΔSp0149: 0.028, ΔSp0750-53: 
0.077) models of infection (Fig 4.17). These results are similar to those obtained with 
Sp0149
- and Sp0750- IDM mutant strains of S. pneumoniae (mean CI in lungs: Sp0149-:  
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Fig 4.16 Radioactive substrate binding assay expressed as pmoles of amino acid bound per 
mg of purified His6-Sp0749 lipoprotein (A) Binding affinities of His6-Sp0749 towards 14C-
Labelled isoleucine (Ileu), leucine (Leu) and amino isobutryic acid (AIB) (B) Competitive 
amino acid ligand binding of His6-Sp0749 to 14C-AIB (negative control), 14C-isoleucine, 
AIB, leucine, valine and threonine in the presence of 14C-isoleucine.
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Fig 4.17 In vivo phenotype analysis of ΔSp0149 and ΔSp0750-53 deletion mutants measured 
by CIs, expressed as log10 results for the ΔSp0149 and ΔSp0750-53 deletion mutants compared 
to the wild-type strain (0100993) in mouse models of pneumonia (A and B), septicaemia (C). 
In both the models, each symbol represents the CI obtained from an individual animal.
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Fig 4.18 Survival of groups of 10 mice were intranasally inoculated with 107 cfu of ΔSp0149
(A) and ΔSp0750-53 (B) deletion mutant strains compared to mice inoculated with the 
wild-type S. pneumoniae strains (0100993).  
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0.023, Sp0750-: 0.016) (mean CI in spleens: Sp0149-: 0.067, Sp0750-: 0.017) models of 
infection in mice (discussed in chapter 3). 
 
4.5.2 Survival studies 
In order to asses the ability of S. pneumoniae strains to cause fatal disease, group of 10 
CD1 mice strain were intranasally inoculated with S. pneumoniae (0100993) wild-type, 
ΔSp0149 and ΔSp0750-53 strains and their survival curves were determined (Brown et 
al., 2001). The mice were inoculated intranasally with the challenge dose of 107 cfu of 
the wild-type, ΔSp0149 and ΔSp0750-53 strains and monitored for the progress of 
infection. Fig 4.18 demonstrates that there was no difference in the survival of mice 
inoculated with the wild-type, ΔSp0149 and ΔSp0750-53 strains. Only 50% of mice 
cleared infection and survived after inoculation with the wild-type strain. This was an 
unexpectedly high level of clearance, as disease usually progresses into fatal infection 
in 80 to 90% of mice when the wild-type S. pneumoniae is inoculated Therefore this 
experiment should be repeated to ensure a small survival benefit in mice given the 
mutant strains has not been missed.  
 
4.6 SUMMARY 
The Sp0148-53 and Sp0749-53 ABC transporters of S. pneumoniae were investigated 
in detail for their in vitro and in vivo phenotypes. The relative mRNA expression of 
Sp0149 and Sp0749 lipoprotein genes in S. pneumoniae were analysed in THY, human 
blood and during infection in mice after IP infection. The results demonstrated that 
Sp0149 and Sp0749 genes are expressed during infection in mice, and suggest that the 
expression of Sp0749 is actually increased during infection compared to culture in 
either THY or blood in the laboratory.  
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From the localisation studies of Sp0149 and Sp0749, Western blot analysis 
demonstrated that both Sp0149 and Sp0749 are associated with the membrane 
compatible with being lipoproteins. Western blot analysis using the Δlsp and lspc 
strains showed that Sp0149 is enzymatically processed by Lsp. Loss of Lsp resulted in 
an unusual phenotpye for Sp0749, with reduced band strength in the Δlsp strain, 
suggesting Lsp activity is required for efficient attachment of Sp0749. ΔSp0149 and 
ΔSp0750-53 deletion mutants were successfully constructed by OEP. In vitro 
phenotypes of these strains did not detect any consistent phenotype in growth in 
specialised media or laboratory assays associated with the predicted functions of the 
corresponding ABC transporter. Uptake assays failed to demonstrate the uptake of 
amino acids. However, using the purified His6-Sp0749 lipoprotein, tryptophan 
fluorescence spectroscopy and radioactive ligand binding assays demonstrated that 
purified Sp0749 binds to BCAAs with a higher affinity towards isoleucine at 
submicromolar concentrations. 
The in vivo phenotype of ΔSp0149 and ΔSp0750-53 mutant strains was assessed 
using CIs, demonstrated a marked decrease in the virulence in pulmonary and 
septicaemia models of infection in mice for both strains. However contrasting results 
were obtained when survival studies were performed, with no impaired ability of the 
ΔSp0149 and ΔSp0750-53 mutant strains to cause fatal disease in a pulmonary model of 
infection in mice. Hence loss of these ABC transporters results in a significant 
impairment of the mutant strains to compete with the wild-type strain during infection 
but the mutants are still able to cause fatal infection. 
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    Chapter 5 
Investigation of Sp0149 and Sp0749 vaccine 
potential against systemic S. pneumoniae disease 
 
The data from chapters 3 and 4 have shown that Sp0149-52 and Sp0749-53 ABC 
transporters have role in S. pneumoniae virulence and that the Sp0749 lipoprotein is a 
branched chain amino acid binding protein. In this chapter, the potential of the 
recombinant Sp0149 and Sp0749 lipoproteins as vaccine candidates are investigated 
against S. pneumoniae septicaemia in two different mouse models (outbred CD1 and 
inbred BALB/c) using a virulent serotype 2 (D39) as the S. pneumoniae challenge 
strain. The immune responses that may be elicited due to intraperitoneal immunisation 
of Sp0149 and Sp0749 lipoproteins are also presented.  
 
5.1 EXPRESSION AND PURIFICATION OF SP0149 AND SP0749 LIPOPROTEINS 
The phenotype analysis of Sp0149-52 and Sp0749-53 ABC transporters using 
Sp0149
- and Sp0750- mutant strains demonstrated marked attenuation in murine 
models of septicaemia and pneumonia models compared to the parental wild-type 
strain. Hence the lipoprotein components of these ABC transporters were chosen for 
investigation as potential novel S. pneumoniae vaccine candidates. This required the 
expression and purification of the recombinant lipoproteins of both ABC transporters. 
The genes encoding the lipoproteins, Sp0149 for Sp0149-0153 and Sp0749 for 
Sp0749-0753, were amplified with the primers listed in chapter 2 using S. 
pneumoniae strain 0100993 genomic DNA as the template. To design the primers, the 
nucleotide and derived amino acid sequence of Sp0149 and Sp0749 genes were 
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analysed from the available complete genome sequence of a serotype 4 strain of S. 
pneumoniae (Tettelin et al., 2001) to identify the lipobox, the conserved amino acid 
sequence where the N-terminal signal sequence of the prolipoprotein is enzymatically 
cleaved after the attachment to the membrane (Khandavilli et al., 2008; Sutcliffe and 
Russell, 1995, Hutchings et al., 2009). The lipobox has the consensus amino acid 
sequence [LVI] [ASTVI] [GAS] C, where the leucine is highly conserved and the 
cysteine (a site of covalent attachment to the cell membrane phospholipid) is strictly 
conserved (Sutcliffe and Russell, 1995). To avoid potential secretion of recombinant 
lipoproteins by E. coli, primers were designed to amplify Sp0149 and Sp0749 
excluding the N-terminal lipoprotein signal sequence (Table 2.1 and 2.2). Sp0149 
primers were designed without flanking restriction sites, and the amplified PCR 
product (Fig 5.2 A) ligated into the pQE30UA expression vector (a TA cloning vector 
that relies on the addition of terminal thymidine and adenosine residues to the product 
of PCR for ligation) (Fig 5.1 A). The Sp0749 gene was amplified using the forward 
primer with additional nucleotides encoding a BamHI recognition site, and the 
Sp0749 reverse primer with an additional SalI restriction site (Fig 5.2 A). The 
amplified PCR product of Sp0749 was ligated into a TA cloning vector (pGEM-T 
easy) for efficient restriction digestion, the digested PCR product was gel extracted, 
and ligated into the dephosphorylated BamHI and SalI digested pQE30 vector (Fig 5.1 
B). The ligation mixture was digested with SacI to linearize the uncut pQE30 vector 
(SacI is present between the BamHI and SalI restriction sites) and transformed into 
the M15 strain of E. coli. The presence of plasmids containing the correct inserts in 
the right orientation was confirmed by PCR using the vector-specific forward primer 
(pQE30F) and an insert-specific reverse primer (149Rev and 749Rev) (Fig 5.2 B and 
C). The sizes of the PCR products were confirmed by gel electrophoresis. For final 
PCR productA
PTS LacO LacO RBS ATG 6x His MCS Stop codons
U
MCSU
A
m
pi
ci
lli
n
pQE30UA
3500 bp
ColE
B HI S lI
PCR productB
PTS LacO LacO RBS ATG 6x His MCS Stop codons
Sa
cI
am a
pQE30
3400 bp
A
m
pi
ci
lli
n
Fig 5.1 (A) Map of Sp0149 lipoprotein gene (800 bp) ligated into prelinearised pQE30UA expression 
vector. (B) Map of Sp0749 lipoprotein gene (1000 bp) ligated into BamHI and SalI restriction sites of 
ColE
the pQE30 expression vector.
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Sp0149          Sp0749         -ve control
1000 bp
800 bp
A
21     22   23   24    25    26       
Clones
1000 bp
B
1                     2                    3
Clones
C
1000 bp
Fig 5.2 (A) Amplified PCR product of Sp0149 (0.8 kb) and Sp0749 (1 kb) lipoprotein genes from 
S. pneumoniae (0100993 strain) genomic DNA used for the ligation into pQE30UA and pQE30 
expression vector. (C) Colony PCR of Sp0749 lipoprotein gene using pQE30F and Sp0749 Rev
primers to confirm the orientation of Sp0749 gene after the ligation into pQE30 expression vector              . 
M15 strain of E. coli clones 1 and 2 showing the correct orientation of Sp0749 gene. (B) E. coli
M15 colony PCR for amplification of inserts containing the Sp0149 lipoprotein gene in the expression 
plasmid pQE30UA, using the forward primer pQE30F and the reverse primer Sp0149Rev to confirm 
the correct orientation of Sp0149. Clones 21, 23, 24, 26 contain plasmids carrying Sp0149 in the 
correct orientation.
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MKIKKWLGLAALATVAGLA  LAAC  GNSEKKADNATTIKIANH2
Signal peptide Lipobox Functional domain
A
B
cat cac cat cac cat cac gga tcc cac gtg ata tcc tca atc gct tct tgc gga aac tca gaa aag aaa gca gac aat
H H H H H H G S H V I S S I A S C G N S E K K A D N
gca aca act atc aaa atc gca act gtt aac cgt agc ggt tct gaa gaa aaa cgt tgg gac aaa atc caa gaa ttg gtt aaa
A T T I K I A T V N R S G S E E K R W D K I Q E L V K
aaa gac gga att acc ttg gaa ttt aca gag ttc aca gac tac tca caa cca aac aaa gca act gct gat ggc gaa gta gat
K D G I T L E F T E F T D Y S Q P N K A T A D G E V D
ttg aac gct ttc caa cac tat aac ttc ttg aac aac tgg aac aaa gaa aac gga aaa gac ctt gta gcg att gca gat act tac
L N A F Q H Y N F L N N W N K E N G K D L V A I A D T Y
atc tct cca atc cgc ctt tac tca ggt ttg aat gga agt gcc aac aag tac act aaa gta gaa gac atc cca gca aac gga
I S P I R L Y S G L N G S A N K Y T K V E D I P A N G
gaa atc gct gta ccg aat gac gct aca aac gaa agc cgt gcg ctt tat ttg ctt caa tca gct ggc ttg att aaa ttg gat gtt
E I A V P N D A T N E S R A L Y L L Q S A G L I K L D V
tct gga act gct ctt gca aca gtt gcc aac atc aaa gaa aat cca aag aac ttg aaa atc act gaa ttg gac gct agc caa
S G T A L A T V A N I K E N P K N L K I T E L D A S Q
aca gct cgt tca ttg tca tca gtt gac gct gcc gtt gta aac aat acc ttc gtt aca gaa gca aaa ttg gac tac aag aaa tca
T A R S L S S V D A A V V N N T F V T E A K L D Y K K S
ctt ttc aaa gaa caa gct gat gaa aac tca aaa caa tgg tac aac atc att gtt gca aaa aaa gat tgg gaa aca tca cct aag
L F K E Q A D E N S K Q W Y N I I V A K K D W E T S P K
gct gat gct atc aag aaa gta atc gca gct tac cac aca gat gac gtg aaa aaa gtt atc gaa gaa tca tca gat ggt ttg gat
A D A I K K V I A A Y H T D D V K K V I E E S S D G L D
caa cca gtt tgg taa
Q P V W *
Fig 5.3 N-terminal signal sequence and the lipobox of Sp0149 (A) Sp0149 was ligated into pQE30UA
by designing the forward primer from the nucleotide sequence encoding the cysteine residue of the
lipobox. (B) Inframe sequence obtained from sequencing the expression vector (pQE30UA) after
Ligation of Sp0149 into pQE30UA expression vector. Text in bold; 6xHis tag followed by
sequence of pQE30UA.
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MLLLFALSFVALASVAL  LAAC  GEVKSGANTAGNSNH2
Signal peptide Lipobox Functional domain
A
B
cat cac cat cac cat cac gga tcc tgt  gga  gaa  gtg  aag  tct  gga  gca  gtc aac act  gct  ggt aac tca gta  gag  gaa  aag  aca att aaa 
H   H    H   H   H   H    G    F C    G     E     V    K    S    G      A    V   N   T     A    G   N   S    V    E     E      K     T    I   K
atc  ggg  ttt aac ttt  gaa gaa tca  ggt  tct  tta  gct  gca tac gga aca gct gaa caa aaa ggt gcc caa ttg gct gtt gat gaa atc aat gcc gca 
I G F N F E E S G S L A A Y G T A E Q K G A Q L A V D E I N A A
ggt ggt atc gat gga aaa caa atc gaa gta gtc gat aaa gat aat aag tct gaa aca gct gag gct gct tca gtt aca act aac ctt gta acc caa
G G I D G K Q I E V V D K D N K S E T A E A A S V T T N L V T Q                                                                                                            
tct aaa gta tca gca gtc gta gga cct gcg aca tct ggt gcg act gca gct gcg gta gcg aac gct aca aaa gca ggt gtt cca ttg atc tca
S K V S A V V G P A T S G A T A A A V A N A T K A G V P L I S
cca agt gcg act caa gat gga ttg act aaa ggt caa gat tac ctc ttt att gga act ttc caa gat agc ttc caa gga aaa att atc tca aac tat gtt
P S A T Q D G L T K G Q D Y L F I G T F Q D S F Q G K I I S N Y V
tct gaa aaa tta aat gct aag aaa gtt gtt ctt tac act gac aat gcc agt gac tat gct aaa ggg att gca aaa tct ttc cgc gag tca tac aag
S E K L N A K K V V L Y T D N A S D Y A K G I A K S F R E S Y K
ggt gaa atc gtt gca gat gaa act ttc gta gca ggt gac aca gac ttc caa gca gcc ctt aca aaa atg aaa ggg aaa gac ttt gat gct atc gtt
G E I V A D E T F V A G D T D F Q A A L T K M K G K D F D A I V
gtt cct ggt tac tat aat gag gct ggt aaa att gta aac caa gcg cgt ggc atg gga att gac aaa cca atc gtt ggt ggt gat gga ttc aac ggt
V P G Y Y N E A G K I V N Q A R G M G I D K P I V G G D G F N G
gag gag ttt gta caa caa gca act gct gaa aaa gca tca aac atc tac ttt atc tca ggc ttc tca act act gta gaa gtt tca gct aaa gct aaa
E E F V Q Q A T A E K A S N I Y F I S G F S T T V E V S A K A K
gcc ttc ctt gac gct tac cgt gct aag tac aat gaa gag cct tca aca ttt gca gcc ttg gct tat gat tca gtt cac ctt gta gca aac gca gca
A F L D A Y R A K Y N E E P S T F A A L A Y D S V H L V A N A A
aaa ggt gct aaa aat tca ggt gaa atc aag aat aac ctt gct aaa aca aaa gat ttt gaa ggt gta act ggt caa aca agc ttc gat gca gac cac
K G A K N S G E I K N N L A K T K D F E G V T G Q T S F D A D H
aac aca gtc aaa act gct tac atg atg acc atg aac aat ggt aaa gtt gaa gca gca gaa gtt gta aaa cca taa
*N T V K T A Y M M T M N N G K V E A A E V V K P
Fig 5.4 N-terminal signal sequence and the lipobox of Sp0749 (A) Sp0749 was ligated into pQE30 by 
designing the forward primer from the nucleotide sequence encoding the cysteine residue of the lipobox. 
(B) Inframe sequence obtained from sequencing the expression vector (pQE30) after ligation of Sp0749 
into pQE30 expression vector. Text in bold; 6xHis tag followed by sequence of pQE30. 
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Induction Purification DialysisA                                                                           
36 KD
U   I    U  I U     I   CL  FT W1 W2 E1 E2  E3  E4
Protein concentration: 4.3mg/ml
30KDa including His tag
 a
Induction                                      Purification                                      DialysisB
50 KDa
U    I     U   I U     I    CL  FT  W1 W2 E1 E2  E3    E4
Protein concentration: 7mg/ml
39.7KDa including His tag
Fig 5.5 Induction, purification and dialysis of recombinant His6-Sp0149 (A) and His6-Sp0749 (B) 
lipoproteins from E. coli. Key: U, Uninduced; I, Induced; CL, Cell lysate; FT: Flow through; W1-2, 
Washes; E1-4, elutions.
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confirmation of the identity of the PCR products, the PCR products were sequenced 
(Fig 5.3 A, B and Fig 5.4 A, B). The recombinant lipoproteins were expressed as 
histidine tag fusion proteins, and expressed and purified as described in chapter 2 
using conventional techniques. The purity and quantity of His6-Sp0149 and His6-
Sp0749 lipoproteins were checked by running on SDS-PAGE electrophoresis gels. 
The obtained molecular weight of His6-Sp0149 and His6-Sp0749 were 30 KDa and 40 
KDa respectively, correlating closely with the expected molecular weights after 
excluding the N-terminal signal sequence of 29 KDa and 38 KDa respectively. The 
purity and concentration of Sp0149 and Sp0749 were improved by dialysis. After 
dialysis, His6-Sp0149 and His6-Sp0749 were greater than 95% pure, although faint 
high molecular weight bands were observed in both samples (Fig 5.5 A and B), and 
had protein concentrations of 4.3 mg ml-1 and 7 mg ml-1 respectively.  
For systemic immunisation purposes, PspA and PsaA were used as positive 
controls as their efficacy as vaccine candidates against S. pneumoniae infection has 
been previously studied. 
 
5.2 CONSERVATION OF SP0149 AND SP0749 GENES IN S. PNEUMONIAE STRAINS 
A prerequisite for a protein based vaccine candidate is the conservation and 
widespread distribution of the target antigen amongst clinically important capsular 
serotypes of S. pneumoniae. Therefore whether the Sp0149 and Sp0749 lipoprotein 
genes were present in a range of S. pneumoniae strains was analysed by PCR using 
primers Sp0149For and Sp0149Rev, and Sp0749Fwd and Sp0749Rv. Genomic DNA 
obtained from strains representative of common multi-locus strain types (MLST) 
lineages for each vaccine capsular serotype (3, 4, 6B, 9V, 14, 18C, 19F, 23F, a kind 
 
AB
C
D
2       3      4      6B   9V    14C  18C   19F  23F   His6-Sp0149 protein
Fig 5 6 (A B) Conservation of Sp0149 (A) and Sp0749 (B) genes in the representative strains of
2       3       4     6B    9V    14C  18C  19F  23F     His6-Sp0749 protein
 .  ,               
capsular serotypes present in the 7-valent conjugate vaccine. (C, D) Immunoblot of whole cell lysates 
of the representative strains of capsular serotypes from the 7-valent conjugate vaccine (plus the ST2, 
strain D39 and the ST3 strain 0100993 used for the laboratory studies) probed with anti-Sp0149 (C) 
and anti-Sp0749 (D). Identical loading of whole cell lysates were used for (C) and (D).
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gift from Professor Brian Spratt) and from the laboratory strain D39 (capsular 
serotype 2) were used as the templates. For both Sp0149 and Sp0749 identical sized 
fragments were amplified from all the tested strains, indicating that there was likely to 
be a high degree of conservation of these genes amongst S. pneumoniae strains (Fig 
5.6 A, B). To further explore whether these proteins are conserved amongst different 
S. pneumoniae strains, Western blots were performed against whole cell lysates of the 
S. pneumoniae strains discussed above using antisera raised in mice to recombinant 
Sp0749 and Sp0149 raised in mice. Anti-Sp0149 antisera gave good signals for all 
strains probed, whereas the anti-Sp0749 antisera gave a variable strength signal 
between strains, with strong signals only for serotypes 2, 4, 6B and 23F. This suggests 
that the expression of Sp0749 lipoprotein varied with strain background in S. 
pneumoniae (Fig 5.6 C and D). 
 
5.3 ELISA 
To analyse the antibody response after the immunization of mice with the antigens 
His6-Sp0149, His6-Sp0749, His6-PspA, and His6-PsaA and with alum, ELISAs were 
performed using sera obtained by cardiac puncture from 4 to 5 immunized CD1 or 
Balb/c mice 2 weeks after the third booster dose of antigens as described in chapter 2. 
Antibody titres of IgG from individual mouse sera were determined. Both His6-
Sp0149 and His6-Sp0749 induced good titres of specific IgG in most mice, albeit with 
marked variation between mice. His6-PspA induced IgG titres similar to those 
obtained with His6-Sp0149 (median titre of 4.8) and His6-Sp0749 (median titre of 5.4) 
(data not shown). Vaccination of Balb/c mice with His6-PsaA, His6-Sp0149 and His6-
Sp0749 also produced good titres of specific IgG antibody with the exception of the 
results for one mouse serum versus His6-PsaA (Fig 5.7 A). ELISA was also used to  
Fig 5.7 IgG antibody titres measured by ELISA using the sera obtained from Balb/c mice after three  
IP immunisations with purified His6-Sp0149, His6-Sp0749 lipoprotein, PsaA (positive control) or alum 
alone (negative control). (A) Total IgG titres obtained from the sera of Balb/c mice after the IP 
immunisation and cross-reactivity between Sp0149 and Sp0749 lipoproteins (B) IgG1a and IgG2a 
antibody titres in the immunised sera against purified His6-Sp0149 and His6-Sp0749 lipoproteins.
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cross-reaction
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demonstrate that there was no cross-reaction of His6-Sp0149 lipoprotein with anti-
Sp0749 IgG antibodies and vice versa, suggesting there was very little or no antigenic 
similarity between the two proteins (Fig 5.7 A). As expected no detectable antibody 
response was observed in anti-alum antisera. To demonstrate whether the His6-
Sp0149 and His6-Sp0749 lipoproteins elicit a Th1 or a Th2 immune response, IgG1a 
and IgG2a antibody titres were analysed (Jomaa et al., 2005). Fig 5.7 B demonstrates 
that both antigens mainly stimulate an IgG1a subclass in Balb/c mice following IP 
immunisation, suggesting mainly a Th2 response. A similar result was obtained using 
CD1 mice sera following IP immunisation. The results of the ELISAs demonstrate 
that the purified antigens are immunogenic and induce a good IgG antibody response. 
 
5.4 C3 DEPOSITION 
To assess whether anti-Sp0149 and anti-Sp0749 were functional, their effect on the 
deposition of C3b/iC3b on several S. pneumoniae strains was analysed by a well-
established flow cytometry assay (Yuste et al., 2005). The pooled sera of anti-Sp0149 
and anti-Sp0749 showed a small increase in the C3b/iC3b deposition (Fig 5.8 A), but 
the combination of pooled sera containing anti-Sp0149 and anti-Sp0749 increased the 
size of the effect (Fig 5.8 B). C3b deposition assay was also performed by incubating 
the pooled sera containing anti-Sp0149, anti-Sp0749 and anti-alum with capsular 
serotype 3, 6B and 9V (Fig 5.9 A, B, C). Fig 5.9 A and B showed a decrease in the 
C3b/iC3b deposition on serotypes 3 and 6B using anti-Sp0149 anti-Sp0749 sera when 
compared to anti-alum sera. Fig 5.9 C showed a significantly lower C3b/iC3b 
deposition on capsular serotype 9V after incubation in sera containing anti-Sp0749. 
Overall, the data suggest that anti-Sp0149 and anti-Sp0749 have a weak effect in 
 
7500
9000A
**
D39
3000
4500
6000
es
ce
nc
e 
in
de
x 
C
3b
 
de
po
si
tio
n alum
anti-Sp0149
anti-Sp0749**
**
0
1500
Fl
uo
re
1 in 2 dilution1 in 5 dilution
6000
8000
10000
alum
anti-Sp0149 + 
anti-Sp0749
**
B D39
x 
C
3b
 
2000
4000
 
**
Fl
uo
re
sc
en
ce
 in
de
x
de
po
si
tio
n
Fig 5.8 The role of anti-Sp0149 and anti-Sp0749 in the deposition of C3 on the surface of S. pneumoniae
0
1 in 2 dilution1 in 5 dilution
D39 strain using flow cytometry. The proportion of bacteria positive for the C3 after incubating with 
FITC-goat anti-mouse C3 antibody were analysed using Balb/c mice sera. (A) C3 deposition on D39 
strain using pooled sera of anti-Sp0149 and anti-Sp0749 on D39 strain (p value <0.01). (B) Effect of C3 
deposition on D39 strain upon mixing the pooled anti-Sp0149 and anti-Sp0749 sera (p value ≤ 0.01). 
p values were obtained using Student’s-t-test by comparing alum with anti-Sp0149 and anti-Sp0749. 
C3 deposition on S. pneumoniae serotypes 3.
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Fig 5.9 C3 deposition on S. pneumoniae serotypes (A) 3, (B) 6B and (C) 9V  (p value < 0.05) using the 
pooled sera of the anti-Sp0149 and anti-Sp0749 at 1/2 dilution obtained after the second immunisation 
experiment in CD1 mice strain. p values were obtained using Student’s t-test by comparing alum with 
anti-Sp0149 and anti-Sp0749. 
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increasing deposition of complement on the surface of some S. pneumoniae strains 
such as serotypes 3, 6B and 9V. 
 
5.5 OPSONOPHAGOCYTOSIS 
Effective antibodies may stimulate phagocytosis directly through Fcγ receptors in 
addition to improving opsonisation of bacteria by increasing C3b/iC3b deposition on 
their surface. Hence the effect of anti-Sp0149 and anti-Sp0749 on phagocytosis of S. 
pneumoniae by human neutrophils was assessed using an in vitro flow cytometry 
assay (Lehmann et al., 2000) which measures the association of S. pneumoniae with 
phagocytes (Yuste et al., 2008). Fluorescently-labelled bacteria were incubated with 
anti-Sp0149 and anti-Sp0749 at different dilutions before incubation with cells from 
the neutrophil cell line HL60, and then the association of bacteria and cells measured 
by flow cytometry. The role of complement in the in vitro opsonophagocytosis of S. 
pneumoniae by HL60 cells was analysed by using heat-treated sera, which inactivates 
complement, as a source of antibody in the presence and absence of exogenous 
supplementation with purified rabbit complement. Both anti-Sp0149 and anti-Sp0749 
increased the proportion of serotype D39 S. pneumoniae associated with HL60 cells 
by 40% in 1 in 20 dilution of serum. Heat treatment prevented increased association 
of bacteria with HL60 cells for both anti-Sp0149 and anti-Sp0749 sera (Fig 5.10 B). 
Similarly, exogenous supplementation with purified rabbit complement also increased 
the proportion of S. pneumoniae associated with HL60 cells (Fig 5.10 A), suggesting 
the beneficial effect was complement-mediated. Phagocytosis assays were also 
performed for representative strains of various S. pneumoniae capsular serotypes (6B, 
9V, 23F, 4, 14 and 19) (Fig 5.10 C). In the presence of anti-Sp0149, there was a 
statistically significant increase in the association of S. pneumoniae serotype 4 with 
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Fig 5.10 (A, B and C) In vitro opsonophagocytosis assay performed using the anti-Sp0149 and 
anti-Sp0749 sera obtained after the immunisation experiment in CD1 (A) and Balb/c (B, C) mice 
strain. Analysis of the role of complement in the opsonophagocytosis of S. pneumoniae (D39) in the 
presence of exogenous addition of purified rabbit complement (A), role of mouse complement and              
antibodies (B), and opsonophagocytosis of representative S. pneumoniae vaccine serotypes using anti-
Sp0149 and anti-Sp0749 sera (C). 197
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HL60 cells compared to alum sera (p < 0.01) but non-significant increases for 
serotypes 9V and 14. In the presence of anti-Sp0749, a statistically significant 
increase in the association of S. pneumoniae with HL60 cells was observed for 
serotypes 6B, 9V, 4, 19 (p < 0.01) and 14 (p < 0.05) compared to sera from mice 
vaccinated with alum alone. Overall, these results suggest that anti-Sp0149 and anti-
Sp0749 could improve complement-dependent opsonophagocytosis of S. pneumoniae 
and therefore aid immunity against S. pneumoniae infection (Jomaa et al., 2005).  
 
5.6 ACTIVE IMMUNIZATION STUDIES 
To assess the efficacy of the purified His6-Sp0149 and His6-Sp0749 lipoproteins as 
vaccine candidates, the degree of protection provided by these two lipoproteins in a 
septicaemia model of S. pneumoniae infection was evaluated. Three separate IP 
immunization experiments were performed using three different challenge doses of 
the virulent capsular strain of S. pneumoniae (D39) in naïve outbred CD1 and inbred 
Balb/c mice as described in chapter 2. 
The initial immunization experiment was performed in male outbred CD1 mice. 10 µg 
of the purified His6-Sp0149 and His6-Sp0749 lipoproteins with alum as an adjuvant 
and alum alone as the negative control were injected intraperitoneally followed by 
two booster doses at 7 days intervals. After 2 weeks of immunization, mice were 
challenged by i.p injection of 105 cfu of the virulent capsular serotype 2 S. 
pneumoniae strain D39 and the progress of infection monitored over two weeks (Fig 
5.11 A, B). Mice immunized with His6-Sp0149 and His6-Sp0749 lipoproteins 
exhibited only a small delay of about 4 hours in the progress of infection compared to 
alum alone. Of the 19 mice challenged with D39 strain of S. pneumoniae, 100% 
mortality was observed in the alum group, while only one mouse was alive in His6- 
Fig 5.11 Survival curves after the first IP active immunisation in CD1 mice strain with purified 
(A) His6-Sp0149, (B) His6-Sp0749 and alum (negative control) followed by challenge with 105
(B) cfu of S. pneumoniae (D39) for a group of 19 mice. 
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Fig 5.12 Survival curves after the second IP active immunisation in CD1 mice strain with (A) 
purified His6-Sp0149, (B) His6-Sp0749, (C) PspA (positive control) and alum (negative control) 
followed by challenge with 103 cfu of S. pneumoniae (D39) for a group of 19 mice. 
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Fig 5.13 Survival curves after the third IP active immunisation in Balb/c mice strain with (A) 
purified PsaA (positive control), (B) His6-Sp0149, (C) His6-Sp0749 and alum (negative control) 
followed by challenge with 104 cfu of S. pneumoniae (D39) for a group of 19 mice
201
A
B
C
 202 
Sp0149 group and 3 mice were alive in His6-Sp0749 group until the end of the 
experiment. 
To ensure the small differences in the progress of infection in the vaccinated 
mice were not due to an overwhelming bacterial challenge, the immunization 
experiment was repeated with a lower S. pneumoniae (D39) challenge dose of 103 cfu. 
In the second vaccination experiment (Fig 5.12 A, B and C), His6-PspA 
(pneumococcal surface protein) was also included as a positive control. His6-Sp0149 
and His6-PspA failed to exhibit any protection, but mice immunised with His6-Sp0749 
exhibited a non-significant delay (p = 0.08) in the lethal progression of the disease of 
approximately 9 hours. 
Since the His6-Sp0149 failed to exhibit protection and His6-Sp0749 only exhibited a 
delay in the lethal progression of the disease in CD1 mice strain, the immunisation 
experiment was repeated in Balb/c mice strain. Balb/c mice were chosen because they 
are inbred strain of mice and are relatively resistant to S. pneumoniae infections 
unlike the outbred CD1 mouse strain (Gingles et al., 2001). PsaA (pneumococcal 
surface adhesion A), a lipoprotein component of S. pneumoniae manganese ABC 
transporter was used as positive control and a challenge dose of 104 cfu given by IP 
inoculation after immunisation with the purified lipoproteins. Both His6-PsaA and 
His6-Sp0149 failed to protect the mice from fatal infection. Again, His6-Sp0749 
seemed to delay the lethal progression of infection, although the results were not 
statistically significant. After 144 hours only one mouse was alive in the alum group, 
3 mice alive in the His6-PsaA and His6-Sp0149 group, and 5 mice alive in His6-
Sp0749 group (Fig 5.13 A, B and C).  
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5.7 SUMMARY 
The Sp0149 and Sp0749 lipoproteins were chosen for analysis of their efficacy as 
vaccine candidates as the mutant strains affecting the corresponding ABC transporters 
had marked attenuation of virulence in murine models of septicaemia and pneumonia. 
The PCR–amplified products of the lipoprotein genes, Sp0149 and Sp0749 were 
ligated into the expression vectors, pQE30UA and pQE30 respectively (excluding the 
N-terminal signal sequence) and the lipoprotein components were successfully 
expressed in E. coli and relatively high concentrations of good quality protein 
obtained. Vaccination of mice generated high titres of specific antibodies to both 
Sp0149 and Sp0749 and there was no evidence of cross reaction of antibodies to 
Sp0149 with the protein Sp0749 and vice versa. PCR and western blot analysis 
demonstrated that Sp0149 and Sp0749 are conserved in the serotypes present in the 7-
valent conjugate vaccine. In vitro immune assays measuring the effects of polyclonal 
murine anti-Sp0149 and anti-Sp0749 on C3b deposition and phagocytosis 
demonstrated improvements in both complement deposition and phagocytosis for 
several S. pneumoniae strains. Active immunization with the purified Sp0149 and 
Sp0749 lipoproteins and challenge with D39 strain of S. pneumoniae indicated that 
there was a small but non-significant degree of protection when mice were vaccinated 
with recombinant Sp0749.  
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    Chapter 6 
 Investigation of Sp0749 vaccine potential 
against S. pneumoniae pneumonia 
 
In this chapter, data regarding the vaccine potential of the recombinant Sp0149 and 
Sp0749 lipoproteins against S. pneumoniae pneumonia are presented. Many variations 
are adopted in the immunisation-challenge methodology in this chapter compared to 
the methodology presented in chapter 5. These variations include mouse strains, use 
of adjuvant, S. pneumoniae challenge strains and the route of lipoprotein and S. 
pneumoniae administration. In this chapter, the intranasal immunisations and S. 
pneumoniae challenge (using 0100993 and D39 strains) experiments were performed 
in two different mouse strains (outbred CD1 and inbred CBA/Ca). Cholera toxin was 
used as the adjuvant for intranasal immunisation unlike alum which was used as 
adjuvant for the intraperitoneal immunisation in chapter 5. The role of Sp0749 alone 
and in combination with previously investigated lipoproteins of iron uptake ABC 
transporters PiaA and PiuA in eliciting protective immune response was also 
investigated and the data are presented in this chapter. 
 
6.1 EXPRESSION AND PURIFICATION OF PIAA AND PIUA LIPOPROTEINS 
PiaA and PiuA are lipoproteins components of iron uptake ABC transporters of S. 
pneumoniae whose vaccine potential were previously investigated by my supervisor 
Dr. Brown. Brown et al previously identified that intraperitoneal and intranasal 
immunisation with the recombinant PiaA and PiuA lipoprotein components protected 
the mice against S. pneumoniae septicaemia and pneumonia (Brown et al., 2001,  
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Fig 6.1 Antibody titres measured by ELISA after IN immunisations with the purified lipoproteins. 
Total IgG (serum) and IgA (BALF) antibody titres were determined using purified His6-Sp0749 and 
His6-PiaA. Each point represents the anti-PiaA or anti-Sp0749 antibody titre of serum or BALF from 
individual mouse. The titres are represented as the reciprocal of the dilution of serum which resulted 
in an OD405 ≥ 0.30. No detectable antibody titres were obtained in sera and BALF from PiaA or 
PiaA-Sp0749 immunised mice when tested against cholera toxin (CT) (data not shown). 
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Jomaa et al., 2005). Therefore the recombinant PiaA and PiuA lipoproteins were used 
for the intranasal immunisation and challenge experiments in mice as positive 
controls in order to evaluate the vaccine potential of Sp0749. The PiaA and PiuA 
lipoproteins were expressed and purified according to (Brown et al., 2001) with some 
modifications. The PiaA (Sp1032) and PiuA (Sp1872) lipoprotein genes were 
amplified using the primers PiaA F and PiaA R for the PiaA gene and PiuA F and 
PiuA R for the PiuA gene and 0100993 genomic DNA as template as described in 
chapter 2 and 4. The primers were designed using the TIGR 4 genome to exclude the 
DNA sequence encoding the signal peptide as described in chapter 4. The amplified 
PCR products were ligated into the expression vector pQE30UA and transformed into 
the M15 strain of E. coli. The positive clones for the lipoprotein genes were 
confirmed by colony PCR using the vector-specific forward primer (pQE30F) and the 
insert specific reverse primer (PiaA R and PiuA R) and by sequencing. The positive 
clone for each of the lipoprotein gene was then induced for over expression of His-
tagged lipoproteins and purification of the his-tagged protein performed according to 
the QIAexpressionistTM manual. The purified his-tagged lipoproteins were dialysed 
and analysed by SDS-PAGE. 
 
6.2 ELISA 
In order to analyse the antibody responses after the IN immunisations of mice with 
purified lipoproteins (His6-PiaA, and His6-Sp0749), serum and bronchoalveolar 
lavage fluid (BALF) were obtained from 4 to 5 immunised CD1 and CBA/Ca mice 2 
weeks after the second booster dose of antigens and used for ELISAs (Jomaa et al., 
2005). Cholera toxin (CT) was used as the adjuvant with the lipoproteins and CT 
alone was used as the negative control for the immunisation experiments and CT is 
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routinely used as an adjuvant with different S. pneumoniae proteins for IN 
immunisations (Pimenta et al., 2006; Shah et al., 2009). Outbred CD1 mice were used 
because they are less expensive where as inbred CBA/Ca mice were used because 
they are genetically less variable and are susceptible to IN infection (Kadioglu and 
Andrew, 2005; Gingles et al., 2001). Purified His6-PiaA lipoprotein was used as 
positive control as it has been demonstrated to induce good systemic and mucosal 
antibody responses upon pulmonary and systemic immunisations in mice (Brown et 
al., 2001; Jomaa et al., 2006). IN immunisation with both His6-PiaA and His6-Sp0749 
induced significant serum IgG titres to purified PiaA and Sp0749 in the CD1 mouse 
strain (Fig 6.1). Titres of IgG and IgA were measured using BALF obtained from 
CBA/Ca mice immunised IN with combination of proteins (His6-PiaA plus His6-
Sp0749). Fig 6.1 demonstrates that His6-PiaA and His6-Sp0749 induced good IgG 
titres in BALF, with similar levels to the IgG titres found in sera from CD1 mice. 
However, when the IgA titres in the BALF of the CBA/Ca mice were measured, 
negligible amounts of anti-Sp0749 IgA were present and anti-PiaA IgA were only 
elicited in two mice. These data suggest that after IN immunisation both the proteins 
elicit a good systemic and some local IgG response but only a poor mucosal IgA 
response. 
 
6.3 BACTERIAL CFUS IN TARGET ORGANS 
To further investigate whether IN immunisation of CBA/Ca mice with His6-PiaA and 
His6-PiaA plus His6-Sp0749 of CBA/Ca mice protects against S. pneumoniae 
challenge, the cfu counts in target organs were determined from the BALF, lungs and 
blood. The immunised mice were intranasally challenged with 105 cfu of S. 
pneumoniae and the target organs were harvested 48 hours after IN inoculation. The  
Fig 6.2 S. pneumoniae (D39) cfu determined from the target fluids and organs such as BALF (A), lungs 
(B) and blood (C) of IN immunised of CBA/Ca mice (using CT alone, CT + His6-PiaA or CT + His6-
PiaA + His6-Sp0749, n = 6 in each group) 48 hours after S. pneumoniae IN challenge with 105 cfu / 
mouse. p-value analysed by Mann-Whitney test. 
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Table 6.1 Median and interquartile range (IQR) of S. pneumoniae (D39) cfu determined from BALF, 
lungs and blood after the IN immunisation of CBA/Ca mice with CT alone, CT + His6-PiaA, CT + 
His6-PiaA + His6-Sp0749 (n = 6 in each group) followed by S.  pneumoniae challenge 48 hours after 
the inoculation of 105 cfu / mouse. 
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target organs were then homogenised in sterile PBS, serially diluted and appropriate 
dilutions were plated to determine the cfu / ml in the target organs (Fig 6.2 and Table 
6.1). Although CBA/Ca mice immunised intranasally with His6-PiaA plus His6-
Sp0749 had reduced S. pneumoniae cfu in BALF (Fig 6.2 A), lung (Fig 6.2 B) and 
blood (Fig 6.2 C) compared to mice immunised with CT alone, and mice immunised 
with His6-PiaA alone had reduced S. pneumoniae cfu in blood, these reductions failed 
to attain statistical significance. However, data were obtained from a relatively small 
number of mice and varied widely between mice in the same vaccine group. 
 
6.4 CYTOSPINS OF BALF 
BALF cellular content was analysed before and 48 hours after the S. pneumoniae 
challenge (D39) of the CBA/Ca mice immunised with CT alone, His6-PiaA and His6-
PiaA plus His6-Sp0749 proteins. Total cell counts in BALF were determined using a 
haemocytometer and microscopy of the cytospins was used to assess the proportion of 
macrophages, neutrophils and lymphocytes present as described in chapter 2. Total 
cell counts of BALF did not demonstrate significant differences before and after the S. 
pneumoniae challenge (Table 6.2). The BALF cytospin differential counts (Fig 6.3) 
demonstrated significantly higher neutrophil numbers post-challenge with S. 
pneumoniae in all three immunised groups (Fig 6.3 B), whereas the proportion of 
macrophages and lymphocytes were significantly reduced (Fig 6.3 A and B). 
Neutrophil counts were very low in all the three immunisation groups before 
challenge and therefore the data are not shown. A statistically significant increase in 
the neutrophil counts was obtained in the post-challenge mice immunised with both 
His6-PiaA (p = 0.0022) and His6-PiaA plus His6-Sp0749 (p = 0.0043) when compared 
to pre-challenge groups.  
Table 6.2  Median and IQRs of the total cell counts in BALF and lungs of  CBA/Ca mice 
after the IN immunisation with CT alone, CT + His6-PiaA and CT + His6-PiaA + His6-
Sp0749 (n = 6) pre and post S. pneumoniae challenge (D39, 105 cfu / mouse). 
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Fig 6.3 Differential cell counts of macrophages, lymphocytes and neutrophils present in the 
BALF of IN immunised CBA/Ca mice (n = 6 in each group) with CT alone, CT + His6-PiaA, 
and CT + His6-PiaA + His6-Sp0749 pre (A) and post (B) S. pneumoniae challenge (D39, 105
cfu / mouse). p value for pre vs post-challenge comparisons analysed by Mann-Whitney test.
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6.5 IMMUNE RESPONSE TO CT, HIS6-PIAA AND HIS6-PIAA PLUS HIS6-SP0749 AFTER 
IN IMMUNISATION AND S. PNEUMONIAE CHALLENGE 
To investigate the effects of immunisation of mice with CT, His6-PiaA or His6-PiaA 
plus His6-Sp0749 on the host immune response, leukocytes were isolated from the 
BALF and lungs of CBA/Ca mice immediately before and 48 hours after challenge 
with S. pneumoniae as described in chapter 2. Total cell counts of the homogenised 
lung were determined using a haemocytometer, and cells incubated with 
fluorescently-labelled antibodies to lymphocytes and macrophage surface markers 
were analysed by flow cytometry to identify the proportion of cells belonging to each 
lymphocyte subgroup and the proportion of these cells that are activated (Brown et 
al., 2002).  
There were only small differences in lung cell counts before and after S. 
pneumoniae challenge between the vaccine groups (Table 6.2). The results of the cell 
surface marker experiments were highly variable between mice and it was difficult to 
identify clear trends. There were no clear differences in the proportions of CD4, CD8 
and B cells between the vaccinated groups with the exception of activated CD4 and 
CD8 cells in the lungs (Fig 6.5 C, D).  
In the BALF, the proportion of activated CD4 and CD8 (CD45RB –ve) cells 
(Fig 6.4 C, D) showed a statistically significant decrease in all the three post-
challenge vaccinated groups compared to pre-challenge (for all groups p < 0.01 for 
the comparison of results pre and post-challenge of activated CD4 cells) (for all 
groups p < 0.05 for the comparison of results pre and post-challenge of activated CD8 
cells). 
In the lungs, there was a statistically significant increase in the proportion of  
 
Fig 6.4 Flow cytometry analysis of the host’s immune response in the BALF by immune cell surface 
staining following the IN immunisation (pre) and subsequent challenge (post). The proportion of (A) 
CD4 positive cells, (B) CD8 positive cells, (C) CD4 positive cells (CD45RB –ve) (p < 0.01 for 
comparisons pre vs post for all groups), (D) CD8 positve cells (CD45RB-ve) (p < 0.05 for 
comparisons pre vs post for all groups). p value were analysed by Kruskal-Wallis test 
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Fig 6.5 Flow cytometry analysis of the host’s immune response in the lungs by immune cell surface 
staining following the IN immunisation and challenge. The proportion of (A) CD4 positive cells, (B) 
CD8 positive cells (p < 0.05 for comparisons pre Vs post for all groups), (C) CD4 positive cells 
(CD45RB –ve) (p < 0.01 for comparisons pre Vs post) and (D) CD8 positive cells (CD45RB -ve) (p < 
0.01 for comparisons pre Vs post for all groups). p values were analysed using Kruskal-Wallis test 
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Fig 6.6 Flow cytometry analysis of the proportion of B220 positive cells in the (A) BALF and (B) 
lungs (p < 0.05 for comparisons pre vs post for all groups) by immune cell surface staining following 
the IN immunisation and challenge. p values analysed using Kruskal-Wallis test. 
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Fig 6.7 Flow cytometry analysis of the host’s immune response in the BALF (A, B) and lungs (C, D) 
by immune cell surface staining following the IN immunisation and challenge. The proportion of 
CD80 positive for macrophages in the (A) BALF (p < 0.05 for comparisons pre vs post for all groups) 
and (C) lungs. The proportion of macrophages positive for MHC class II antigens (I-A-I-E) in the 
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CD8 positive lymphocytes in the His6-PiaA plus His6-Sp0749 compared to CT alone 
after S. pneumonie challenge (for all groups p < 0.05 for the comparison of results pre 
and post-challenge) (Fig 6.5 B). His6-PiaA plus His6-Sp0749 vaccinated group 
showed a statistically significant decrease in the proportions of CD4 and CD8 
(CD45RB –ve) cells post-challenge compared to pre and post-CT and pre-PiaA (for 
all groups p < 0.05 for the comparison of results pre and post-challenge) (Fig 6.5 C, 
D). However, the proportion of B220 positive cells may be increased in the lungs of 
His6-PiaA plus His6-Sp0749 vaccinated group after S. pneumoniae challenge 
compared to pre-CT (for all groups p < 0.05 for the comparison of results pre and 
post-challenge) (Fig 6.6 B). 
The activation of macrophages before and after the S. pneumoniae challenge 
of the immunised mice were analysed using antibodies to the cell surface marker 
CD80 and the MHC class II antigen I-A-I-E (Fig 6.7). In the BALF, the proportion of 
CD80 positive cells seemed to be similar in the CT group but decrease in the His6-
PiaA plus His6-Sp0749 vaccinated groups upon S. pneumoniae challenge (Fig 6.7 A) 
(for all groups p < 0.05 for the comparison of results pre and post-challenge). In 
contrast in the lungs, the proportion of CD80 positive cells showed no statistically 
significant increase in the His6-PiaA and His6-PiaA plus His6-Sp0749 vaccinated 
groups upon S. pneumoniae challenge compared to all the pre-challenge groups and 
post-CT (Fig 6.7 C). However, the BALF and lungs results using the (I-A-I-E) surface 
marker did not mirror the results for the CD80 cell surface marker (Fig 6.7 B, D). 
Therefore the significance of the CD80 marker results remain unconfirmed. 
Overall, these results suggest that intranasal immunisation with His6-PiaA and 
His6-PiaA plus His6-Sp0749 may affect components of the cellular immune response 
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to S. pneumoniae pneumonia. However these experiments need to be repeated to 
identify clear patterns. 
 
6.6 HISTOLOGICAL ANALYSIS OF INFLAMMATION AFTER S. PNEUMONIAE 
CHALLENGE OF INTRANASALLY VACCINATED MICE 
To investigate the degree of inflammation leading to lung injury of mice vaccinated 
IN with His6-PiaA or His6-PiaA plus His6-Sp0749, lungs obtained from the pre and 
post, S. pneumoniae challenged mice (48 hours) underwent histological analysis. Each 
lung was scored as follows: 1 (visible inflammatory change), 2 (minimal swelling of 
alveolar walls and changes in architecture), 3 (increased swelling with presence of 
erythrocytes and inflammatory cells and an increase in type II pneumocytes), 4 
(considerable haemorrhage with inflammatory cell influx, widespread alveolar 
disorganisation with interstitial swelling and pneumocyte proliferation) as described 
in chapter 2. A total score of the level of inflammation for each mouse was obtained 
by multiplying the percentage of involved lung by the mean score for the areas 
analysed, and data presented as medians with IQRs. Table 6.3 shows the levels of 
inflammation as medians and interquartile ranges of IN immunised CBA/Ca mice 
with His6-PiaA or His6-PiaA plus His6-Sp0749 proteins followed by S. pneumoniae 
challenge. Histological analysis of lungs showed there was a statistically significant 
increase in the level of inflammation after S. pneumoniae challenge in mice 
vaccinated with His6-PiaA or His6-PiaA plus His6-Sp0749 compared to those 
vaccinated with CT alone (Table 6.3). These data suggest that vaccination with these 
proteins may cause a more rapid inflammatory influx into lungs during subsequent S. 
pneumoniae challenge however these experiments needs to be repeated. 
 
CT
His6-PiaA
His6-PiaA+
His6-Sp0749
Pre-challenge  
Median   (IQR)
Post-challenge   
Median (IQR)
11.25 (6.6-25.6)
22.5 (16.6-35.6)
76.25 (45.4-94)
84.2 (56.3-113.3)
185.8 (147.9-375)
130.8 (103.3-300)
Table 6.3  Histological analysis of the level of inflammation in the lungs of CBA/Ca mice 
after the IN immunisation with CT alone, CT + PiaA and CT + PiaA + Sp0749 pre and post 
S. pneumoniae challenge (D39, 105 cfu / mouse). Degree of lung inflammation before and 
after the S. pneumoniae challenge is represented as medians and IQRs. p values were 
analysed using Kruskal-Wallis test (CT Vs PiaA or PiaA-Sp0749, p < 0.001 or  p < 0.01 or p
< 0.05) and Mann-Whitney test for all groups  (Pre-challenge vs post-challenge, p = 0.0022).    
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6.7 SURVIVAL OF THE HIS6-SP0149 AND HIS6-SP0749 IMMUNISED MICE AFTER S. 
PNEUMONIAE CHALLENGE  
In order to asses the efficacy of the purified His6-Sp0149 and His6-Sp0749 as 
intranasal vaccine candidates, the degree of protection provided by these two 
lipoproteins in the pulmonary models of infection was evaluated. Purified His6-PiaA 
and His6-PiuA lipoproteins were used as positive controls as both the lipoproteins 
have been investigated as vaccine candidates in the pulmonary and systemic models 
of infection in mice (Brown et al., 2001; Jomaa et al., 2006). Four intranasal 
immunisation experiments were performed using four different challenge doses of the 
virulent capsular strain of S. pneumoniae (D39 and 0100993) in naïve outbred CD1 
mice and inbred CBA/Ca mice as described in chapter 2.  
Two separate IN immunisations were performed in CD1 mice using 2.5µg of 
the purified His6-PiaA, His6-PiuA, His6-Sp0749, His6-PiaA plus His6-Sp0749 and 
His6-PiaA plus His6-Sp0149 plus His6-Sp0749 lipoproteins with CT as an adjuvant 
and CT alone as the negative control were injected intranasally followed by two 
booster doses at 7 days intervals. Two weeks after immunization, mice were 
challenged by intranasal injection of 106 cfu of the virulent capsular serotype 2 S. 
pneumoniae strain D39 and the progress of infection monitored over two weeks (Fig. 
6.1 and 6.2). Fig 6.8 A and B represents pooled data of two separate experiments in 
which mice were immunised IN with His6-PiaA and His6-PiaA plus His6-Sp0749 and 
D39 challenge experiments in CD1 mice strain (n = 10+10). IN immunisation with 
His6-PiaA (p = 0.405) did not exhibit protection, although His6-PiaA plus His6-
Sp0749 exhibited a statistically non-significant delay (p = 0.083) in the progression of 
S. pneumoniae infection compared to CT. However the immunisation with His6-PiuA 
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Fig 6.8 Survival curves after the intranasal (IN) immunisation of CD1 mice with cholera toxin CT 
(squares), PiaA, PiuA, Sp0749 and combinations of PiaA with Sp0749 (diamonds). IN immunisation 
of CD1 mice with CT alone, CT + PiaA (p = 0.405) (A), CT + PiaA + Sp0749 (p = 0.083) (B) and CT 
+ PiuA (C) followed by IN challenge with S. pneumoniae D39 (106 cfu / mouse). A and B are the 
pooled results of two separate IN immunisation and challenge experiments (n = 10 + 10, n = 
number of mice) and p values are analysed by the log rank. 222
C
B
A
AB
Fig 6.9 Survival curves after the IN immunisation of CD1 mice (n = 10) with CT (squares) 
Sp0749 and combinations of PiaA with Sp0149 and Sp0749 (diamonds). IN immunisation of 
CD1 mice with CT alone, CT + Sp0749 (A), CT + PiaA + Sp0149 + Sp0749 (B) followed by 
IN challenge with S. pneumoniae D39 (106 cfu / mouse). p values are analysed by the log 
rank test.
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Fig 6.10 Survival curves after the IN immunisation of  CBA/Ca mice (n = 15) with CT 
(squares), PiaA, Sp0749 and combinations of PiaA with Sp0749 (diamonds). IN immunisation 
of CBA/Ca mice with CT alone, CT + PiaA (A), CT + PiaA + Sp0749 (B) followed by IN 
challenge with S. pneumoniae D39 (105 cfu / mouse). IN immunisation of CBA/Ca mice (n = 
20) with CT alone, CT + Sp0749 (C) followed by IN challenge with S. pneumoniae 00100993 
strain (105 cfu / mouse). p values are anaysed by the log rank test. 224
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(Fig 6.8 C), His6-Sp0749 (Fig 6.9 A), and His6-PiaA plus His6-Sp0149 plus His6-
Sp0749 (Fig 6.9 B) lipoproteins in CD1 mice strain (n = 10) did not show any 
protection compared to CT alone.  
The third intranasal immunisation experiment was performed in the inbred 
CBA/Ca mouse strain .Groups of CBA/Ca mice (n = 15) were immunised with CT 
alone, His6-PiaA, His6-PiaA plus His6-Sp0749 followed by intranasal challenge with 
105 cfu of S. pneumoniae D39. Mice immunised with His6-PiaA, His6-PiaA plus His6-
Sp0749 showed only delayed progression of disease after S. pneumoniae challenge 
(Fig 6.10 A and B). The fourth intranasal immunisation experiment was also 
performed in CBA/Ca mice strain with groups of mice (n = 20) immunised with CT 
alone, His6-Sp0749 followed by intranasal challenge with 10
5 cfu of S. pneumoniae 
0100993 strain. Fig 6.10 C shows that His6-Sp0749 failed to exhibit any protection 
and that the survival curve of His6-Sp0749 was almost similar to mice immunised 
with CT alone. 
Overall these data suggest there may be some protective effect in these models 
after the combined immunisation with PiaA and Sp0749 lipoproteins, but any 
protective effect of individual lipoproteins was too weak to be detected by the 
infection models used for these experiments. 
 
6.8 SUMMARY 
PiaA and PiuA his-tagged lipoproteins were expressed and purified in order to use as 
positive controls for the intranasal immunisation studies. Following intranasal 
immunisation with PiaA and Sp0749, good IgG titres were demonstrated in sera 
obtained from CD1 mice and BALF obtained from CBA/Ca mice. However, anti-
PiaA IgA titres in BALF were variable and no detectable anti-Sp0749 IgA titres were 
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found. When the S. pneumoniae load was determined from the target organs such as 
BALF, lungs and blood 48 hours after challenge of vaccinated mice with S. 
pneumoniae, statistically non-significant reductions in S. pneumoniae cfu were 
demonstrated in the BALF, lungs and blood of mice vaccinated with PiaA plus 
Sp0749 compared to CT group. Mice immunised with PiaA alone showed non-
significant reductions of S. pneumoniae cfu in blood only compared to CT group. The 
differential cell counts in the BALF of the CT, PiaA and the PiaA plus Sp0749 
immunised mice demonstrated a statistically significant increase in the neutrophil 
infiltration in PiaA vaccinated mice upon challenge with S. pneumoniae compared to 
CT alone. Flow cytometry analysis of the lymphocytes in the BALF and lung 
homogenate of the immunised CBA/Ca mice before and after the S. pneumoniae 
challenge by cell surface marker staining was performed. Flow cytometry analysis 
after immune cell surface staining did not indicate a particular trend and the results 
were highly variable between mice. Intranasal immunisation demonstrated that PiaA 
in combination with Sp0749 only slightly delayed the progression of lethal S. 
pneumoniae infection. In summary, although vaccination with PiaA and Sp0749 
causes evidence of an altered immune response to subsequent pneumonic infection, 
the protective effects of this seems limited.
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    Chapter 7 
    Discussion 
  
There has been strong interest in S. pneumoniae proteins as vaccine candidates 
because they offer the potential to overcome the limitations of the currently available 
S. pneumoniae vaccines based on capsular polysaccharide antigens. Important 
features for a protein to qualify as a potential S. pneumoniae vaccine candidate are 
surface exposure, immunogenicity, conservation amongst a range of clinically 
important serotypes and the ability to elicit a protective immune response. A role for 
virulence would be beneficial as this would suggest that the protein candidate is 
expressed during systemic infection. The antibodies elicited against the protein in the 
host may inhibit the function of the protein thereby affecting the S. pneumoniae 
virulence. In addition, an important role in virulence means that the expression of the 
protein is necessary for the survival of S. pneumoniae in the host to cause disease. 
Genes encoding such proteins which are necessary for the S. pneumoniae survival in 
the host rarely undergo mutations. Therefore use of such proteins as vaccine antigens 
induces immunity to help prevent immune evasion of S. pneumoniae. Simultaneous 
immunisation with several S. pneumoniae surface proteins has been shown to protect 
mouse models against S. pneumoniae pulmonary and systemic infections (Briles et 
al., 1997; Briles et al., 1996; Brown et al., 2001; Briles et al., 2003; Ogunniyi et al., 
2007) and a vaccine containing several protein antigens is likely to offer advantages 
in efficiency and greater serotype coverage. 
One group of surface proteins which are important for the survival of S. 
pneumoniae in the host, thereby playing important role as virulence determinants, are 
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ABC transporters (Unsworth and Holden, 2000) (Garmory and Titball, 2004) (Benton 
et al., 2004). Bioinformatic analysis of the genome of S. pnemoniae has identified as 
many as 73 ABC transporters (Harland et al., 2005), many of which are predicted to 
be involved in nutrient acquisition from the host (Bergmann and Hammerschmidt, 
2006). Several S. pneumoniae ABC transporters are known to be important for 
virulence such as PiaA, PiuA (Brown et al., 2004) and PsaA (Dintilhac et al., 1997), 
but the role of many S. pneumoniae ABC transporters during virulence has yet to be 
investigated. I have therefore chosen 11 ABC transporters from the annotated 
completely sequenced genome of capsular serotype 4 of S. pneumoniae (TIGR4) that 
have previously not been characterised and investigated their role in virulence and 
selected two of these for assessment as potential vaccine candidates. The S. 
pneumoniae ABC transporters chosen for these studies were the majority of the 
remaining 18 uncharacterised ABC transporters that are organised as operons of three 
or more genes containing at least two of the three main components of ABC 
transporters (the lipoprotein, ATPase and transmembrane permeases). Disruption of 
these ABC transporters was thought to be more likely to give a strong phenotype as 
most or all of the components of that ABC transporter would be co-transcribed. 
Components of some of the ABC transporters chosen for this study (Sp0092, Sp0150, 
Sp2086 and Sp2108) have been identified as potential virulence factors by STM 
screening (Hava and Camilli, 2002; Lau et al., 2001). Mutant strains were constructed 
by disruption of the predicted first gene of the operon using IDM to try and ensure the 
disruption of transcription of the whole operon and therefore the generation of a 
stronger phenotype. Nine mutant strains of the chosen 11 ABC transporter operons of 
S. pneumoniae were successfully constructed by IDM. However I failed to obtain any 
mutant strain for the putative amino acid transporter encoded by Sp0707-0711 even 
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after repeated attempts, possibly because some regions of the genome may be 
resistant to transformation or because that disruption of this gene may prove to be 
lethal for the bacterium. In another mutant strain, Sp2084-, the putative phosphate 
transporter encoded by Sp2084-2087 had an unstable mutation, a relatively common 
problem for mutant strains made by IDM due to the duplicated regions flanking the 
inverted plasmid allowing homologous recombination to excise the plasmid 
containing the gene for antibiotic selection. 
BLAST searches indicated that several of the chosen ABC transporters are 
likely to be sugar ABC transporters (Sp0090-92, Sp0846-48, Sp1796-98, and Sp2108-
10), which is not surprising given the large range of sugars that S. pneumoniae is 
thought to be able to utilise (Tettelin et al., 2001). BLAST searches also indicated that 
Sp0607-10, Sp0707-11 and Sp0749-53 are putative amino acid ABC transporters. 
Sp0749-53 was identified a putative branched-chain amino acid (BCAA) transporter. 
The S. pneumoniae genome also contains genes encoding enzymes required for 
BCAA synthesis (Sp0445-50) (Hendriksen et al., 2008) which may partially 
compensate for BCAA uptake by S. pneumoniae. Sp0149 was identified as a putative 
cation lipoprotein, but other genes of this operon did not correlate with the likely 
function of cation uptake. However another transport classification system (Saier, Jr., 
2000) indicated Sp0148-52 as a putative methionine ABC transporter. A similar 
discrepancy between the BLAST alignment and the transport classification system 
was also observed when predicting the possible substrate for Sp0846-48. BLAST 
alignment predicted Sp0846-48 as a putative sugar transporter, whereas the transport 
classification system predicted it is a possible nucleoside ABC transporter. Detailed 
characterisation of these ABC transporters is needed to confirm their ligand binding 
properties.  
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Many ABC transporters seem to be highly conserved amongst different S. 
pneumoniae strains (eg PiaA, PsaA and PiuA) (Whalan et al., 2006), (Sampson et al., 
1997). BLAST alignment of the predicted lipoprotein genes of the chosen ABC 
transporters to 18 other available S. pneumoniae genomes demonstrated a high degree 
of amino acid conservation between S. pneumoniae strains (Basavanna et al., 2009). 
BLAST alignment of the chosen ABC transporters showed that 8 of the eleven ABC 
transporters have the greatest degree of amino acid homology to various streptococci 
(Sp0090-92, Sp0148-52, Sp0607-10, Sp0707-11, Sp0749-53, Sp0846-48, Sp1796-98 
and Sp2108-10). However no close homologues amongst streptococci were found for 
Sp1688-90 (a putative cation ABC transporter), Sp2084-87 (a putative sugar 
transporter), or Sp1824-26 (a putative phosphate ABC transporter). Previously, the 
iron uptake ABC transporter PiaA was shown to be highly conserved in S. 
pneumoniae strains but absent in oral streptococci, including the S. mitis group 
(Whalan et al., 2006), suggesting horizontal gene transfer of this loci into S. 
pneumoniae from unrelated bacterial species has occurred, and a similar mechanism 
might explain why Sp1688-90, Sp2084-87 and Sp1824-26 are not found amongst 
other streptococci.  
The genetic organisation of all the 9 ABC transporters were analysed using 
TIGR4 genome, and their organisation investigated by RT-PCR using 0100993 strain 
of serotype 3 RNA. The RT-PCR analysis using 0100993 strain showed that the 
probable transcriptional structure of the Sp0149-152, Sp0749-53, Sp0846-48, 
Sp2108-10 loci correlated with the TIGR4 genome. Amplification of cDNA from the 
RNA of 0100993 S. pneumoniae grown in THY for these genes was straightforward 
suggesting these regions are significantly expressed during growth in THY. However 
Sp1794-99 and Sp1822-28 ABC transporter loci were poorly expressed in THY and 
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therefore it was difficult to assess the transcriptional organisation of these operons 
using RT-PCR. The transcriptional structure of other ABC transporter loci did not 
match well with what would be predicted from the TIGR4 genome (Sp0090-92, 
Sp0607-11, Sp1689-91), and sequencing of these regions in the 0100993 S. 
pneumoniae strain may help clarify these results.  
PCR amplification of the junctions of Sp1794-99 and Sp1822-28 ABC 
transporter loci using 0100993 genomic DNA as template showed that some genes of 
these ABC transporter loci may be absent. As discussed earlier, the BLAST alignment 
of Sp1794-99 ABC transporter loci against 18 available S. pneumoniae genomes 
showed that this region was absent in some of the S. pneumoniae strains (Basavanna 
et al., 2009). However why some genes of Sp1822-28 ABC transporter loci were 
absent in 0100993 strain is not clear. I therefore speculate whether the expression of 
Sp1822-28 is induced under certain conditions such as oxidative, osmotic stress, or a 
minimal nutrient supply and that the genes of this region may not be constitutively 
expressed in THY.  
Which transcriptional regulators regulate these S. pneumoniae ABC 
transporters warrants further investigation as the information is very limited at 
present. In other bacteria such as S. mutans and S. agalactiae, genes of methionine 
uptake are under the control of the transcriptional regulator MetR / MtaR respectively 
(Sperandio et al., 2007) (Shelver et al., 2003), and whether Sp0149-152 is regulated 
in a similar fashion needs to be identified. However, Sp0749-73 and the BCAA 
synthesis operon Sp0445-50 have been shown to be negatively regulated by CodY 
(Hendriksen et al., 2008), although the relationship between CodY repression of 
Sp0749-53 requires further investigation to clarify its functional consequences and 
role during bacterial physiology. 
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The phenotype of each of the mutant strains was analysed using in vitro and in 
vivo CIs. CI tests the ability of the mutant strain to replicate compared to the wild-
type parental strain in the test condition (as long as the mutant phenotype cannot be 
complemented by the extracellular secretion of the missing protein(s) by the wild-type 
strain). In vitro CIs performed in a rich complete medium (THY) showed no growth 
defects of the mutant strains except a mild impairment for Sp0750-. Similarly, all the 
mutant strains grew well in the osmotic stress media (THY + 100 mM NaCl) except 
strain Sp0610- which had partial attenuation thereby suggesting a role of this ABC 
transporter for aiding growth in high osmotic stress conditions. Osmotic stress is one 
physiological stress that pathogens have to overcome in order to cause invasive 
infection, and decreased resistance to osmotic stress has been associated with 
decreased virulence for some pathogens. For example, expression of the three-gene 
operon of S. pneumoniae, phgABC, has been reported to be important for growth 
during high osmotic conditions and is required for the full virulence in pulmonary and 
systemic infection (Brown et al., 2004), and a proline ABC transporter of S. aureus is 
important for the virulence of S. aureus and protects against high osmolarity by 
accumulating proline within the cell (Schwan et al., 2004). 
To indicate a potential role of the selected S. pneumoniae ABC transporters 
during invasive infections, CIs were performed on human blood as an ex vivo culture 
system that closely represents at least some of the physiological conditions during 
infection such as limited availability of nutrients, pH, and relative hyperosmolarity. 
Culture on blood also replicates some of the interaction with different cell types and 
immune system components such as neutrophils and complement that occur during 
infection (Mereghetti et al., 2008). In this more stringent environment, mutant strains 
Sp0090
-, Sp0149-, Sp0610-, Sp0750-, Sp1824- were moderately impaired in growth 
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compared to the wild-type, suggesting that these ABC transporters may contribute to 
growth of S. pneumoniae in normal physiological fluid. These strains would therefore 
be predicted to have impaired virulence and in general, the CIs in human blood 
mirrored the in vivo CIs in mouse models of pneumonia and septicaemia. Unlike the 
in vitro CIs, where the mixed inocula of wild-type and the mutant strains were grown 
for a period of 8 hours in various growth conditions, the in vivo CIs performed in the 
mouse models of infection results in the interaction of the mutant and the wild-type 
strains in various cells, tissues and body compartments during a period of 24-48 
hours. This allows even small differences in virulence between mutant and wild-type 
strains to be identified. Of the nine ABC transporter mutant strains successfully 
constructed, seven were impaired in full virulence in mouse models of sepsis and / or 
pneumonia (Sp0090-, Sp0149-, Sp0610-, Sp0750-, Sp0846-, Sp1824- and Sp2108-). Of 
the seven attenuated ABC transporter mutant strains, five were partially reduced in 
virulence (Sp0090-, Sp0610-, Sp0846-, Sp1824- and Sp2108-) and two were markedly 
attenuated (Sp0149- and Sp0750-) in mouse models of sepsis and / or pneumonia. For 
two of the ABC transporter mutant strains (Sp1690-, Sp1796-) the impairment in 
virulence was relatively small, comparable to the effect of loss of a single iron 
transporter (Brown et al., 2002), and this maybe because their functions are partially 
redundant. For example, BLAST alignments suggest several of the ABC transporters 
investigated encode sugar transporters, and more than 30% of S. pneumoniae 
transporters are predicted to be sugar transporters which also includes non-ABC 
transporter uptake systems such as phosphoenolpyruvate-dependent sugar transporters 
(Tettelin et al., 2001). Hence disrupting the function of a single sugar ABC 
transporter could be compensated for by the others or by non-ABC transporter uptake 
mechanisms such as phosphoenolpyruvate-dependent sugar transporters (Tettelin et 
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al., 2001). Dual mutations in genes encoding components of ABC transporters with 
related functions may have a much more marked effect on virulence as has been 
shown for the PiuA and PiaA iron transporters (Brown et al., 2001). Two strains 
Sp0149
- and Sp0750- were markedly more attenuated in virulence in pneumonia and 
septicaemia models of S. pneumoniae infection compared to the other strains. The 
functions of proteins encoded by these genes are indicated by BLAST searches to be 
methionine / cation and BCAA uptake respectively. Sp0750- had greater degree of 
attenuation of virulence in pneumonia model than in the septicaemia model of S. 
pneumoniae infection suggesting that this ABC transporter may be particularly 
important for the infection of the respiratory tract. As well as ABC transporters 
encoded for by groups of genes investigated in this and previous studies, there are 
many additional ABC transporters components encoded by isolated single genes or 
gene pairs within the TIGR4 genome, some of which STM screens suggest affect 
virulence (Hava and Camilli, 2002; Lau et al., 2001). These ABC transporter 
components also warrant further investigation, although their specific putative 
functions may be in general be even less apparent than those encoded by several 
adjacent genes in putative operons. 
S. pneumoniae disease process is complex and requires the bacterium to 
acclimatise in different environments such as nasopharynx, lungs, blood, ear and 
brain. The optimal survival of S. pneumoniae in any of these niches would depend on 
the expression of virulence factors (Ogunniyi et al., 2002). Since Sp0149 and Sp0749 
ABC transporters have been shown to be important for S. pneumoniae virulence as 
demonstrated by in vivo CIs, their relative abundance in different conditions were 
investigated. The relative expression of Sp0149 and Sp0749 mRNA, were compared 
with the well-characterised virulence protein genes, psaA and Sp1386 (potD, 
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polyamine ABC transporter) (Shah et al., 2008) in the THY, human blood and mice 
blood 12 hours after IP infection with S. pneumoniae. Relative mRNA expression of 
the virulence genes (Sp0149, Sp0749, psaA and Sp1386) in THY were used as 
baseline. psaA was abundantly present in the THY and human blood, therefore I did 
not investigate the relative abundance of psaA gene in mouse blood due to limited 
recovery of total S. pneumoniae RNA. Also similar work has been performed by 
Ogunniyi et al (Ogunniyi et al., 2002) and they have demonstrated that psaA is 
expressed abundantly during in vitro conditions and during pulmonary and systemic 
S. pneumoniae infection in mice. Sp1386, a lipoprotein component of a polyamine 
ABC transporter demonstrated lower expression than psaA and Sp0149 in THY, but 
increased mRNA expression was demonstrated in human blood and in the blood of 
mice recovered 12 hours after IP inoculation of S. pneumoniae suggesting a role in 
this physiological fluid and thereby contributing to S. pneumoniae virulence. Shah et 
al have also demonstrated that the expression of the S. pneumoniae polyamine ABC 
transporter is up-regulated during oxidative stress and high temperature (Shah et al., 
2008) such results that are compatible with the lower expression of Sp1386 in 
favourable growth conditions such as THY. 
In the mouse blood, the relative abundance of Sp0149 was increased compared 
to THY and human blood. However, Sp0749 was only expressed in mouse blood and 
no detectable levels were found in THY and human blood. Previous work by Carlos 
Orihuela and collegues has shown that the Sp0149 lipoprotein gene and Sp0750-53 
operon are both up-regulated in a rabbit model of meningitis suggesting their gene 
expression may contribute towards S. pneumoniae virulence (Orihuela et al., 2004). 
The genes of Sp0749-53 are under the negative control of the transcriptional regulator 
CodY (Hendriksen et al., 2008) but the relationship between CodY repression, in 
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vitro and in vivo expression of Sp0749-53 and BCAA transport requires further 
investigation. There is also a need to repeat the experiment using more sensitive 
technique such as real-time PCR, which would allow more accurate quantification of 
the differential expression of these ABC transporter genes in both in vitro and in vivo 
(systemic and pulmonary murine models).  
The subcellular localisation of the lipoproteins Sp0149 and Sp0749 was 
investigated using Triton X-114 extracts of the S. pneumoniae membrane associated 
proteins. Immunoblots identified that Sp0149 and Sp0749 are membrane localised. 
Reports for other Gram positive bacteria such as Mycobacterium tuberculosis (Sander 
et al., 2004) Listeria monocytogenes (Reglier-Poupet et al., 2003) and S. suis (De et 
al., 2003) have shown that their lipoproteins are processed by Lsp, and that disruption 
of lsp in L. monocytogenes (Reglier-Poupet et al., 2003), S. suis (De et al., 2003) and 
recently by my supervisor’s group in S. pneumoniae (Khandavilli et al 2008) results 
in retention of the N terminal signal peptide by lipopeptides. Hence I investigated the 
effects of deletion of lsp on the Sp0149 and Sp0749 lipoproteins. As expected, the 
Sp0149 gave a higher molecular weight signal in the whole cell lysate of Δlsp strain 
due to incomplete processing of the lipoproteins in the absence of Lsp. However in 
the whole cell lysate of lspc strain, the Sp0149 did not revert to the normal wild-type 
molecular weight. Whether the differences of Sp0149 is due to the rate of migration 
of proteins or due to incomplete Lsp function in the complementation mutant as 
described by Khandavilli and collegues (Khandavilli et al 2008) needs to be 
investigated. With respect to Sp0749 there was a weak signal in the whole cell lysate 
of the Δlsp strain, but the intensity of expression was similar in the wild-type and lspc 
strain. At present there is no clear explanation for why there is lower expression of 
Sp0749 in the absence of Lsp. However, the localisation of Sp0149 and Sp0749 
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within the membrane and that they are affected by Lsp does indicate that both are 
lipoproteins and could be investigated as potential vaccine candidates against S. 
pneumoniae. Analysis of the effect of loss of lgt on the processing of Sp0149 and 
Sp0749 would also be of interest as this would be predicted to result in loss of both 
lipoproteins from the cell membrane associated protein fraction. 
The data obtained with the disruption mutant strains suggested that the ABC 
transporters encoded by Sp0149-52 and Sp0749-53 have the most crucial roles during 
S. pneumoniae infection. For further investigation of the function of the Sp0149-52 
and Sp0749-53 ABC transporters, mutant strains were made in the S. pneumoniae 
0100993 background in which Sp0149 and Sp0750-53 were deleted from Sp0149-52 
and Sp0749-53 operons using constructs made by overlap extension PCR (OEP) 
(Shevchuk et al., 2004). OEP is a relatively new technique for constructing deletion 
and complemented mutant stains to allow complete replacement of an operon with an 
antibiotic resistance cassette. Different techniques have also been used in recent years 
to construct mutations in S. pneumoniae such as IDM, in vitro mariner transposon 
mutagenesis, and gene replacement using Janus cassette and OEP. IDM however has 
been used to for many years to make disruption mutants in S. pneumoniae using 
plasmids as it is rapid and a relatively simple technique. However, due to homologous 
recombination of duplicated regions flanking the inverted plasmid, the entire plasmid 
may be excised allowing the plasmid containing the gene for antibiotic selection to be 
excised and this is a relatively common problem with IDM. The advantages of OEP 
are that it is a relatively quick method to obtain the desired constructs for mutations 
and does not involve plasmids and restriction digestion. However the main 
disadvantage of OEP is the induction of random mutation due to amplification by 
PCR into the mutant construct. Two other relatively new methods to construct S. 
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pneumoniae mutants are in vitro mariner transposon mutagenesis and gene 
replacement using Janus cassettes. In vitro mariner transposon mutagenesis is rapid 
and is particularly useful for the identification of genes required for growth and 
survival, but causes random insertions into the target sequence rather than a clean 
deletion (Akerley et al., 1998). Gene replacement using Janus cassette is a method for 
negative selection particularly useful to construct substitutions and inframe deletions 
which allows the selection for gene acquisition and loss. Therefore use of Janus 
cassette circumvents the problem of accumulation of antibiotic markers in the mutated 
strains (Sung et al., 2001), but is more complex than OEP and was not necessary as 
multiple mutations in the one strain were not planned. I therefore used OEP to 
construct deletion and complementation mutant strains of Sp0149 and Sp0750-53 in 
S. pneumoniae as this method is relatively quick, stable and it is possible to construct 
in frame mutations. For phenotype analysis of mutant strains it is important if possible 
to have a complemented mutant so any phenotypes observed is linked directly to the 
genetic manipulation of the gene of interest. However, although after several attempts 
I was able to construct the complementation construct of Sp0149 this construct failed 
to transform in S. pneumoniae, and I was also unable to obtain the complementation 
construct of Sp0750-53 possibly due to its larger size.  
The role of S. pneumonaie Sp0149-53 and Sp0749-53 ABC transporters were 
investigated in detail for their possible substrate specificity and role in virulence using 
the ΔSp0149 and ΔSp0750-53 S. pneumoniae deletion mutants. The role of Sp0149-53 
ABC transporter was investigated in vitro by comparing the growth rates of the wild-
type and the ΔSp0149 deletion mutant strains under normal laboratory conditions. 
Particular phenotypes associated with the specific functions of the Sp0149-53 
(requirement of particular cations, sensitivity to streptonigrin) were also investigated. 
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These assays did not show impairment of growth in the tested conditions such as 
cation depleted media, but as discussed earlier recent data suggested that  Sp0149-53 
is a methionine ABC transporter (Saier, Jr., 2000) rather than a cation transporter. 
Further investigation of this transporter is required using uptake assays and ligand 
binding assays. Methionine ABC transporters are functionally characterised in Gram 
negative bacteria such as E. coli (Kadner, 1974) and S. enterica serovar Typhimurium 
(Grundy and Ayling, 1992). To my knowledge, there have been no reports 
demonstrating a role for the methionine uptake in the virulence of Gram positive 
pathogens including S. pneumoniae. In S. mutans, the Sp0149-53 homologues encode 
AtmBDE, an ABC transporter that was identified as a likely methionine uptake 
transporter, with functional studies suggesting AtmBDE has a strong affinity for L-
methionine but also transports other sulphur compounds such as selenomethionine, D-
methionine, or homocysteine (Sperandio et al., 2007). MtaR, a transcriptional 
regulator, was also identified which not only regulates methionine synthesis and / or 
uptake genes (AtmBDE) in S. mutans (Sperandio et al., 2007) and S. agalactiae, but 
was also essential for the survival of S. agalactiae in a rat model of septicaemia 
therefore contributing towards virulence (Shelver et al., 2003). It would therefore be 
interesting to investigate the role of Sp0149-53 as a putative methionine ABC 
transporter using methionine as the potentially preferred substrate.  
In order to identify particular phenotypes associated with the specific 
functions of the Sp0749-53 putative BCAA ABC transporter, toxicity towards 
azaleucine, radioactive uptake assays, tryptophan fluorescence spectroscopy and 
radioactive binding assay were performed. Loss of Sp0749-53 ABC transporter did 
not result in a particular requirement for BCAA in the conditions used such as THY, 
and the wild-type strain was resistant to the toxicity of azaleucine, so we were unable 
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to identify significant uptake of the BCAA leucine by S. pneumoniae. Hence in the 
conditions used for these experiments (ie., the complete medium THY and the defined 
medium CDEM) there seems to be very little BCAA uptake by S. pneumoniae. 
Tryptophan fluorescence spectroscopy and radioactive binding assays using 14C-
leucine, isoleucine and valine demonstrated that His6-Sp0749 binds specifically to 
BCAA, strongly supporting the hypothesis that Sp0749-53 encodes a BCAA ABC 
transporter. Both the tryptophan fluorescence spectroscopy and radioactive binding 
assays suggest that His6-Sp0749 has the highest affinity for isoleucine, moderate 
affinity for leucine, with the least affinity for valine (Basavanna et al., 2009). These 
data suggest strongly that Sp0749 to 0753 does encode a BCAA transporter despite 
the lack of evidence for BCAA uptake in vitro. 
In mouse models of infection the Δ750-53 and the ΔSp0149 deletion strains were 
both significantly out-competed by the wild-type strain. These data suggest there is an 
important role for the S. pneumoniae BCAA and putative methionine ABC 
transporters specifically during in vivo growth, a conclusion that is supported by 
previous publications at least for BCAAs, with disruption of BCAA synthesis 
affecting virulence of the unrelated pathogens B. pseudomallei and M. bovis (Atkins 
et al., 2002; McAdam et al., 1995). However the effect of loss of Sp0750-53 and 
Sp0149 on virulence were only detectable in competitive infection experiments and 
after IN inoculation with the ΔSp0149, ΔSp0750-53, or wild-type strain, progression 
of infection was similar. Hence, Sp0149-53 and Sp0749-53 ABC transporters do not 
have a powerful effect on S. pneumoniae virulence. This could reflect redundancy 
associated with S. pneumoniae ABC transporters. For example, the S. pneumoniae 
genome contains genes encoding enzymes required for BCAA synthesis (Sp0445-50) 
(Tettelin et al., 2001) (Hendriksen et al., 2008) may partially compensate for impaired 
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BCAA uptake in vivo. Whether the loss of Sp0149 is perhaps compensated by other 
gene(s) involved in methionine metabolism is not known. Exactly why loss of genes 
encoding putative methionine and BCAA affects virulence is not clear. The most 
obvious explanation is a nutritional requirement for methionine and BCAA in vivo. 
However, the marked difference in CI between growth in blood and during infection 
for the Sp0149- and Sp0750- mutant strains indicates that the loss of virulence maybe 
more complex than simple impaired growth under physiological conditions. As stated 
above BCAA metabolism and uptake genes in various bacteria have been identified to 
be regulated by CodY. CodY, a nutritional repressor identified in L. lactis (Guedon et 
al., 2001), C. difficile (Dineen et al., 2007), S. pyogenes (Malke et al., 2006), and L. 
monocytogenes (Bennett et al., 2007), S. aureus (Majerczyk et al., 2008) and S. 
pneumoniae (Hendriksen et al., 2008) is known to inhibit the genes involved in amino 
acid metabolism. It is highly conserved in Gram positive bacteria and responds to 
intracellular concentrations of BCAAs and GTP (guanosine triphosphate), thereby 
sensing carbon, nitrogen availability and aids the bacterium to adapt to survive under 
harsh conditions. Therefore CodY plays a central role in the regulation of bacterial 
metabolism (Somerville and Proctor, 2009; Tojo et al., 2008) and will influence 
growth and therefore virulence in vivo. In S. pneumonaie, the CodY regulon consists 
of genes involved in BCAA and general amino acid metabolism. Upregulation of 
BCAA metabolism and uptake genes including Sp0749-53 was observed in a codY 
mutant strain suggesting that CodY directly controls the intracellular BCAAs in S. 
pneumoniae (Hendriksen et al., 2008).  
As the Sp0149-0153 and Sp0749-53 ABC transporters are important for 
virulence, and their corresponding lipoprotein genes, Sp0149 and Sp0749 are surface 
localised, they were chosen for further investigation as vaccine candidates analogous 
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to other protein antigens such as PiaA, PiuA and PsaA. Western blotting of the cell 
lysates of clinically important serotypes responsible for S. pneumoniae infections with 
polyclonal antibodies to Sp0149 and Sp0749 demonstrated the presence of the 
lipoproteins Sp0149 and Sp0749 in all serotypes investigated. Furthermore, the 
proteins were of the same size in all strains and PCR amplified identical sized gene 
products. This suggests that both Sp0149 and Sp0749 are identically sized and 
conserved amongst S. pneumoniae strains, making them potentially attractive vaccine 
candidates. Compatible with the results of the in vitro assays and RT-PCR analysis for 
Sp0749 function, the expression of Sp0749 generally seemed to be low compared to 
the expression of Sp0149, with probing with anti-Sp0749 giving a variable and much 
weaker signal compared to probing with anti-Sp0149 serum. ELISA demonstrated 
that Sp0149 and Sp0749 lipoproteins are immunogenic as they elicited good IgG 
antibody titres comparable to that of PsaA which was used as positive control. The 
antibody results were predominantly IgG1 subclass, although a IgG2a subclass 
response was also observed. Hence the lipoproteins may induce a Th2 immune 
response similar to that observed upon immunisation with PiaA and PiuA (Jomaa et 
al., 2005). No cross reactivity between antibodies to the two proteins was seen 
suggesting that both the lipoproteins are antigenically dissimilar. Incubation with anti-
Sp0149 and anti-Sp0749 resulted in small but a significant increase in the deposition 
of complement on S. pneumoniae and aided phagocytosis. Antibodies to iron uptake 
ABC transporters do not inhibit ABC transporter function (Jomaa et al., 2005), and 
although antibodies to Sp0149 and Sp0749 seems to have immunological effects, it is 
not known whether anti-Sp0149 and anti-Sp0749 also inhibits the function of Sp0149 
and Sp0749 lipoproteins. However this would be difficult to assess due to potential 
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redundancy and the lack of a specific phenotype in vitro that could be used to assess 
the function of these ABC transporters (Brown et al., 2001).  
Immunisation with Sp0149 or Sp0749 lipoproteins and subsequent challenge 
by the intraperitoneal route with D39 strain to simulate a model of S. pneumoniae 
septicaemia involving experiments were performed twice in the CD1 mouse strain. In 
the initial immunisation experiment, CD1 mice were challenged with 105 cfu of D39 
strain of S. pneumoniae. Only a minor delay in the development of fatal infection was 
observed in the mice immunised with the lipoprotein groups. Since the lipoproteins 
failed to confer strong protection, one of the questions that arose is whether these 
lipoproteins are unstable in the laboratory storage conditions and whether they have 
degraded from the time of purification to the immunisation or failed to induce good 
antibody responses. Western blotting suggested that this was not the case, as 
polyclonal antisera raised against the purified Sp0149 and Sp0749 lipoproteins 
produced specific signals when used to probe whole cell lysates of S. pneumoniae and 
the purified His6-Sp0149 and His6-Sp0749. The disappointingly weak protective 
effect of immunisation with His6-Sp0149 and His6-Sp0749 may reflect a challenge 
dose that may be overwhelmingly high leading to fast multiplication of S. pneumoniae 
in the host even if the vaccine antigens had elicited protective responses.  
As well as a negative control group vaccinated with alum alone, the efficacy 
of these lipoproteins as vaccines also needs to be evaluated in comparison with a 
positive control whose efficacy as a vaccine candidate has been previously 
determined. I therefore used PspA, a surface protein known to be protective against 
several clinically important serotypes, as a positive control for the second 
immunisation experiment. Unfortunately PspA is a weak vaccine candidate against 
D39 (McDaniel et al., 1991), but this protein was the only alternative vaccine protein 
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available in our laboratory at the time of second immunisation experiment. A lower 
challenge dose of 103 cfu of S. pneumoniae was used in the second immunisation 
experiment to increase the likelihood of detecting protective responses. PspA did not 
exhibit protection against D39 strain of S. pneumoniae, and the survival of mice 
vaccinated with Sp0149 was similar to that of mice immunised with PspA or alum 
alone. Sp0749 showed a statistically non-significant delay the development of fatal 
infection, perhaps suggesting that Sp0749 may be an alternative protein vaccine 
antigen. CD1 mice were used for the immunisation-challenge experiments because 
they are an outbred strain, as well as being cheaper, experiments using outbred mice 
are more likely to be of greater relevance than positive results obtained with an inbred 
mouse population. The immunisation experiment was therefore repeated in the inbred 
mice strain Balb/c. Unfortunately, no protection against S. pneumoniae challenge was 
observed after immunisation with the Sp0149 or Sp0749 lipoproteins, nor with the 
positive control protein PsaA. Why Sp0149, Sp0749 and PsaA did not demonstrate 
protection despite the in vitro data suggesting they induce a significant and 
immunologically relevant response is not clear. One probable explanation is that the 
intraperitoneal route may be too stringent an infection route, and that any protective 
response elicited by the lipoproteins may be masked by the severe S. pneumoniae 
septicaemia induced by this route of inoculation. 
As S. pneumoniae pneumonia is a common disease affecting both the elderly 
and infants to which the available vaccines do not provide efficient protection, 
intranasal immunisation and challenge studies were performed in mice to investigate 
whether immunisation with the protein antigens can protect against S. pneumoniae 
pneumonia. The protective efficacy of the purified Sp0149, Sp0749 by itself or in 
combination with the previously investigated lipoprotein vaccine candidates PiaA and 
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PiuA (Jomaa et al., 2006) against S. pneumoniae pneumonia was investigated through 
the intranasal route (instilling the purified lipoproteins and bacteria into mouse 
nostrils, IN). This simulates the natural route of infection in humans. Cholera toxin 
was used as the adjuvant as it is well established and used as adjuvant with different 
S. pneumoniae proteins for IN immunisation experiments (Jomaa et al., 2006) 
(Pimenta et al., 2006; Shah et al., 2009). Experiments assessing survival after IN 
immunisation and challenge were performed in outbred CD1 mice due to the cost, 
whereas inbred CBA/Ca mice were used for experiments assessing immunological 
responses in more detail in order to minimise mouse to mouse variation in results that 
may compromise the results of the experiment and its analysis.  
The antibody titres, types of immune cell activation and histological 
examination of the degree of inflammation in the lungs elicited against the immunised 
lipoproteins were analysed. Sp0749 in combination with PiaA elicited good IgG titres 
in the sera and respiratory secretions such as BALF after the IN immunisation, 
although greater IgG titres were demonstrated in the sera after IP immunisation with 
Sp0749. Perhaps surprisingly given the immunisation route Sp0749 specific IgA 
antibodies were not detected and PiaA specific IgA antibodies were detected in the 
BALF of only two mice immunised with PiaA and Sp0749. Nevertheless, ELISA 
demonstrated that the IN immunisation with Sp0749 and PiaA can induce specific 
local and systemic IgG antibodies.  
To investigate the detailed host immune responses upon S. pneumoniae 
challenge, cells were isolated from the BALF and lungs of CT, PiaA and 
PiaA+Sp0749 immunised mice before and 48 hours after the S. pneumoniae challenge 
and analysed using labelled lymphocyte and macrophage antibody markers and flow 
cytometry. The total cell counts in the BALF and lungs determined using a 
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haemocytometer indicated only small differences before and after the S. pneumoniae 
challenge between the vaccine groups. The results of the cell surface marker 
experiments were highly variable between mice and it was difficult to identify clear 
trends. However, there was an indication of an increase in the proportion of B220 
cells. As expected, differential cell counts of the BALF cytospins indicated an 
overwhelming increase in the neutrophil infiltration upon S. pneumoniae challenge in 
all groups. Macrophage activation in the vaccine groups upon S. pneumoniae 
challenge was also analysed by flow cytometry using two macrophage surface 
markers (CD80 and I-A-I-E). In the lungs, the results suggests both the active vaccine 
groups had an increase in CD80 positive cells suggesting a greater recruitment of 
activated macrophages in these mice compatible with a positive immunological 
benefit of vaccination with lipoproteins. However, flow cytometry using I-A-I-E 
surface marker did not mirror the results obtained using the CD80 surface marker, 
therefore the significance of the results obtained by CD80 are unconfirmed.  
Interestingly the histological examination of the lung tissues from the control 
and vaccine groups indicated more inflammation in the vaccine groups than the 
control group, with greater degree of inflammation in the PiaA immunised group 
upon S. pneumoniae challenge. Why there was increased level of inflammation in the 
vaccine groups after the S. pneumoniae challenge is not immediately clear, but could 
indicate a more rapid inflammatory response in actively vaccinated mice which could 
aid protective immunity. An analysis of the cytokine response would help identify 
whether there are differences in the inflammatory response between vaccinated and 
control mice after S. pneumoniae challenge. Inflammatory cytokines such as IL-1, 
TNF and IL-6 are present in both the patients (Dehoux et al., 1994) and mice with 
pulmonary infection caused by S. pneumoniae (Bergeron et al., 1998). Blocking the 
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expression or action of cytokines such as TNF-α, and IL-6 impairs the host’s immune 
response to S. pneumoniae with reduced bacterial clearance and reduced survival in 
experimental mice models of pneumonia (Takashima et al., 1997; Van der et al., 
1997). However, studies have demonstrated that the host’s cytokine response depends 
on the specific strain of S. pneumoniae in addition to the type of infection such as 
pneumonia / septicaemia and host’s genetic background (Mohler et al., 2003). 
Furthermore, differences in bacterial cfu present at different time points could make 
the interpretation of a direct comparison of cytokine levels between groups complex. 
Hence a careful selection of the mouse strain and time point for cytokine analysis will 
be necessary. To determine which of the observations on differences in the immune 
response after IN immunisation with PiaA and Sp0749 or the control group are 
consistent and biologically significant and assess their potential importance for 
control of S. pneumoniae infection, these experiments will need to be repeated. 
Despite the evidence of some modifications of the immunological response to 
infection in the pneumonia model in mice vaccinated with the lipoproteins, little 
protection was found after intranasal vaccination with the lipoproteins. Sp0149 alone 
and in combination with PiaA and PiuA in the triple vaccination gave no protection. 
Sp0749 showed a statistically non-significant (p = 0.083) weak level of protection 
when combined with PiaA, but not when used alone or in combination with Sp0149 
and PiaA in a triple antigen vaccination. The results obtained with PiaA and PiuA 
contrast to previously published data on these antigens as intranasal vaccines (Jomaa 
et al., 2006). The reasons why both PiaA and PiuA did not protect in both CD1 and 
CBA/Ca mice strain when previously they had shown protection against pulmonary S. 
pneumonaie infection (Jomaa et al., 2006) are not clear, but could be due to variations 
in the serotype of S. pneumoniae used (1x 106 cfu of serotype 1 in CBA/Ca mice). 
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The results of S. pneumoniae cfu enumeration 48 hours after the S. pneumoniae 
challenge in the BALF, lungs and blood of immunised CBA/Ca mice were compatible 
with the results of the survival experiments. There was a statistically non-significant 
decrease in the bacterial counts in BALF, lungs and blood of mice immunised with 
PiaA and PiaA+Sp0749 when compared to CT alone, suggesting that the 
immunisation with these lipoproteins may perhaps have some weak effect on the 
clearance of S. pneumoniae that might not be enough to influence overall survival in 
this model. These experiments require repetition to identify whether the differences in 
cfu are consistent and to increase the numbers for a more accurate assessment of their 
statistical significance. 
One explanation for the weak protective effects on S. pneumoniae clearance 
from the target organs is that CBA/Ca mice are particularly susceptible to intranasal 
infection. Previous work by Gingles et al. demonstrated that the median survival time 
of CBA/Ca mice after challenge with 106 cfu of D39 was 28 hours, whereas that of 
Balb/c was greater than 168 hours (Gingles et al., 2001). In the future it would be 
important to enumerate S. pneumoniae cfu at an earlier time point in CBA/Ca mice 
strain or to use Balb/c mice, although these mice may be too resistant to S. 
pneumoniae pneumonia for consistent results in the negative control group. When 
designing S. pneumoniae vaccination experiments careful consideration of a range of 
variables such as the quantity of the antigen, type of adjuvants, route of immunisation, 
strain and dose of S. pneumoniae and mice strain is required (Chiavolini et al., 2008; 
Tai, 2006). However at present there is a lack of accepted standard mouse strain / 
bacterial strain combinations as well as positive controls for the different types of 
immunisation-challenge studies for investigating S. pneumoniae vaccine antigens. 
Overall the lack of efficacy of the lipoprotein vaccine candidates was disappointing  
Table 7.1: Flow chart to summarise the novel results of Sp0149-52 and Sp0749-53 ABC transporters 
Chosen 11 ABC transporter operons from TIGR4 genome
Amino acid homology searches using BLAST
Constructed IDM mutants for nine of the 
eleven ABC transporters in 0100993
Analysis of genetic organisation in 
0100993 using RT-PCR
Four of the eleven ABC transporter regions of 
0100993 are similar to TIGR4 genome 
In vivo phenotype screening by CIs:In vitro phenotype screening by CIs:
Detailed phenotype analysis of Sp0149-53 and 
Sp0749-53 using ΔSp0149 and ΔSp0750-53 deletion 
mutant strains 
Investigation of vaccine potential of Sp0149 
and Sp0749 lipoproteins
Sp0149-52 and Sp0749-53 are important for S. pneumoniae virulence
In vitro phenotype analysis demonstrated that:
• Sp0149 and Sp0749 are membrane bound 
lipoproteins
• Sp0749 lipoprotein is a branched chain amino acid 
binding protein.
In vivo phenotype analysis demonstrated that:
• Sp0149 and Sp0749 are differentially expressed in 
mice after systemic S. pneumoniae infection 
• Deletion of Sp0149 and Sp0750-53 affects S. 
pneumoniae virulence in mixed infection models, but 
were able to cause fatal disease when given as pure 
inoculum
• Sp0149 and Sp0749 are present in S. pneumoniae
capsular serotypes present in 7-valent vaccine
• Sp0149 and Sp0749 lipoproteins elicits good IgG
immune response, predominantly Th2 type immune 
response after IP and IN immunisation with Sp0149 
and Sp0749.
• Anti-Sp0149 and anti-Sp0749 induces small increase 
in in vitro complement deposition and 
opsonophagocytosis after IP immunisation with 
Sp0149 and Sp0749.
• IN immunisation with Sp0749 with PiaA may 
increase the activation of lung macrophages.
• IN immunisation with Sp0749 and PiaA increased 
inflammation in lung sections.
• Survival studies after IP and IN immunisation with 
Sp0149, Sp0749 and PiaA did not protect after S. 
pneumoniae challenge
Four mutant strains showed partial 
growth defect in human blood  
Sp0149- and Sp0750- mutant strains were markedly 
attenuated in systemic and pulmonary S. pneumoniae
infection
Sp0749 is a branched chain amino acid binding lipoprotein and Sp0149 and Sp0749 do not aid protection against
S. pneumonaie septicaemia and pneumonia. 
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and suggests that Sp0149 or Sp0749 are not likely to be major vaccine candidates. 
They may contribute as an additional antigen for a multivalent vaccine, but any 
benefit they might add over and above major vaccine antigens such as PiaA, PspA, or 
PsaA would require careful evaluation. Flowchart 7.1 summarises the novel findings 
of Sp0149-52 and Sp0749-53 ABC transporters. 
 
7.1 SUMMARY 
I selected 11 ABC transporters using the annotated TIGR4 S. pneumoniae genome, 
constructed disruption mutant strains for nine of the ABC transporter operons in 
0100993 strain. BLAST searches showed that several of the chosen S. pneumoniae 
ABC transporters have close homologues in streptococci. However, some discrepancy 
in the prediction of the substrate specificity occured using BLAST searches and 
transport classification system (Sp0149-52, Sp0846-48). Of the nine ABC transporter 
mutant strains successfully constructed, six were impaired in full virulence in mouse 
models of sepsis and / or pneumonia (Sp0090-, Sp0149-, Sp0610-, Sp0750-, Sp1824- 
and Sp2108-). Of these six ABC transporter mutant strains, Sp0149-, and Sp0750- 
were highly attenuated in virulence in mouse models of sepsis and pneumonia 
compared to the other strains. These ABC transporters were predicted by BLAST 
searches to be methionine and BCAA uptake respectively. Semi-quantitative RT-PCR 
indicated that the lipoprotein components of these ABC transporters Sp0149 and 
Sp0749 are expressed in mouse blood during systemic infection, suggesting these 
transporters are expressed under physiological conditions and supporting a role for 
virulence. I also constructed S. pneumoniae ΔSp0149 and ΔSp0750-53 deletion 
mutant strains in the 0100993 background, but failed to obtain complemented strains 
despite several attempts. Membrane localisation studies using the polyclonal mouse 
 251 
antibodies to recombinant Sp0149 and Sp0749, a lipoprotein processing mutant strain 
(Δlsp), and lipoprotein fraction triton-X-114 extracts showed that both Sp0149 and 
Sp0749 are membrane bound lipoproteins and therefore could be potential vaccine 
candidates against S. pneumoniae. Fluorescence spectroscopy and radioactive binding 
assays demonstrated that the Sp0749 lipoprotein is a BCAA binding protein. Similar 
experiments needs to be performed to identify if methionine is the preferred substrate 
for Sp0149 lipoprotein. After IN inoculation with the ΔSp0149, ΔSp0750-53, or wild-
type strain progression of infection were similar, and the effect of loss of Sp0149 and 
Sp0750-53 on virulence were only detectable in competitive infection experiments. 
These data suggest that although Sp0149-53 and Sp0749-53 ABC transporters are 
required for full virulence these ABC transporters do not have a powerful effect on S. 
pneumoniae virulence, perhaps because of functional redundancy of methionine or 
BCAA uptake by these ABC transporters. 
PCR and Western blot analysis demonstrated that Sp0149 and Sp0749 are 
conserved in the S. pneumoniae serotypes present in the 7-valent conjugate vaccine. 
Systemic immunisation with Sp0149 and Sp0749 lipoproteins induced good IgG 
antibody titres, predominantly of a Th2 type immune response. Good IgG titres were 
obtained in the sera and BALF after IN immunisaton with Sp0749, but IgA titres were 
not detected. There was a small but significant increase in in vitro complement 
deposition and opsonophagocytosis assays in the presence of polyclonal antibody to 
Sp0149 and Sp0749. Detailed assessment of the mouse immune response to S. 
pneumoniae pneumonia after IN vaccination with Sp0749 plus another lipoprotein 
vaccine candidate PiaA suggested a possible increase in the activation of lung 
macrophages. Histological analysis of the lung sections also indicated an increased 
degree of inflammation in actively vaccinated mice compared to the controls upon S. 
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pneumoniae challenge. However, despite these immunological effects of vaccination 
with these lipoproteins , IP and IN immunisations with Sp0149 and Sp0749 did not 
significantly delay the progression of infection after systemic or pulmonary S. 
pneumoniae challenge in mice, although IN immunisation with Sp0749 in conjunction 
with PiaA may perhaps have weak effect on the S. pneumoniae clearance in the 
BALF, lungs and blood  
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7.2 POTENTIAL FUTURE DIRECTIONS 
 
 
 To screen for specific substrates as predicted by BLAST searches of the 
chosen ABC transporters using tryptophan fluorescence spectroscopy, 
radioactive binding and uptake assays and their detailed in vitro and in vivo 
characterisation.  
 To investigate the ligand binding properties of Sp0149 using methionine as a 
potentially preferred substrate using different forms of methionine such as D, 
L- methionine, selenomethionine and homocysteine. 
 To investigate the phenotype in vitro and in vivo of a strain containing a 
deletion of the Sp0749-53 BCAA ABC transporter and the Sp0445-50 BCAA 
synthesis enzymes  
 To repeat and investigate in more detail the host’s immune response and S. 
pneumoniae clearance from the target organs after intranasal immunisation 
with Sp0749, perhaps using mouse and bacterial strains that are more likely to 
identify differences between groups. 
 To perform intranasal immunisation-challenge experiments with Sp0749 and 
different combination of potential lipoprotein vaccine candidates such as PiaA, 
PiuA, PsaA and PotD to identify potential optimal combinations of protein 
antigens for a multivalent vaccine.  
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Appendix 
MEDIA 
 
Cden medium 
To prepare 395 ml Cden medium 
 
Cden base   200 ml 
HYR    50 ml 
Glutamine (1 mg ml-1) 10 ml (stock solution) 
Vitamins (without choline  10 ml 
Sodium pyruvate (2%) 5 ml (stock solution 
SAC solution   40 ml 
Supplement   13 ml 
KPO4 (1 M; pH 8.0)  15 ml 
Leucine (10 mg ml-1)  10 ml (stock solution) 
Phenylalanine (10 mg ml-1) 5 ml (stock solution) 
Lysine (10 mg ml-1)  9 ml (stock solution) 
Choline chloride (1 mg ml-1) 2 ml (stock solution) 
Distilled water  26 ml 
 
Filter sterilize before use. 
 
Cden base 
 
Glycine     190 mg 
Alanine   350 mg 
Valine    720 mg 
Isoleucine   760 mg 
Proline    1160 mg 
Serine    590 mg 
Threonine   450 mg 
Methionine   310 mg 
Tryptophan   140 mg 
Asparagine   720 mg 
Glutamic acid   2200 mg 
Cysteine   150 mg 
 
Dissolve in the final volume of 2 litres (L), adjust the pH to 7.0 and filter sterilize. 
 
HYR (Histidine, Tyrosine, Arginine) 
 
Histidine   640 mg 
Tyrosine   122 mg 
Arginine   800 mg 
 
Vitamins without choline 
 
Adam’s I solution  12 ml 
Asparagine (5 mg ml-1) 32 ml (stock solution) 
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Distilled water  36 ml 
 
Dissolve and filter sterilize 
 
Adam’s I Cden solution 
 
Biotin (0.5 mg ml-1)  60 μl (stock solution) 
Nicotinic acid   30 mg 
Pyridoxine   35 mg 
Calcium pantothenate  120 mg 
Thiamine hydrochloride 32 mg 
Riboflavin   14 mg 
 
Dissolve in final volume of 200 ml, filter sterilize and store at 4ºC in dark. 
 
SAC solution 
 
Sodium chloride  12 g 
Anhydrous sodium acetate 12 g 
 
Dissolve in final volume of 1 L. 
 
Supplement 
 
3 in 1 salts   60 ml 
Glucose (20%)  120 ml (stock solution) 
Sucrose (50%)  6 ml (stock solution) 
Adenosine (2 mg ml-1) 120 ml (store at room temperature) 
Uridine (2 mg ml-1)  120 ml (store at room temperature) 
 
Filter sterilize 
 
3 in 1 salts 
 
MgCl2.6H2O   100 g 
CaCl2 (anhydrous)  0.5 g 
MnSO4 (0.1 M)  200 μl (stock solution) 
 
Dissolve in final volume of 1 L, autoclave or filter sterilize. 
 
TE-DOC 
 
Tris    50 mM 
EDTA    5 mM 
Sodium deoxycholic acid 0.01% 
 
NAES buffer 
 
Sodium acetate  50 mM, pH 5·1 
EDTA     10 mM 
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SDS    1% 
 
SDS-PAGE gels 
 
10% resolving gel 
 
30% acrylamide mix  6.7 ml 
1M Tris (pH8.8)  7.5 ml 
10% SDS   0.2 ml 
10% ammonium persulphate 0.2 ml 
TEMED   0.008 ml 
Distilled water  5.4 ml 
 
Stacking gel 
 
30% acrylamide mix  0.83 ml 
1M Tris (pH6.8)  0.63 ml 
10% SDS   0.05 ml 
10% ammonium persulphate- 0.05 ml 
TEMED   0.005 ml 
Distilled water  3.4 ml 
 
10X running buffer for SDS-PAGE 
 
Tris base (0.25 M)  30.3 g 
Glycine (1.92 M)  144 g 
SDS (1% )   10 g 
Distilled water  1000 ml  
 
Adjust the pH to 8.3 
 
5X Laemeli buffer 
 
Tris (312 mM, pH 6.8) 3.125 ml of 1M stock 
SDS (10%)   1 g 
Glycerol (20%)  2 ml 
Dithiothretol (50 mM) 0.5 ml 
Bromophenol blue  Add until dark blue 
Distilled water  10 ml 
 
Coomassie brilliant blue stain (CBB) 
 
CBB R-250   0.025 g 
Methanol   40 ml 
Acetic acid   10 ml 
Distilled water  100 ml 
 
Filter through Whatman No 1 paper. 
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Destaining solution 
 
Methanol   40 ml 
Acetic acid   10 ml 
Distilled water  100 ml 
 
Transfer buffer (1x) 
 
Glycine   2.93 g 
Tris    5.81 g 
SDS    0.375 g 
Methanol   200 ml 
 
Dissolve in 1 L of distilled water. 
 
Tris buffered saline (10x TBS) 
 
Tris    24.2 g 
NaCl    80 g 
 
Dissolve in 1 L of distilled water and adjust the pH to 7.6. 
 
1x TBS-Tween 
 
Dilute 10x TBS to 1x TBS and add 0.1% Tween-20. 
 
Protein purification buffers (E. coli) 
 
Buffer B 
 
NaH2PO4 (100 mM )  13.8 g 
TrisCl (10 mM)  1.2 g 
Urea (8M)   480.5 g 
 
Dissolve in 1 L of distilled water and adjust the pH to 8.0 using HCL. 
 
Cell Lysis buffer 
 
NaH2PO4 (50 mM)  6.90 g 
NaCl (300 mM)  17.54 g 
Imidazole (10 mM)  0.68 g 
 
Dissolve in 1 L of distilled water and adjust the pH to 8.0 using NaOH. 
 
Wash buffer 
 
NaH2PO4 (50 mM)  6.90 g 
NaCl (300 mM)  17.54 g 
Imidazole (20 mM)  1.36 g 
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Dissolve in 1 L of distilled water and adjust the pH to 8.0 using NaOH. 
 
Elution buffer 
 
NaH2PO4 (50 mM)  6.90 g 
NaCl (300 mM)  17.54 g 
Imidazole (250 mM)  17 g 
 
Dissolve in 1 L of distilled water and adjust the pH to 8.0 using NaOH 
 
RBC lysis buffer 
 
NH4Cl    8.29 g 
KHCO3   1 g 
EDTA    37.2 mg 
 
Dissolve in 1 L of distilled water, adjust the pH to 7.3. Filter sterilize and store at 4ºC. 
 
PBS / 1% BSA / 0.1% azide 
 
Sterile PBS (1x)  100 ml 
BSA    1 g 
Azide    0.1 g 
 
Store at 4ºC. 
 
Buffers for ELISA 
 
TSA buffer 
NaCl (132 mM)  7.72 g 
Tris-HCl (125 mM)  3.03 g 
NaN3    0.5 g 
 
Dissolve in 1 L of distilled water and adjust the pH to 7.5. 
 
10x ELISA wash buffer 
 
NaCl    43.83 g 
Tris    3.03 g 
Triton-X-100   5 ml 
HCl (1M)   18 ml 
 
Dissolve in 5 L of distilled water and adjust the pH to 7.6. 
 
BSA-Tween buffer 
 
NaCl    8 g 
Triethanolamine (0.25 M)     50 ml 
Tween-20   0.5 ml 
NaN3    200 mg 
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BSA    200 mg 
 
Dissolve in 1 L of distilled water and store in dark. 
 
Enzyme diluent (for secondary antibody) 
 
NaCl    8 g 
Triethanolamine (0.25 M) 50 ml 
500 x Mg/Zn   2 ml 
BSA    200 mg 
NaN3    200 mg 
 
Dissolve in 1 L of distilled water  
 
500 x Mg/Zn (500 mM MgCl2 / 1.25 mM ZnCl2) 
1 M MgCl2 in 1 M HCL 50 ml 
0.1 M ZnCl2 in 1 M HCL 1.25 ml 
Add 0.1 M HCL to a final volume of 100 ml. 
 
Paraformaldehyde preparation 
 
Paraformaldehyde  3 g 
CaCl2 (100 mM)  100 µl 
MgCl2 (100 mM)  100 µl 
PBS    100 ml 
 
Potassium phosphate buffer 
 
50 mM potassium phosphate buffer, pH 7.2, supplemented with 1 mM magnesium 
chloride 
 
 
 
